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This thesis investigated the possible use of transdermal iontophoresis in 
paediatric care, as an alternative strategy to the oral and intravenous routes. More 
specifically, the potential for non-invasive delivery of ranitidine, midazolam, and 
phenobarbital; and the clinical sampling of iohexol through the skin were examined. 
The feasibility for monitoring kidney function was assessed in vitro and in vivo 
using the glomerular filtration rate (GFR) marker, iohexol. Sampling of iohexol in 
vitro was sensitive to the changes in its subdermal concentration, and 
pharmacokinetic parameters estimated from skin sampling agreed well with 
reference subdermal values. Similar observations were confirmed in vivo in a pilot 
study performed in four children undergoing routine iohexol GFR test. 
Iontophoresis was well tolerated in all subjects and the marker was successfully 
extracted through the skin. In 3 of 4 subjects, the elimination rate constant 
estimated from skin sampling data agreed well with blood sampling results. This 
study demonstrated the potential of transdermal iontophoresis as a non-invasive 
sampling approach which could significantly improve the quality-of-life of children. 
Drug delivery by transdermal iontophoresis was examined in vitro for three 
commonly used paediatric medicaments: ranitidine, midazolam, and phenobarbital. 
Experiments used both intact and compromised pig skin to model the less resistant 
skin of premature babies. Iontophoretic delivery across intact skin was superior 
than passive delivery and optimised conditions were achieved by use of maximal 
molar fraction of the drug, higher current intensity, and appropriate vehicle pH. 
Pluronic® F-127 gels were suitable drug matrices for the iontophoretic delivery of 
ranitidine. Midazolam and phenobarbital transdermal delivery through partially 
compromised skin barriers was controlled by iontophoresis. Across highly 
compromised skin, however, passive diffusion increased drastically and 
iontophoretic control was lost. Overall, it was possible to deliver therapeutically 
meaningful fluxes of all three drugs with acceptable patch application area.   
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A significant unmet need exists in paediatric medicine. Treatment therapy in 
this special population lacks age-appropriate formulations and suitable methods of 
drug administration and clinical sampling. This often results in failure of optimum 
therapy.  
The subject of this thesis proposes an alternative non-invasive approach by 
which drugs and analytes can be delivered and sampled via the skin. The needle-
free technique, known as “transdermal iontophoresis”, makes use of an electrical 
current application which provides a driving force for compounds to move 
efficiently across the skin in a highly controlled and sustained manner [1-3]. This 
active transport of molecules is due to two phenomena. The first mechanism is 
“electromigration” and only concerns the transport of ionised species. It describes 
the direct result of interaction of the applied electrical field with the charged 
molecules [4]. This leads to the migration of the ions to the electrode of opposite 
polarity by moving into and through the skin. The efficiency of electromigration 
depends on the mobility, valence, and concentration of the ion of interest as well as 
the other ions present in the iontophoresis system. The second mechanism is 
“electroosmosis” and describes the movement of solutes along with the convective 
solvent flow, which is induced as a result of the skin’s negative charge and 
therefore its permselectivity to cations over anions under the influence of current 
application [5]. The transport of neutral compounds during iontophoresis is mostly 
due to electroosmosis. The transport of cations is supplemented by electroosmosis 
as the latter phenomenon occurs in the same direction as the cation’s 
electromigration across the skin. To distinguish drug delivery from clinical sampling, 
the term “reverse iontophoresis” is conventionally used to describe the extraction 
of analytes from the body.  
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1. Aims of the thesis 
The objectives of this thesis are to evaluate the potential applications of 
transdermal iontophoresis as an alternative non-invasive route for drug 
administration and for clinical sampling in paediatric medicine. The validation of 
such approach is drug-specific and requires separate investigation for each 
individual therapeutic agent. For this reason, the aim of this thesis is more 
specifically focused on the feasibility to use transdermal iontophoresis as a non-
invasive strategy for the delivery/sampling of four therapeutic agents, which were 
chosen from the list shown below. 
2. List of candidates for possible iontophoretic applications 
The therapeutic agents investigated in this thesis were selected from the 
following candidates: A) Drug delivery: tacrolimus (immunosuppressant), 
carbamazepine (for epilepsy, mood stabilisation, and neuralgia), phenobarbital 
(antiepileptic), midazolam (sedative), digoxin (for various heart conditions), 
ranitidine (for gastric acid reduction), furosemide (diuretic), and ondansetron 
(antiemetic). B) Clinical sampling: digoxin and tacrolimus (therapeutic drug 
monitoring necessary due to narrow therapeutic index), and iohexol (marker for 
kidney function).  
These therapeutic agents are commonly used in paediatric medicine but the 
available dosage forms, at present, require significant improvement. The 
conventional routes of administration are by oral or intravenous delivery while 
clinical sampling is performed solely by intravenous means. Inherent disadvantages 
of the latter include the significant pain experienced during blood sampling, the 
potential risk of infection, and the technical difficulties associated with needle 
insertion. The same drawbacks, obviously, apply to drug delivery by the intravenous 
route. Even though oral delivery is the preferred route of administration, it is not 
appropriate in certain clinical conditions whereby, for example, the child is seriously 
ill, suffers from nausea/vomiting, is uncooperative, or in very young babies.  
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Paediatric oral delivery of the drugs mentioned earlier suffers from various 
pitfalls. The formulations of some drugs are only available as solid dosage forms 
(tacrolimus [6]) which is unsuitable for infants and young children due to inability of 
swallowing. Other medicaments are available in liquid forms but the conventional 
formulation can be too concentrated (e.g. phenobarbital [6]) for accurate and 
consistent dilutions to be made. Some liquid formulations are also alcohol-based 
(furosemide, phenobarbital, ranitidine [6]), a solvent usually avoided in paediatric 
treatments. Moreover, the unpalatability of some liquid formulations (midazolam 
[7]) may eventually lead to refusal of intake and failure to comply. Noncompliance 
may also arise with drugs of short half lives (midazolam, furosemide, ondansetron, 
ranitidine [8]) as they would have to be administered several times a day to 
maintain effective plasma concentrations. Many of the drugs listed above are also 
characterised by low and/or highly variable oral bioavailability (midazolam, 
ranitidine, digoxin, tacrolimus and carbamazepine [8-11]) both in children and 
adults. The continuous developmental changes in the child’s digestive system also 
lead to highly unpredictable rates and extents of oral absorption and first-pass 
metabolism [12]. It follows that drugs with narrow therapeutic index such as 
digoxin and tacrolimus can have a detrimental effect on the child’s health if slightly 
less or more of the drug is absorbed. 
3. Selection criteria for suitable iontophoresis candidates 
The therapeutic agents, investigated in this thesis for transdermal 
iontophoretic delivery and clinical sampling, were selected from the above list of 
candidates based on the following factors: Firstly, for drug delivery the smaller the 
dose required daily, the better possibility transdermal iontophoresis could deliver 
therapeutically meaningful levels of the drug. Conversely, for clinical sampling the 
higher the systemic concentration of the free (unbound) therapeutic agent in the 
body, the more likely there will be a successful extraction across the skin. Secondly, 
low molecular weight, charged, and hydrophilic molecule properties are the ideal 
physicochemical characteristics for efficient iontophoretic transport [13-16]. The 
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reasons being that: A) molecular weight is inversely proportional to the mobility of 
the compound which will directly affect its iontophoretic transport efficiency [16-
18]. B) charged molecules are preferred over neutral compounds because transport 
rates achieved with electroosmosis are usually considered secondary to the effects 
electromigration usually exerts on the transport rates of relatively small charged 
permeants [5, 14]. While electromigration acts directly on the charged molecule 
providing a high driving force through the skin, the transport of neutral molecules is 
due to electroosmosis which is a stream of solvent flow created indirectly as a 
result of the skin’s net negative charge. Cationic molecules are favoured over 
anionic compounds because, in addition to electromigration effect, the 
iontophoretic transport of the former is supplemented by electroosmosis, while the 
transport of the latter is against the stream of solvent flow [5, 14]. C) Several 
studies reported that iontophoresis of cationic lipophilic compounds attenuated or 
even reversed electroosmosis [19-21]. Lipophilic neutral solutes also exhibited 
lower electroosmotic transport compared to more hydrophilic compounds [22].   
3.1 Selection for drug delivery applications  
The following table provides details on the paediatric daily doses of the 
potential drug candidates along with their molecular weight, dissociation constant 
(pKa), lipophilicity (LogP), and aqueous solubility.  
The daily doses required for tacrolimus and digoxin are very small but their 
physicochemical properties predict less suitability for iontophoretic delivery. The 
neutrality, high molecular weight, and water insolubility are all unfavourable 
characteristics for ideal iontophoresis candidates. In addition, the very high 
lipophilicity of tacrolimus is likely to affect its transport across the skin. The 
molecular weight of carbamazepine is significantly lower than the previous two 
drugs, however the required dose to achieve therapeutic systemic levels is very 
high for transdermal applications. This is in addition to carbamazepine being a 
neutral molecule with very low water solubility. Low solubility of furosemide is also 
an obstacle for transdermal applications in addition to the high daily doses 




 from references [6, 23]; 
(2)
 from reference [24]; 
(3)
 from reference [25].  
 
and ranitidine) may all be potentially good candidates for transdermal delivery by 
iontophoresis. 
3.2 Selection for clinical sampling applications 
Three candidates for potential non-invasive sampling applications by reverse 
iontophoresis were examined. Digoxin and tacrolimus sampling for therapeutic 
drug monitoring purposes, and iohexol extraction for the estimation of glomerular 
filtration rate. 
As already mentioned earlier, for an analyte to be efficiently extracted, its 
systemic “unbound” concentration must be sufficiently high for extracted samples 


















Tacrolimus 0.03 – 0.1 804.0 Neutral 6.1 
Practically 
insoluble 
Digoxin 0.004 – 0.01 780.9 Neutral 1.3 
Practically 
insoluble 
Carbamazepine 10.6 – 31.7 236.3 Neutral 2.5 
Very slightly 
soluble 
Furosemide 8 – 20 330.8 4.7 (acid) 2.6 
Practically 
insoluble 




Ondansetron 0.5 293.4 7.4 (base) 2.1 
Sparingly 
soluble (salt) 
Phenobarbital 1.5 – 7.8 232.2 7.4 (acid) 1.5 
Freely soluble 
(salt) 








blood is 5 – 20 ng/ml, 99 % of which is bound to erythrocytes and plasma proteins 
[11]. It follows that the maximum unbound fraction of tacrolimus possibly available 
for extraction across the skin is < 0.2 ng/ml. As yet, the lowest quantitation limit 
reported in the literature is 0.1 ng/ml [11, 26], and given that the extraction 
efficiency of neutral molecules by iontophoresis does not usually exceed 20 
µl/h.mA [3], tacrolimus sampling by reverse iontophoresis is not feasible. Similarly, 
the neutral drug digoxin does not appear to be, as yet, a suitable analyte that can 
be monitored non-invasively by reverse iontophoresis. This is due to its low 
systemic concentration (0.8 – 2 ng/ml) [6] and an analytical quantitation limit 
reported at only 0.25 ng/ml [26].  
Iohexol is an exogenous non-ionic glomerular filtration rate marker. The dose 
administered to the patient is high (1.3 – 3.2 g) and distributes across the whole 
extracellular fluid. It does not bind to proteins or cells and it does not enter cells. 
The typical concentration of the marker 2 and 6 hours after administration of 3.2 g 
dose to children are reported at > 100 and 10 µg/ml, respectively [27]. It follows 
that with analytical quantitation limits reported as low as < 0.2 ng/ml [28], reverse 
iontophoresis of iohexol appears to have a potential application. 
To sum up, based on balancing the properties preferred for transdermal 
iontophoresis candidates, three drugs were selected for investigation of possible 
delivery applications (ranitidine, midazolam, and phenobarbital) and one 
therapeutic agent was identified for clinical sampling application (iohexol). 
4. Organisation of the thesis 
The first chapter begins with an examination of the principals of conventional 
paediatric medicine. It then introduces the transdermal route as an alternative 
approach for drug delivery and clinical sampling. This is finally followed by a special 
focus on iontophoresis, the centre point of investigation of this thesis. 
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The second chapter presents the in vitro and in vivo examinations of reverse 
iontophoresis of iohexol as an alternative non-invasive technique to blood 
sampling, for the monitoring of kidney function. 
The third, fourth, and fifth chapters investigated the in vitro feasibility of 
iontophoretic delivery of ranitidine, midazolam, and phenobarbital, respectively, 
through the skin at sufficiently high levels as to provide systemic therapeutic 
concentrations. Different conditions potentially affecting the iontophoretic delivery 
of these drugs were evaluated. Iontophoretic delivery of ranitidine was performed 
using both liquid (aqueous solution) and semi-solid (poloxamer gel) formulations. 
Transdermal delivery of midazolam and phenobarbital was examined using both 
intact and compromised skin to mimic the different skin barrier functions found in 
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1. Paediatrics: a special category of medicine 
Paediatric medicine is a discipline concerned with the clinical care of infants 
and children. The paediatric population is subdivided into age-related groups, 
starting from the neonate or newborn (birth – 1 month old), then the infant (1 – 12 
months old), followed by the child (1 – 12 years old), and finally the adolescent (13 
– 18 years old) [1]. Traditionally, drug therapy for children has been based on the 
principle that a child is just a “small” adult. This concept has been found to be 
therapeutically incorrect as a child is not only different from an adult by size and 
weight but also due to age-related physiological developments which lead to 
differences in the pharmacology of drugs and distinct drug efficacy, toxicity, and 
dosing regimen profiles [2-5]. The body of the paediatric subject is continuously 
developing from the most immature form at birth until it is equivalent to that of a 
young adult. The first year of life experiences the most rapid changes and 
development continues thereafter but at a slower pace [3]. Organs and systems 
whose development progressively changes during childhood include the 
gastrointestinal tract, the liver, the kidneys, and the body weight proportions 
contributed by the total body water (the sum of intracellular and extracellular 
water volume), body fat, and proteins [2-4]. All these features affect the drug 
disposition in the body (i.e. its pharmacokinetics: absorption, distribution, 
metabolism, and elimination) [3, 6, 7]. Although not as widely studied as the 
developmental changes affecting drug pharmacokinetics, age-dependent 
pharmacodynamic differences, either by alteration of the drug-receptor binding 
affinity or in the relation of the pharmacological effect exerted by the drug to its 
plasma concentration, have been reported for several drugs [8-11]. 
Unfortunately, the insufficiency or sometimes even the absence of clinical 
studies evaluating paediatric medicines leaves the physician in a dilemma as to 
what is the optimum dose to give; and with no guidance on the efficacy and toxicity 
they are forced to follow a “trial-and-error” approach whereby the licensed adult 
dosage regimen is scaled down according to the child’s weight/size and response is 
monitored. A previous study evaluated the extent of using unlicensed and off-label 
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drugs in more than 600 children (Age: 4 days – 16 years) and found that over half of 
the prescriptions were outside the license of the medicine [12]. Another survey 
collected data from treatment courses prescribed to 70 neonates in the intensive 
care unit and found that more than 90 % of administered therapies were not 
approved (including both unlicensed and off-label use) [13]. 
2. Conventional routes of drug administration and clinical sampling 
The principal routes of drug administration to paediatric patients are oral and 
intravenous. The former is the preferred route of administration as it is the least 
“interfering” to the quality of life of the patient [14]. In ideal paediatric practice, 
oral formulations are designed to be child-appropriate (e.g. solid and liquid based) 
to suit the swallowing ability and willingness of the child; and at various strengths 
to meet the different dosage requirements which vary according to the age and 
weight of the child. In reality, however, there is a significant lack of choice of 
available paediatric formulations. The “Make Medicines Child Size” initiative which 
was launched by the World Health Organisation at the end of 2007 highlights this 
crucial shortfall in paediatric practice and calls for the promotion of child-specific 
medicine.  
Unlike adults, the formulation in which the drug is incorporated is crucial in 
paediatrics because it is the fundamental reason for successful oral delivery intake. 
Solid dosage forms such as tablets and capsules are inappropriate for neonates, 
infants, and young children. Even though it is usually accepted that children of 
school age are able to swallow solid dosage forms after some training [15, 16], the 
risk of accidental choking or aspiration should always be considered. Furthermore, 
many tablets are only available as fixed high strength doses originally designed for 
adults. To deliver age-appropriate doses for children, they are usually split to 
provide the smaller doses but this practice leads to highly variable doses even when 
a commercially available tablet cutter is used [17]. One study reported a difference 
of 50 – 150 % of the theoretical weight of the split portion of the tablet [18].  
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Liquid formulations are the most acceptable oral dosage forms for children 
but unfortunately they are not available for many essential paediatric drugs and 
clinicians often resort to crushing the tablets and dispersing fractions in a suitable 
vehicle (which can be water or even soft food) and probably other excipients to 
improve the solubility. Such practice is common and can lead to wide variability in 
the dose ingested, as well as stability, bioavailability, and safety issues [14, 19-21]. 
Commercial liquid formulations of bitter-tasting drugs are difficult, and often 
expensive, to mask the taste and smell of and will potentially lead to refusal of the 
child to consume the medication [22]. Stability of drugs present another limitation 
in liquid based formulations, especially in the case of diluted medicaments which 
are often executed because the available dose formulations are too concentrated 
for the child. Measurement of the required volume from a liquid formulation can 
also introduce inaccuracies in the dose delivered which may be detrimental to the 
patient’s health especially with potent drugs with a narrow therapeutic index, or 
when given to very young babies.  
The absorption of oral drugs can be highly variable and unpredictable due to 
the incomplete maturation of the child’s gastrointestinal tract [3]. Examples of the 
developing physiological processes include gastric acidity and emptying time, 
intestinal surface area and motility, gastrointestinal enzymes and efflux 
transporters, biliary function, first-pass metabolism, and enterohepatic 
recirculation [2-4, 6, 7]. Furthermore, gastro-oesophageal reflux which is very 
common in babies up to the age of 1 year may result in regurgitation of the 
administered drug into the oesophagus and can therefore affect its absorption. 
The intravenous route is employed when the clinical condition of the child 
does not allow for oral administration. Examples include seriously ill children, 
patients with nausea/vomiting, and uncooperative children. Very young babies are 
also administered drugs mainly by the intravenous route. In addition, certain drugs 
are either inactive or cause irritation when given orally and are therefore 
administered intravenously. The intravenous route is superior to oral delivery in 
that it by-passes losses due to incomplete absorption and first pass metabolism and 
results in 100 % bioavailability and a fast onset of action. However, the procedure 
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causes significant stress, pain and discomfort to the paediatric patient. In fact, 
needle insertion was found to be one of the most frightening hospital experiences 
that children recall [23, 24]. Additional pitfalls include the invasive nature of the 
intravenous route as well as the risk of causing infection and extravasation. These 
risks are even greater in children receiving multiple intravenous drug therapy, 
which is the case for most patients in the intensive care unit, who often have 
several intravenous access lines to avoid compatibility issues. Technical difficulties 
may, in addition, pose a challenge to the medical team whereby, for example, it 
may be very hard to find a suitable vein in a distressed child or a very young baby. 
Commercial intravenous formulations are often too concentrated and toxicity has 
been reported after slight over-administration of a small undiluted volume of the 
drug [25]. Hence, physicians resort to serial dilutions but these are commonly 
associated with calculation and measurement errors [26], in addition to the stability 
and sterility concerns of such extemporaneous preparations. Finally, formulation 
safety requirements must be taken into consideration including the pH, osmolality 
[27], and the type of solvents and excipients used [28, 29].  
The intravenous route is the major sampling pathway for therapeutic drug 
monitoring and diagnostic testing in paediatric patients. As well as the 
disadvantages outlined above concerning distress to the child, risk of infection and 
technical difficulties, the volume of blood specimen to be sampled must be 
minimal. This is especially important in neonates who only have around 80 ml/kg 
circulating blood volume [30]. Blood sampling for this special group is also 
performed more frequently than any other paediatric subpopulation and anaemia 
in young infants is frequently reported as a result. This often leads to blood 
transfusions to compensate for the lost blood [31, 32] and adds additional risks 
associated with blood transfusions. 
There is clearly a persistent unmet need for paediatric research and for 
tailored, age-appropriate dosage forms which provide optimum therapy; and the 
younger the age of the child the greater requirement for improvement. Optimum 
therapy not only includes achievement of accurate, predictable, and effective 
dosing and avoidance of adverse effects; but it also needs to address patient 
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acceptance (e.g. distress caused by injections, unpalatability of liquid oral 
formulations) and ability (e.g. swallowing solid oral dosage forms) which will 
ultimately lead to noncompliance issues. Children were described as “therapeutic 
orphans” back in 1968 [33] and although much has improved since then, paediatric 
medicine has still not realized the same achievements of “adult” medicine. 
Evidently, not only much improvement is needed within the oral and intravenous 
pathways but also other routes of administration/sampling should be explored. In 
this thesis, a “paediatric-friendly” yet potentially effective strategy to deliver and 
sample medicinal compounds by the transdermal route is considered. 
3. The transdermal route: Alternative non-invasive drug delivery and 
clinical monitoring  
Drug delivery and clinical sampling through the skin as an alternative route is 
very attractive in the paediatric population. First of all, it circumvents many of the 
difficulties faced with the oral and intravenous routes. It is easily accessed, 
minimally invasive, and painless as it does not involve the use of needles. 
Treatment using the transdermal route is therefore more likely to be acceptable for 
the paediatric patient. In addition, the transdermal route by-passes the first pass 
metabolism of oral delivery, the unpredictable oral absorption, as well as the 
unpalatability issue of liquid formulations. Transport rates can be controlled to 
deliver doses or sample analytes over extended periods of time. This makes 
transdermal delivery ideal for drugs used for chronic conditions (it is estimated that 
1 in 5 children in the UK suffers from a chronic illness [34]) to provide steady levels 
of drug input and avoid the peak and trough effects observed with many oral 
products and with bolus intravenous injections; yet without the requirement for an 
intravenous infusion. Neonates will also benefit significantly from the transdermal 
route as they are often administered drugs by multiple and prolonged intravenous 
access. Sampling of drugs or clinical markers such as glucose by the transdermal 
route allows for frequent extraction points without the drawbacks of multiple blood 
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samples. This will allow for more accurate profiling of the levels of the analyte of 
interest minus the disadvantages and risks associated with intravenous sampling. 
3.1 The skin 
The skin is the largest organ in the body and is the interface between the 
internal body components and the external environment [35]. The characteristics of 
the skin in almost all of the paediatric sub-populations resemble adult skin [36, 37]. 
The exception is with premature babies born before 34 weeks gestation where the 
structure of the skin is not fully developed and the stratum corneum in particular is 
thinner than normal [36-39].  
The structure of mature human skin is composed of 3 distinct layers (Figure 
1): the subcutaneous tissue (also called hypodermis), the dermis, and the 
epidermis. Specialised structures including hair follicles, sebaceous glands, sweat 
glands (eccrine and apocrine), nerve endings and blood vessels are also present [35, 
40].  
The subcutaneous tissue is composed of a network of fat cells, fibroblasts and 
macrophages and is the innermost layer of the skin which connects to the dermis 
by collagen and elastin fibers. It serves as an insulator to the body by protecting it 
from heat and physical shock. In addition, the subcutaneous tissue carries the 
major neural and vascular systems for the dermis.  
The dermis is composed of connective tissue which embeds several 
specialized structures. These include dermal adipose cells, hair follicles, sebaceous 
and sweat glands, lymphatic vessels and nerve endings. The dermis is also highly 
vascularised and the blood microcirculation is organised into two networks: the 
superficial vascular plexus spread just below the epidermis-dermis interface, and 
the deep plexus located at the junction of the dermis-subcutaneous tissue [41]. 
Through the vascular system, the dermis has an important role in the regulation of 
body temperature and the supply of oxygen and nutrients to the epidermis and 
dermis  itself  while  also  removing  waste  and  toxins. Other important roles of the  
Figure 1: Illustration of 
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This mixture mainly includes ceramides, cholesterol, and free fatty acids. Other 
lipids present in the “mortar” phase are di- and triglycerides, cholesterol sulphate, 
and sterol/wax esters.  
The special architecture of the stratum corneum is responsible for the highly 
tortuous path to permeation and ensures excellent protective barrier function both 
inside-out, by controlling the exit of endogenous substances such as water loss, and 
outside-in barrier against the entrance of pathogens, chemicals, and radiation to 
the body. The stratum corneum is, therefore, a very effective barrier against the 
transdermal passive delivery and sampling of drugs and analytes [35, 40] and 
successful transport at therapeutically acceptable levels is limited to molecules with 
very specific properties [44]. 
As mentioned earlier, the structure of the skin in the premature neonate, 
born before 34 weeks gestation, is underdeveloped and is considerably different 
from that of the full-term neonate [36-39] in which case it exists as a fully functional 
barrier resembling intact adult skin [36, 37, 45]. Underdevelopment is observed in 
all layers of the skin structure (i.e. subcutaneous tissue, dermis and epidermis) [36, 
38, 46] but probably the most important immaturity is in the epidermis layer and 
more critically the stratum corneum. The latter is strikingly thinner with altered 
lipid composition and structure [36-39, 47]. Nevertheless, the skin of premature 
infants will reach full maturity after 2 – 3 weeks of postnatal period [37] but very 
premature neonates may require up to 8 weeks for full development to be achieved 
[45]. The two major clinical hazardous consequences from an immature skin are the 
excessive water and heat losses from the body [48]. The stratum corneum is 
significantly more permeable and application of topical products (for example 
alcohols used as antiseptics [49]) may lead to significant systemic absorption and 
eventually life-threatening toxic effects. The increased permeability property could, 
however, be explored to the neonate’s advantage by transdermal delivery or 
sampling of drugs and clinical analytes which may be otherwise considered 
unsuitable candidates to permeate through a fully developed skin barrier.  
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The following section provides examples of in vivo permeation studies and 
approved transdermal systems, some of which are applicable to paediatric subjects 
including the premature subgroup.  
3.2 Passive transdermal systems:  
The use of the transdermal route to therapeutically deliver and sample 
analytes into and from the body is significantly limited by the low permeability of 
the intact skin barrier and specifically the stratum corneum. Drugs applied on the 
skin permeate through by passive diffusion [50] and the permeability coefficient of 
the drug (Kp), which is formulation-dependent, is given by: 
 = ∙                                                                                                   Equation (1) 
Where K is the drug’s partition coefficient between the donor vehicle and the outer 
layer of the stratum corneum. H is the length of the diffusion path and D is the 
diffusivity of the drug within it. Drug permeation at steady state can be described 
by Fick’s first law of diffusion, and the flux per unit area (Jss) is defined in a simple 
form as [51]:  
 		 =  ×                                                                                 Equation (2) 
Where C is concentration of the drug in the donor vehicle. According to the 
previous two relations, transdermal drug delivery by passive diffusion can be 
optimised by manipulation of K, D, and C. 
Since the start of the transdermal patch developments in the 1970s, over ten 
transdermal passive drug systems reached approval and commercialization. These 
include the passive delivery of the first-approved transdermal drug: scopolamine 
for motion sickness, fentanyl for chronic pain management (approved for children > 
2 years old), methyphenydate for attention deficit hyperactivity disorder (approved 
for children > 6 years old), buprenorphine for chronic pain relief, selegiline for 
depression, nitroglycerin for angina, clonidine for hypertension, nicotine for 
smoking cessation, oxybutynin for overactive bladder, rotigotine for Parkinson’s 
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disease, testosterone for hormone replacement, and oestradiol and northisterone 
for hormone therapy and contraception [52, 53]. In addition to the transdermal 
patches, other drugs used for local effects include the anaesthetic lidocaine which is 
licensed for the dermal relief of pain associated with post-herpetic neuralgia in 
adults. It is also marketed as a cream (EMLA®, AstraZeneca PLC, London, UK) 
containing a eutectic mixture with prilocaine and is widely used in children > 1 year 
old to provide dermal anaesthesia prior to clinical procedures (e.g. venipuncture 
and intravenous catheter placement) [52, 54]. Most of the drugs mentioned above 
have common properties in that they are therapeutically very potent agents (i.e., 
daily doses < 10 mg) and possess certain physicochemical properties (e.g., MW < 
500) which render them suitable for passive delivery [44].  
There are no transdermal passive systems currently approved for premature 
neonates. A few in vivo studies investigated the passive permeation of the 
methylxanthines: theophylline and caffeine through the premature neonate skin 
and delivery at therapeutic levels was achieved [55-58]. These drugs are frequently 
used in the treatment of neonatal apnea, a very common condition in premature 
infants which requires several weeks of treatment [59]. In addition, therapeutic 
drug monitoring especially in the case of theophylline is important to avoid 
dangerous side effects (e.g. tachycardia) [59]. A previous study [60] attempted 
transdermal passive extraction of theophylline in premature babies and the rates of 
extracted drug were shown to correlate to the corresponding plasma 
concentrations measured by the conventional blood sampling method [60].  
As stated above, for a compound to be suitable for transdermal passive 
delivery, it must meet strict characteristics. This poses a great limit to the range of 
therapeutic agents that can be delivered or sampled transdermally. In addition, a 
major pitfall with passive transdermal systems is the significant lag time for the 
permeation rates to provide a therapeutic systemic concentration. For example, for 
theophylline and caffeine permeation studies mentioned earlier, this was found to 
be 22 and 48 hours, respectively [56, 57].  
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The following sections introduce the concept of iontophoresis which is a 
physical enhancement method by which a wider spectrum of medicinal compounds 
can be delivered/sampled efficiently at significantly higher quantities by the 
transdermal route and at shorter lag times required to reach therapeutic systemic 
levels. 
3.3 Active transdermal delivery systems: Iontophoresis  
Transdermal iontophoresis is one of the many physical enhancement 
methods used to improve the delivery/sampling of medicinal compounds through 
the skin [44, 61]. The basic mechanisms of iontophoresis were recognised over 100 
years ago but it was only in the past few decades that interest in drug 
delivery/sampling applications has been renewed. Iontophoresis has been used for 
both local delivery and systemic applications and a small number of approved 
products have reached the market [62, 63] as a result of extensive in vitro and in 
vivo studies [64-66]. The technique involves the application of a low electrical 
current (≤ 0.5 mA/cm
2
) across the skin to enhance the transdermal passage of 
molecules at levels significantly higher than passive transport and in a highly 
controlled and sustained manner [65, 67, 68]. The spectrum of compounds that 
could be delivered or sampled is considerably extended when iontophoresis is used, 
relative to passive diffusion, to include: macromolecules such as peptides, proteins, 
and nucleotides, and charged and/or hydrophilic compounds. The characteristics of 
such compounds make them the least ideal candidates for passive diffusion.  
3.3.1 Description 
A typical iontophoretic device (Figure 2) consists of two electrode compartments, 
anodal and cathodal. Each chamber, already filled with a current-conducting 
medium (e.g., solution or gel), is applied on a different site of the skin and a pair of 
electrodes is placed in direct contact with the formulations held in the 
compartments [65]. A small electrical current is then applied via a current source 
which is connected to the electrodes. This causes the following electrochemical 
reactions:  oxidation at  the anode electrode  surface  and  reduction at the cathode   
 Figure 2: A schematic diagram illustrating a 
mechanisms of iontophoretic transport 
arrows for electromigration and grey arrows for electroosmosis.
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charged molecules (anions) migrate towards the anode. This is the principal 
concept for the direct effect of the applied electrical field on the transport of ions 
through the skin. 
3.3.2 Transport mechanisms  
There are three contributions to the total transport flux of a molecule (JT) 
during iontophoresis [68]: 
 =                                Equation (3) 
P denotes passive diffusion of the molecule which occurs irrespective of 
electrical current application and is the result of the concentration gradient present 
at each side of the skin. Passive diffusion of the permeant may however increase 
during the course of iontophoresis due to increased permeability of the skin. 
Electromigration (EM) is the direct interaction of the applied current with charged 
species which results in the ion’s migration to the electrode of opposite charge 
(Figure 2) [71]. Electroosmosis (EO) is due to the convective solvent flow induced as 
a result of the skin’s negative charge [72].  
Separation of the individual contribution of each of the above mentioned 
mechanisms is difficult. However, passive diffusion for charged and polar molecules 
across intact skin is usually negligible relative to the transport obtained with 
iontophoresis and it is generally assumed, and expected, that only electromigration 
and electroosmosis are the two dominant mechanisms during iontophoresis.   
3.3.2.1 Electromigration 
As mentioned earlier, ions (including the drug or analyte of interest) migrate 
towards the electrode chamber of opposite polarity in order to maintain 
eletroneutrality disturbed by the oxidation and reduction processes taking place at 
the anode and cathode, respectively, as a result of current flow. The rate at which 
each ion moves (i.e. electromigration flux, , mole/s) can be described by 
Faraday’s law [71]: 
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 = × !×"                           Equation (4) 
Where I is the current intensity applied (amperes), F is Faraday’s constant 
(coulombs/mole), # and $ are, respectively, the numerical value of the valence and 
the transport number of the ion. As equation (4) outlines, the transport flux of the 
ion is directly influenced by the current intensity applied (controlled externally by 
the iontophoresis device) and by the transport number of the drug. The latter 
parameter describes the efficiency of the ion of interest as a charge “carrier” 
relative to the other ions (both co- and counter- ions) present in the iontophoresis 
system which also compete to carry a fraction of the charge. The conservation of 
charge principle implies that the total applied electrical current must equal the sum 
of individual currents carried by each of the ions present in the system. The 
transport number of the drug ($%) depends on its own properties as well as those of 
competing ions [71]: 
$% = &'×('×!') *&+×(+×!+,+                 Equation (5) 
Where µ, c, and z are, respectively, the mobility, concentration, and absolute 
valence, within the skin, of either the drug (d) or any charge-carrying ion (i) in the 
iontophoresis system. For a binary cation delivery system, for example, the drug 
“-” competes with a co-ion “.-” in the anode and a counter-ion “.” (typically 
chloride which represents the principal skin charge carrier ion that competes 
against the cations by migrating from the opposite side (subdermal) of the skin). 
The same is true for a binary anion delivery system where the negatively charged 
drug competes along with another anion present in the cathode donor formulation 
and also competes with counter-ions migrating from the subdermal side of skin 
(typically sodium ions). 
 Further development of equation (5) by Phipps and Gyory yielded the 









                               Equation (6) 
Where $%/;  and $</;  are the transport numbers of the drug “-” and the co-
ion “.-” when present separately as the sole cation in the donor formulation 
(otherwise known as the single-ion condition) and, therefore, the only competition 
each cation is faced with is that from the counter-ion migrating from the opposite 
side of the skin. = is a proportionality constant which links the concentration ratio 
of the two cations within the skin to that in the donor formulation. >- and ?- are, 
respectively, the valence ratio (#</ #%/@ ) and the molar fraction ratio (A</ A%/@ ) of 
the two cations in the donor formulation (A</  A%/ = 1). The validity of this 
expression for several binary systems has been demonstrated by experimental data 
[71, 73]. However, prior knowledge of the factor = limits the usefulness of such 
application. A growing number of data have also revealed a simple direct linear 
trend between the transport number of some drugs and their molar fraction in the 
donor solution [73, 74]. 
Equation (5) also demonstrates that to achieve maximal transport for the 
drug, competition from the other ions (co- and counter- ions) must be minimised as 
much as possible. Competition from the endogenous counter-ions (principally 
chloride or sodium ions) is inevitable and cannot be modified. However, co-ions 
present in the donor formulation along with the drug can be minimised or 
sometimes even eliminated. The latter condition “single-ion”, as predicted by 
Kasting and Keister [75], demonstrates that the transport number of the drug 
becomes independent of concentration and is only a function of the drug’s 
diffusivity (C%) within the membrane relative to that of the counter ion (C<):   
$%; = ''-+                                                                              Equation (7) 
Finally, a note is made about the transport number which is sometimes 
referred to as “transference” number. This is when iontophoretic transport fluxes 
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cannot be solely attributed to electromigration only (i.e., electroosmosis also 
contributes to the total flux observed) [76]. 
3.3.2.2 Electroosmosis 
Electroosmosis is induced as a result of the skin’s negative charge at 
physiological pH which makes the membrane more permselective to cations [77-
79]. Hence, the electric current applied induces an electroosmotic convective 
solvent flow in the direction of cations migration (i.e., anode to cathode) [72, 77, 
80]; and any dissolved solutes including neutral and charged molecules will be 
carried along with this stream of solvent. It follows that the iontophoretic transport 
of cations is supplemented by electroosmosis as it occurs in the same direction as 
their electromigration. Nevertheless, the contribution of electroosmosis to the 
iontophoretic transport of relatively low molecular weight cations is small and 
electromigration tends to dominate [81, 82]. However, for neutral species and high 
molecular weight cations, it is especially important as 1) neutral molecules 
experience no electromigration; and 2) electromigration of larger cations is small 
because of their low transport efficiency relative to the total system (i.e., low 
transport number). 
The electroosmotic solvent flow (Jvs, volume.time
-1
) has been quantified 
directly but this is not readily simple [79, 83-86]. Indirect measurements through so 
called “electroosmotic markers” have been used extensively in previous research 
studies. Examples of markers used in previous work are mannitol and 
acetaminophen [81, 87]. The electroosmotic flux of a solute (Jeo, solute) can be 
expressed as follows [83]: 
DE,	EGHID = J	 ∙ 	EGHID ∙ *1 − L	EGHID, = > ∙ 	EGHID       
         Equation (8) 
Where Csolute and σsolute are, respectively, the solute concentration and its 
reflection coefficient at the membrane-solution interface [83, 88-90]. Z represents 
the iontophoretic transport efficiency of the solute through the skin; and is related 
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to the convective flow of the solvent (Jvs) as well as the reflection coefficient of the 
solute. The latter is a solute-membrane dependent index which reports on the level 
of reflection the permeant experiences, relative to the solvent, from the membrane 
as it is dragged through by the process of electroosmosis. 
3.3.3 Drug delivery applications 
A large number of studies have shown the ability of iontophoresis to deliver 
therapeutic doses of a wide variety of medicinal compounds. These include 
peptides and proteins [91, 92], oligonucleotides [93, 94], analgesics and local 
anaesthetics [95-106], anti-inflammatory drugs [107-117], anti-viral compounds 
[118-121], anti-Parkinson drugs [122-124], and anti-migraine agents [125-127].   
There are currently three approved iontophoretic drug-prefilled delivery 
devices. The Macroduct
®
 (approved for all ages including neonates) which locally 
delivers pilocarpine to diagnose cystic fibrosis (Figure 3), the LidoSite
TM
 system 
(approved for children > 5 years old) which delivers lidocaine for local anaesthesia 
(Figure 4), and the Ionsys
TM 
for the systemic delivery of fentanyl to relief post-
operative pain (Figure 5).  
Iontophoretic delivery of pilocarpine has been used extensively for several 
decades as a reliable test for the diagnosis of cystic fibrosis. The iontophoretic 







Figure 3: The Macroduct
®
 iontophoretic system (Wescor Inc, Utah, USA) for 











Figure 4: The LidoSite
TM
 iontophoretic system (Vyteris Inc, NJ, USA) for dermal 
anaesthesia [129]. 
 
then collected in the electrode compartments and quantified for chloride levels. 
High concentrations of chloride are indicative of cystic fibrosis [130]. 
LidoSite
TM
 (Figure 4) was recently launched for use in subjects over 5 years 
old to minimise pain, by means of dermal anaesthesia, associated with invasive 
clinical procedures (e.g. venipuncture and intravenous catheter placement). This 
product is the culmination of considerable research which realised the special 
advantage of rapidly and more efficiently achieving dermal anaesthesia by lidocaine 
iontophoresis relative to passive permeation only. EMLA® eutectic cream is one 
popular example used to passively deliver lidocaine for dermal anaesthesia. While 
the use of this system requires 1 – 2 hours to reach desired effects and at only 3 – 5 
mm depth [131, 132], iontophoresis of lidocaine was shown to have a much faster 
onset of action of ~ 10 minutes and a depth of anaesthesia reaching 6 – 10 mm 
[104, 105, 133-135]. In addition, comparative studies in children showed either 
superior or similar anaesthetic effect with lidocaine iontophoresis relative to EMLA 
cream [95, 106]. The systemic absorption of iontophoresed lidocaine was also 
found to be negligible despite repeated application [136] and the same study 













Figure 5: The Ionsys
TM
 iontophoretic system (Janssen-Cilag Ltd) for acute pain 
control post-operation [137]. 
 
years). The efficacy, safety, and tolerability of lidocaine iontophoresis was further 
confirmed in a large randomized, controlled trial which involved 548 subjects, half 
of which were children (Ages: 5 – 17 years old) [138]. 
Also launched recently is the Ionsys
TM 
transdermal iontophoretic device 
(Figure 5) for the systemic delivery of fentanyl to manage post-operative acute 
pain. In comparison with the passive fentanyl patch mentioned earlier (section 3.2) 
which is only approved for chronic pain management, the fast onset of action of the 
iontophoresis patch granted its application in acute pain management whereby a 
quick onset of analgesia is the ultimate goal for a successful therapy [137, 139]. The 
Ionsys
TM 
system is programmed to deliver, on-demand, a dose of 40µg of fentanyl 
over a period of 10 minutes at 0.17 mA current. This is for a maximum number of 
80 doses or a maximum duration of 24 hours, whichever is first. This dosage 
regimen was based on earlier in vivo studies which studied the systemic 
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concentrations of fentanyl resulting from different current intensities used [140, 
141]. The effectiveness of Ionsys
TM
 at post-operative pain control was reviewed 
relative to the conventional intravenous morphine patient-controlled analgesia 
(PCA) system and an equally effective analgesic effect was found [142] with the 
obvious yet crucial advantage of the non-invasiveness of the transdermal route. 
3.4 Active transdermal systems for clinical sampling: Reverse 
iontophoresis 
3.4.1 Definition 
Owing to the symmetrical nature of iontophoresis, both transdermal delivery 
and sampling of molecules to/from the body are possible [143]. That is, the same 
applied current that promotes exogenous molecules to cross the skin and enter into 
the body, also drives analytes, present in the subdermal (interstitial) fluid, to move 
towards the external surface of the skin and be collected in a suitable collection 
device (Figure 2). The latter is referred to as “reverse iontophoresis” [67, 68]. The 
molecules extracted by reverse iontophoresis are originally present in the 
interstitial (subdermal) fluid that bathes the skin, which in turn is in direct 
communication with the blood, the main compartment for conventional sampling. 
The interstitial fluid can therefore serve as a good alternative sampling matrix for 
analytes.  
Obviously, the transport mechanisms of reverse iontophoresis are exactly the 
same as iontophoresis (section 3.3.2). Cations and neutral analytes are therefore 
sampled at the cathodal side, while anions are assayed at the anodal side of the 
collection device. 
3.4.2 Internal standard 
In order to be able to correlate the reverse iontophoretic flux of the extracted 
analyte to its corresponding systemic concentration in the body, a calibration 
methodology must be employed whereby a proportionality factor is used to 
convert the extraction fluxes into “clinically meaningful” conventional numbers. 
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Moreover, due to potential inter- and intra-subject variations in the 
extraction efficiency of the analytes, a calibration concept using an “internal 
standard” was introduced [144, 145] and its extent of validity was tested in vivo for 
several analytes [146-148]. This approach takes advantage of the fact that: A) 
iontophoresis is non-selective and several analytes are simultaneously extracted to 
the appropriate electrode collection device; and B) amid these extracted analytes 
are some endogenous molecules which tend to be present in the body almost 
always at invariable concentrations (e.g., sodium and potassium). It follows that 
iontophoretic extraction of such molecules (JIS), labelled as internal standards, is 
effectively constant when compared to the solute of interest whose extraction 
values (Jsolute) depend on its respective systemic concentrations (Csolute). A 
proportionality factor (γ) can therefore be drawn relating the extraction fluxes of 
both analytes to their corresponding systemic concentrations: 
MNOPQRS
MTU = V. XNOPQRSXTU               Equation (9) 
If the proportionality factor and the systemic concentration of the internal 
standard (CIS) are indeed constant in a wide subject population, equation (9) can be 
rewritten as:  
MNOPQRS
MTU = V#. 	EGHID             Equation (10) 
Using equation (10), where V# = V  Z@ , the systemic concentration of the 
solute of interest can, indeed, be determined solely from the extraction flux data.  
3.4.3 Clinical sampling applications 
The effectiveness of using transdermal reverse iontophoresis as an alternative 
sampling technique demonstrated its usefulness in humans. Previous in vivo studies 
included lithium monitoring in bipolar patients [146], phenylalanine monitoring in 
phenylketonuria [149], urea sampling for the diagnosis and monitoring of chronic 
kidney disease [150], lactate [151], various amino-acids [152], and glucose sampling 
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3.5 Pathways of transport 
With the exception of some highly lipophilic molecules, the stratum corneum 
is the rate-limiting layer of the skin to the transport of most compounds. There are 
three pathways by which molecules move across intact stratum corneum: 
intercellular (or paracellular), intracellular (also called transcellular), and 
appendageal (also referred to as shunt) routes. The latter transport pathway exists 
due to the hair follicles and sweat ducts which offer low electrical resistance, 
natural “pores” at the surface of the skin. It has, therefore, been suggested that the 
shunt route plays an important pathway to iontophoretic transport [159] because 
the flow of current will follow the least resistant pathway provided by the shunt 
route. This has indeed been confirmed by several studies using different methods 
to identify the contribution of the principal pathway both in the case of ionised and 
neutral compounds.  
Using a vibrating probe electrode to scan the surface of hairless mouse skin, 
the appendageal structures were found to carry most of the applied current [160]. 
Several subsequent studies [85, 161-164] used scanning electrochemical 
microscopy (SECM) to visualise the principal route of transport for both neutral and 
ionised molecules across either hairless mouse skin or human skin; and further 
confirmation of the localization of iontophoretic transport to appendageal 
pathways was found. These observations were subsequently re-enforced by 
another set of studies [165, 166] which employed a different technique to evaluate 
the shunt route contribution by means of using a skin sandwich. The latter 
comprised a piece of human stratum corneum placed on the top of a section of an 
epidermis from the same sample of human skin to effectively block the appendages 
of the lower stratum corneum. Iontophoretic transport of neutral and charged 
molecules was then tested and fluxes were compared to those obtained across 
human epidermis only and confirmed the importance of the appendageal route in 
iontophoresis. 
Nevertheless, the intercellular pathway was also found to contribute as the 
dominant route for the iontophoretic transport of some compounds such as 
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mercuric ions [167]. The contribution of the intercellular and appendageal 
pathways during iontophoresis may well depend on the physicochemical properties 
of the permeant [168-170].  
3.6 Tolerability and safety of transdermal iontophoretic applications 
It must be acknowledged that when evaluating transdermal iontophoresis 
applications, the whole system should be considered. This includes all solutes and 
solvents used in the anode and cathode formulations (including the drug to be 
delivered) as well as the polymers used for example in the adhesive material 
necessary to affix the patch into the skin. All these components may themselves 
provoke skin irritation. Potential irritation or tissue trauma may result from the 
adhesive material and children are also usually scared of adhesive removal. This 
may subsequently lead to noncompliance. Further, the skin of premature neonates 
is especially prone to tissue trauma after adhesive removal because their skin is 
already compromised. There are, however, new technologies with both good 
adhesive properties and gentle effect on the skin when the patch is removed, 
ensuring less perturbation to the stratum corneum [171]. Finally, transdermal 
formulations for drug delivery usually contain high doses of the active ingredient. 
Accidental sucking, chewing, or sometimes ingestion of the transdermal patch by 
the child can potentially lead to fatal toxicities [172]. Strict guidelines for use and 
disposal of the patches are of paramount importance when the transdermal route 
is used in paediatric patients. 
Iontophoresis is well supported, by clinical experience and various non-
invasive bioengineering methods, as a safe procedure. The most frequent effects 
reported are tingling sensation during current application and erythema which 
tends to resolve quickly after current termination [173]. The tingling sensation is 
mostly felt at the beginning of iontophoresis and it can be minimised by “ramping” 
up the current slowly to the desired intensity over the first few minutes of 
iontophoresis. A general upper limit of 0.5 mA/cm
2
 current density ensures minimal 
effects but incorrect use of the iontophoresis system may result in tissue irritation 
or even burning.  
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Several techniques were used in vivo to evaluate the acute effects of 
iontophoresis application on the barrier function of intact skin [174, 175]. These 
include non-invasive biophysical techniques such as transepidermal water loss 
(TEWL), attenuated total reflectance-fourier transform infrared (ATR-FTIR) 
spectroscopy, impedance spectroscopy (IS), and laser doppler flowmetry (LDF). 
TEWL, which as the name suggests measures the loss of water from the skin 
providing a very good indicator of the barrier integrity of the skin, was found to 
increase but this was attributed to enhanced hydration of the skin due to exposure 
to the applied formulation [176, 177]. ATR-FTIR records spectra of IR absorbance by 
the skin components and provides details on the ordering of the intercellular lipids 
of the stratum corneum as well as the level of hydration. From available data, 
iontophoresis does not seem to cause any significant effect apart from that 
associated with formulation exposure effect (in the absence of current) [176, 178]. 
Low-frequency IS, which measures the electrical resistance of the skin to the 
movements of ions through it, revealed a quick decrease in the skin’s resistance 
during current application. This is obviously due to the fact that during 
iontophoresis, ions move across the skin at high levels which will result in reduction 
of the skin’s electrical resistance. The recovery of skin impedance post-
iontophoresis depends on the duration of current application as well as the density 
of the applied current [179]. LDF measures the cutaneous blood perfusion non-
invasively. Local erythema observed post-iontophoresis is indicative of increased 
blood flow to the application area and this has indeed been confirmed by higher 
LDF measurements after iontophoresis application [176, 177]. 
3.7 In vitro transdermal permeation studies:  
For obvious ethical, economic, and practical reasons, skin permeation studies 
are usually evaluated in vitro before in vivo investigations are deemed necessary or 
valid. The design of an in vitro experiment should, therefore, mimic in vivo 
conditions as close as possible. A typical in vitro setup for iontophoretic drug 
delivery involves the use of diffusion cells, a model skin membrane separating the 
diffusion cell compartments, mediums representing the drug formulation in the 
donor chamber and a receptor phase 
finally suitable electrodes and a power source
this thesis are shown in Figure 
either at the anode or cathode chamber depending on the drug’s charge. Similarly, 
for reverse iontophoresis experiments, the analyte, present in the
compartment,  is sampled at either the anode or cathode chambers (or sometimes
both) depending on the analyte’s charge. 
 
  
Figure 8: Schema of side
compartments (left) or three compartments (righ
 
Pig skin was implemented for all permeation studies in this thesis because it is 
considered a suitable biological model to human skin. This is due to the 
considerable similarities observed in skin physiological properties (e.g. stratum
corneum thickness), biophysical properties (e.g. TEWL  and low
permselectivity (isoelectric point), and permeability properties to several 
compounds [78, 180-
Both intact and 
pig skin represented
majority of the paediatric population,
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placed in the subdermal compartment
. The types of diffusion cells used in 
8. The drug formulation to be delivered 
 
-by-side diffusion cells, composed of either two 
t). 
186].  
barrier compromised pig skin were used in this thes
 the fully developed barrier function which is found in the 











underdeveloped skin barrier found in premature neonates. The rationale for using 
compromised pig skin as a model to premature skin is as follows:  
Determination of the thickness of the stratum corneum is usually made by 
sequential tape-stripping of the skin and the level of barrier function removed is 
precisely guided by measurements of TEWL. In a previous study [183], the thickness 
of intact pig skin was found to be 11.8 ± 4.0 µm which was strikingly similar to that 
of human intact skin (10.9 ± 3.5 µm). By using the same concept of TEWL 
measurements, the skin of premature babies, whose barrier function is recognized 
to be compromised due to the incomplete development of the stratum corneum, 
was modelled in vitro by differentially-stripped, and therefore compromised, pig 
skin whereby the TEWL of the barrier function level mirrors that found for the skin 
of premature babies of different post-conceptional age [187]. Figure 9 shows the 
striking similarity when the TEWL measurements from the two barriers were 
superimposed. A subsequent study by the same group demonstrated that, by using 
the in vitro data obtained with differentially-stripped pig skin, the in vivo 
transdermal drug permeation behaviour could be predicted (at least comparatively) 








Figure 9: The transepidermal water loss parameter is used to link the barrier 
function properties of neonates (expressed empirically as days of the post-
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Non-invasive monitoring of kidney 
function: in vitro and in vivo sampling of 






The objective of this study was to assess the feasibility of transdermal reverse 
iontophoresis, as an alternative approach to blood sampling, for monitoring kidney 
function using iohexol as the GFR marker. 
First, in vitro experiments were performed using abdominal pig skin. 
Correlation between iohexol subdermal concentrations and the corresponding skin 
extraction fluxes was evaluated. Then, to reduce the time required for iohexol skin 
sampling to achieve steady extraction, a 3 hour pre-treatment of the skin with 
direct current was introduced. Finally, simulations of iohexol subdermal 
concentration decay over time, representing different pharmacokinetic profiles, 
were performed. Transdermal extraction fluxes were measured to evaluate 
whether the changes in the subdermal concentration of the marker were followed 
and whether kinetic parameters determined from the two sets of data were 
correlated. After a delay, extraction fluxes of iohexol tracked the corresponding 
subdermal concentrations well. The 3 hour pre-treatment period was modestly 
effective in reducing the time for extraction fluxes to reach steady levels. The 
simulated pharmacokinetic parameters of iohexol were estimated reliably and 
precisely from the iontophoretic extraction data. Overall, these in vitro results 
demonstrated encouraging potential for in vivo applications. Such was the focus of 
the subsequent investigation.  
An in vivo study was performed in four children, undergoing a routine iohexol 
GFR test. The test involved an intravenous bolus dose of iohexol, followed by blood 
samples taken approximately 3 and 4 hours later to determine the marker’s 
clearance and hence GFR. Iontophoresis was performed simultaneously for 5.5 
hours, extraction samples were collected at approximately 2.5, 3.5, 4.5, and 5.5 
hours post-injection, and were analysed for iohexol. Iontophoresis was well-
tolerated and all participants completed the study. Iontophoresis caused mild 
erythema and slight tingling and itching sensations. Iohexol was successfully 
extracted by reverse iontophoresis and was quantified together with sodium and 
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potassium. After the first 2 hours of current application, the iohexol extraction rates 
tracked the decreases in iohexol’s blood concentration during the elimination 
phase. In three of the four subjects, elimination rate constants determined from 
reverse iontophoresis agreed well with the blood sampling data. The GFR values 
estimated using both sampling approaches highlight the potential of reverse 
iontophoresis as an alternative sampling approach in the iohexol GFR test. In 
summary, the results obtained provide in vivo proof-of-concept and a larger study is 
now justified for further optimisation and validation. Such non-invasive alternative 
sampling approach would significantly improve the quality-of-life of children 






Monitoring glomerular filtration rate (GFR), as a sensitive indicator of kidney 
function, is an integral part of clinical medicine. It is used for diagnosing and 
monitoring the progression of disease, evaluation of treatment efficacy, and 
achievement of optimum therapy whilst avoiding over- or under- dosing (e.g., in 
chemotherapy). GFR is determined indirectly through measurement of the 
clearance of “filtration markers”. Ideally, these markers are non-toxic substances 
which are exclusively and completely cleared by the glomerulus, are neither bound 
to blood cells or proteins, metabolised, nor renally reabsorbed. It is for the 
aforementioned reasons that the measured clearance of an ideal filtration marker is 
equivalent to the patient’s GFR. 
Rapid advances in the medical field necessitated ongoing efforts to improve 
GFR quantification. Investigations started back in 1928 when the concept of marker 
clearance, as a measure of kidney function, was introduced [1]. Since then, several 
markers have been proposed for GFR measurements [2]; but with limitations: 
creatinine, for example, can give an inaccurate estimation of GFR as its levels in the 
blood are affected by nutrition, diet, and muscle mass (age and gender dependent) 
[3]. Tubular secretion, which can be erratically variable, also plays a role in its 
clearance and this makes creatinine less than an ideal renal marker [3, 4]. Although 
traditionally regarded as the gold-standard for GFR estimation, inulin needs to be 
continuously administered by injection, and collection of timed urine samples is 
required to obtain the correct GFR value. These limitations make the use of inulin 
unpopular especially in children [2, 5, 6]. Radio-labelled markers (e.g., 
51
Chromium-
labelled edetic acid, Cr-EDTA ) have also been used but are impractical owing to the 
expensive cost, the special requirements a hospital needs for the handling, storage, 
and disposal of radioactive compounds, the relatively large blood samples required 









Figure 1: Chemical structure of iohexol (M.W. 821.14, LogP -3.05). 
 
Over the past twenty years, a new filtration marker, iohexol (Figure 1), has 
been increasingly used [3, 8-10] because of its established safety record [11], cost 
effectiveness [7, 8], reliability, accuracy [12], and its non-radioactive nature. It is 
claimed by many to be the new “gold standard” for GFR measurement [3, 5, 8, 13] 
and is used in both adults and children. Other clinical uses of iohexol are as a non-
ionic monomeric contrast agent for various radiography imaging procedures [14]. 
Iohexol does not enter cells and does not bind to proteins or blood cells [7]. Iohexol 
is not metabolised and, after intravenous administration, it is eliminated unchanged 
almost exclusively by the glomerulus [6, 7, 15, 16]. Iohexol distributes into a volume 
equal to the extracellular fluid (plasma + interstitial fluid) volume (ECV) [7, 15-19] 
and for this reason, it has been suggested as a useful tracer of this body 
compartment [17, 20, 21]. 
The iohexol GFR test involves a single intravenous bolus administration of the 
marker. Then, at specific time intervals post-administration, blood samples are 
drawn from the patient, analysed for iohexol, and the results are used to calculate 
the clearance of iohexol which reports directly on the GFR of the patient. The 
iohexol plasma profile [plasma concentration (Cp) versus time (t)] is best described 
by a two-compartment bi-exponential model (Figure 2) [6, 12, 14]. The first-order 
distribution reflects the equilibration process between the intravascular 
extracellular (representing the plasma) and the extravascular extracellular 




















Figure 2: Illustrative example of iohexol plasma concentration (Cp) versus time (t) 
profile. Plasma concentrations may be described by a two-exponential, two-
compartment model of the form: Cp = A e
-αt
 + B e
-βt                       
 
 
3 hours post-iohexol administration [7, 16, 22]. Once the distribution of iohexol 
reaches equilibrium, its plasma disappearance profile follows a first-order decline 
over time governed, only, by the elimination process. 
GFR is equal to the clearance of iohexol (Cl) and is usually expressed 
normalised to a body index. Body surface area (BSA) is the most commonly used 
index and the reference BSA is 1.73 m
2
 (representing the normal BSA of an average 
adult).  
The clearance of iohexol is calculated as follows: 
 = 	




                                                Equation (1) 
Where Dose is the amount of iohexol administered to the patient and ∞ 
is the area under the concentration versus time profile from t = 0 to t = ∞. B and   
respectively denote the Y-intercept and slope of the elimination curve (Figure 2). A 
and α are, respectively, the Y-intercept and slope of the residual curve which 































reflects the distribution process only and is attained from iohexol concentration 
profile by means of deconvolution. 
Accurate determination of iohexol’s clearance using the two compartment 
model (Equation 1) necessitates numerous blood samples taken during the 
distribution and elimination phases. For both practical and ethical reasons, this 
approach has proved unpopular, especially in the paediatric population. As a result, 
simplified models have been introduced whereby only the elimination phase of 
iohexol is considered [23]. Thus, an assumption of a first-order one-compartment 
model can be made (Equation 2) and fewer sampling points, made after equilibrium 
in iohexol distribution is accomplished, are therefore required. 
 =  ∙ ∙ ≅  ∙  !∙                              Equation (2) 
Where C0 is assumed to be the plasma concentration at t = 0, Ke is the 
elimination rate constant (equivalent to  in Equation 1). The clearance of iohexol 
using this simplified model is calculated as follows:  




(            Equation (3) 
Where Vd  is the volume of distribution of iohexol. To account for errors 
arising from this simplification (compare Equations 1 and 3), correction factors are 
used to avoid overestimation of GFR [6, 7, 23-25].  
Even though the use of the simplified mono-compartment approach in the 
iohexol GFR test improves the practicability of the procedure with less sampling 
points required, some disadvantages remain. At least 2 blood samples are still 
essential to provide necessary data about the elimination phase. Blood sampling is 
invasive and may cause infection. In addition, patients (particularly children) may 
experience significant pain and distress. Needle insertion, in fact, is one of the most 
frightening experiences that children remember from a stay in the hospital [26, 27]. 
Technical difficulties when sampling (such as finding a suitable vein in a distressed 
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child) pose a significant issue to the medical team. Finally, the less frequent 
sampling carries the risk of estimation errors limiting, therefore, the precision of 
GFR determination [6, 28]. It follows that the need for a less invasive, but still 
accurate, alternative technique for iohexol sampling is, thus, greatly desirable. In 
particular, the paediatric population would benefit immensely from such 
alternative sampling tools in the iohexol GFR test.  
The principal objective addressed in this study was to assess the feasibility of 
transdermal reverse iontophoresis as an alternative non-invasive sampling tool for 
iohexol. The study is divided into two parts: 
First, an in vitro investigation was performed to provide a preliminary proof-
of-concept for subsequent in vivo evaluation. Correlation between iohexol 
subdermal concentrations, representative of typical, clinical plasma levels usually 
observed in patients, and the corresponding iontophoretic extraction fluxes was 
assessed. Then, an iontophoretic pre-treatment period was introduced prior to 
iohexol sampling to attempt to reduce the time required to achieve steady 
extraction rates. Finally, iohexol transdermal extraction fluxes were followed to 
evaluate the correlation to the subdermal concentration of the marker whose 
disappearance was simulated with different first-order pharmacokinetic models.  
Second, a pilot study verified that iohexol could, indeed, be extracted in vivo 
by transdermal iontophoresis, and then considered whether the extraction fluxes 
were sensitive to the decline of the marker’s blood concentration. This would allow 
the elimination rate constant (Ke) and GFR of each subject to be estimated from the 
skin sampling data and comparison with the corresponding parameters calculated 
from blood sampling. Finally, the local effect of iontophoresis on the skin and 
participant feedback were evaluated. 
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2. In vitro study 
A. Materials and methods 
A.1 Chemicals  
Iohexol (98% pure), acetaminophen (≥99%), silver wire (99.99%), and silver 
chloride (99.999%) were purchased from Sigma Aldrich (Gillingham, UK). Tris base 
(α, α, α-Tris-(hydroxymethyl)-methylamine), sodium chloride, and potassium 
chloride were from Acros (Geel, Belgium). Hydrochloric acid (37 %w/w), methanol, 
and trifluoroacetic acid were obtained from Fisher Scientific (Loughborough, UK). 
All reagents were at least analytical grade and deionised water (resistivity ≥ 18.2 
MΩ.cm, Barnsted Nanopure Diamond
TM
, Dubuque, IA) was used for the preparation 
of all solutions. 
A.2 Skin 
Fresh pig skin was obtained from a local slaughterhouse, cleaned under cold 
running water, and stored in a refrigerator until the following day. Abdominal skin 
was dermatomed (Zimmer™ Electric Dermatome, Dover, Ohio; nominal thickness 
750 µm), cut into pieces of appropriate size, wrapped individually in Parafilm™, and 
then kept in a freezer (-20 °C) until use. Immediately prior to the permeation 
experiment, the skin was thawed at room temperature for 30 minutes and visible 
hairs were carefully cut with scissors. The skin was then mounted directly onto the 
diffusion cells. 
A.3 Iontophoresis 
Anodal iontophoretic transport studies were performed using Ag/AgCl 
electrodes connected to a power supply (KEPCO 1000M, Flushing, NY, USA) which 
delivered direct, constant current. Electrode and subdermal solutions were 
magnetically stirred for the duration of the experiment (Multipoint-6 stirrer, 
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Thermo Scientific Variomag, Cole-Parmer, London, UK). The number of replicates 
was 4 – 12. 
Fixed-subdermal concentration extraction: Experiments were performed 
using side-by-side two-compartment diffusion cells (skin transport area = 0.71 cm
2
, 
volume 3 ml). Abdominal skin was sandwiched between the chambers, with the 
stratum corneum facing the cathode compartment. Prior to iontophoresis, the skin 
was hydrated for 30 minutes in the presence of 25 mM Tris buffer solution in both 
compartments (no iohexol). The subdermal (anode) solution also contained 133 
mM NaCl and 4 mM KCl to mimic physiological conditions. The final pH of both 
solutions was adjusted to 7.4 with HCl.  
The correlation of iohexol iontophoretic extraction with its subdermal 
concentration was investigated. After the 30-minute hydration period, the cathode 
compartment was emptied and refilled with fresh buffer. The anode solution was 
replaced with one of 5 concentrations ranging from 0.15 to 2.44 mM, reflecting the 
clinical range found in GFR measurements. The current (0.36 mA) was applied for 6 
hours. Every hour, the current was stopped, 1 ml from the cathode solution was 
withdrawn for analysis and replaced by the same volume of fresh buffer solution. A 
passive diffusion control was also performed using the highest concentration of 
iohexol (2.44 mM). 
Subsequently, the effect of a 3 hour iontophoretic pre-treatment of the skin 
on iohexol extraction was examined. In this case, post-30 minute hydration, but 
before the introduction of iohexol into the subdermal (anode) compartment, the 
skin was exposed to a constant current of 0.36 mA for 3 hours. Acetaminophen (7.5 
mM) was also present in the anode solution, allowing electroosmotic flow to be 
monitored. After the pre-treatment period, the anode solution was replaced and 
2.44 mM iohexol was added along with 7.5 mM acetaminophen in Tris buffer (25 
mM Tris, 133 mM NaCl, 4 mM KCl; pH 7.4). The current was then re-applied for a 
further 6 hours. Sampling for iohexol and acetaminophen from the cathode 
compartment was performed hourly. A passive diffusion control was also 
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performed in a separate experiment using skin which had been exposed to a 3 hour 
constant current pre-treatment (0.36 mA) in the absence of iohexol. 
Pharmacokinetic simulations: Side-by-side three compartment diffusion cells 
were used (skin transport area = 1.02 cm
2
). Anode and cathode electrode chambers 
(volume 1.9 ml) were each separated from a central compartment (volume 3.75 ml) 
by a piece of excised pig skin oriented so that the stratum corneum was facing 
towards the electrode chambers. The electrode chambers contained 25 mM Tris 
(pH 7.4) in the cathode, and 90 mM NaCl (necessary for electrochemical reactions) 
in 25 mM Tris buffer (pH 7.4) in the anode compartment. Using a syringe pump 
(Genie 8, Kent Scientific Corporation, Torrington CT, USA), the subdermal 
compartment was continuously infused with Tris buffer solution (25 mM Tris, 133 
mM NaCl, 4 mM KCl, pH 7.4) at specific flow rates (Table 1). This allowed the 
progressive clearance of iohexol from the subdermal compartment. Two sets of 
experiments were performed: 
First, after hydration of the skin for 30 minutes (no iohexol), the solutions 
were refreshed and 0.31 mM iohexol was introduced into the subdermal 
compartment. At this point, the syringe pump continuously infused the subdermal 
compartment at 1.5 ml/h rate (i.e., simulation of a mono-exponential decay of 
iohexol); and a 0.5 mA constant current was applied for 6 hours. Every 30 minutes, 
the current was stopped and the entire cathodal solution was replaced with fresh 
buffer. Samples (10 µl) were also collected from the subdermal compartment at the 
mid-point of each iontophoretic sampling period.   
The second set of experiments pre-exposed the skin to 3 hours of constant 
current (0.5 mA) in the absence of iohexol. After the pre-treatment period, all 
solutions were refreshed and iohexol (at 1.22 or 6.04 mM) was introduced into the 
subdermal compartment. Constant, direct current (0.5 mA) was applied for 6 hours. 
At the same time, the syringe pump was used to continuously clear iohexol from 
the subdermal compartment. Samples were collected from both the subdermal and 










Untreated 0.31 1.5 
Pre-treated with 0.5 mA 




First 3 hours:    3.0 
Thereafter:       1.0 
 
A.4 Sample analysis 
Iohexol and acetaminophen were quantified simultaneously by high 
performance liquid chromatography with UV detection (254 nm). The method was 
modified from a previous publication [29] and used an HPLC system (Dionex, 
Sunnyvale, CA) comprising a P680 pump with ASI-100 autosampler, TCC-100 
thermostated column compartment, PDA-100 diode array detector, and an Acclaim 
120, C18 (150 x 4.6 mm, 5 µm) reversed-phase column (Dionex, UK) thermostated 
at 60°C. The mobile phase, 13.5 mM TFA (pH 2.2):MeOH (95:5 v/v), was pumped 
through the system at 1 ml/min. The validation parameters are found in Appendix 
(1A). 
A.5 Data analysis and statistics 
Data analysis and regressions were performed using Graph Pad Prism V.5.00 
(Graph Pad Software Inc., CA, USA). Unless otherwise stated, data are represented 
as the mean ± standard deviation (SD). Extraction fluxes were calculated as the 
amounts transported per unit time. Statistical significance was set at p < 0.05. The 
slopes of the linear regressions of extraction fluxes versus subdermal 
concentrations were compared by ANCOVA test. Fluxes at different times were 
compared by repeated-measures ANOVA followed by Tuckey’s post-test. Two-way 
repeated-measures ANOVA followed by Bonferroni post-test was used to compare 
the experiments evaluating the effect of skin pre-treatment on extraction fluxes. 
The same test was also used for comparison of iontophoretic extraction efficiencies 
of iohexol and acetaminophen.  
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The results from each iontophoresis cell, used for the pharmacokinetic 
simulations of subdermal concentration and extraction flux versus time profiles, 
were individually fitted with the corresponding regression equation.   was 
calculated by the trapezoidal rule (Graph Pad Prism) and ∞ was determined 
from the last measured concentration divided by the elimination rate constant. 
Statistical comparison of the kinetic parameters obtained from the subdermal 
concentration and iontophoretic extraction data were performed with two-tailed 




B. Results and discussion 
B.1 Fixed-subdermal concentration extraction 
Iohexol is a hydrophilic (LogP = -3.05), polar, neutral compound. The 
mechanisms contributing to its extraction flux during transdermal iontophoresis are 
passive diffusion and electroosmosis. Therefore, iontophoretic extraction towards 
the cathode was selected as the most efficient method for iohexol sampling. This is 
because at physiological pH, the net charge on the skin is negative and 
electroosmosis proceeds in the direction of anode to cathode [30]. 
Passive extraction of iohexol was negligible when compared to iontophoresis. 
Its flux only reached 0.06 ± 0.04 nmol/h over 6 hours when 2.44 mM of iohexol was 
present in the subdermal compartment. In contrast, iontophoretic extraction fluxes 
were nearly 80 times higher. Moreover, even when a smaller subdermal 
concentration (0.15 mM, i.e., one-sixteenth of that used in the passive diffusion 
experiment) was iontophoresed, an extraction flux of 0.31 ± 0.08 nmol/h was 
observed. Clearly, therefore, iontophoresis offers a much more efficient sampling 
technique than passive diffusion. 
The first objective was to demonstrate a linear correlation between iohexol 
subdermal concentrations, chosen to represent the clinical range typically observed 
in patients, and the corresponding iontophoretic extraction fluxes. Figure 3 reveals 
that this was indeed the case and such proportionality improves with time of 
iontophoresis (e.g., r
2
 0.88 at 6 h). These findings are in line with previous studies 
reported for other neutral compounds (e.g., glucose, mannitol, phenylalanine, 
phenytoin, and urea) [31-35]. The slopes of this linear relationship (Z, µl/h) after 
different times of iontophoresis are in Table 2, and represent the iontophoretic 
extraction efficiency of iohexol. The values increased with time up to 4 hours after 







Figure 3: Reverse iontophoretic extraction fluxes of iohexol as a function of time 





The delay for reaching constant levels of extraction is due to the time needed 
for the electroosmotic solvent flow to establish a steady stream across the skin but 
may also be solute-specific. When iohexol molecules are dragged along with the 
electroosmotic solvent flow across the skin, a fraction, relative to the solvent, may 
be reflected by the membrane and steady extraction of iohexol is therefore slowed 
down. It is worth noting, though, that this lag time may be artificially long in vitro 
because the skin membranes used in these experiments had a nominal thickness of 
750 µm and therefore a longer diffusion path for iohexol than what would be 
otherwise present in vivo.  
 
Table 2: Linear regressions of iohexol iontophoretic extraction flux (Jt, nmol/h) as a 
function of its subdermal concentration (Ct, mM) at different times of iontophoresis 
[Jt = Z . Ct + Y-intercept*]. Z values are expressed as the best-fit slope values ± 
standard error of the regression (SE). 
Time 
(h) 
1 2 3 4 5 6 
Z 
(µl/h) 
0.23 ± 0.04 0.80 ± 0.08 1.29 ± 0.11 1.62 ± 0.13 1.84 ± 0.13 1.99 ± 0.14 
r
2
 0.52 0.78 0.83 0.86 0.88 0.88 
* The Y-intercept was always ≤ 0.10 nmol/h. 
 



















































B.2  Effect of iontophoretic pre-treatment of the skin on iohexol transport 
The second objective was to examine whether the time required to reach a 
stable efficiency of extraction could be shortened. The relevance of such a goal to a 
clinical application is clear. A three hour iontophoresis (0.36 mA) pre-treatment was 
introduced before addition of iohexol into the subdermal compartment. Three 
hours was chosen because: 1) in the previous set of experiments (section B.1), the 
fluxes stabilised after at least 3 hours of iontophoresis application, and 2) when 
iohexol is administered to patients as a renal marker, its distribution phase takes 2 
– 3 hours to be accomplished. Data from this phase are not used in the calculation 
of GFR (with the simplified approach), and therefore a 2 – 3 hour “window” exists 
that might be used to stabilise the transdermal extraction flux of iohexol. 
The pre-treatment slightly increased the total extraction flux of iohexol 
(Figure 4) and values measured at 2 through 5 hours were significantly higher than 
without pre-treatment (p < 0.001 (2 h) and p < 0.05 (5 h)). However, there was no 









Figure 4: Effects of a 3 hour iontophoresis pre-treatment (0.36mA) on iohexol 
extraction fluxes. The initial subdermal concentration of iohexol was 2.44 mM. Data 
representing “Without pre-treatment” are slightly nudged to the right for clarity. 
Data are presented as mean ± SD of 7 – 12 replicates. 







































Figure 5: Iontophoretic extraction fluxes (mean ± SD, n = 6) of acetaminophen as a 
function of time. Fluxes approach constant values from 4 hours. Electroosmosis is 
the sole contributor to acetaminophen’s transport across the skin, the passive 
diffusion of which was negligible (data not shown). 
 
from J6h = 0.06 ± 0.04 to 0.24 ± 0.04 nmol/h was found when the skin was pre-
iontophoresed but the resulting contribution remained negligible compared to the 
electrotransport. 
The pre-treatment shortened the time required to reach stable extraction 
fluxes of iohexol by about 1 hour. Acetaminophen (pKa 9.5) is uncharged at pH 7.4 
and was used to track electroosmosis throughout the pre-treatment experiment. 
Figure 5 shows that steady extraction of this marker is achieved within 4 hours of 
current application. However, even after skin pre-treatment, iohexol required 3 
hours to reach steady extraction, although the electroosmotic solvent flow is 
already established across the skin at the time of iohexol addition to the subdermal 
compartment. 
The extraction efficiency of iohexol and acetaminophen through untreated 
skin differed significantly (Table 3). For example, after 6 hours of iontophoresis Z = 
1.96 ± 0.51 µl/h for iohexol and 3.21 ± 0.74 µl/h for acetaminophen. The values are, 
however, less than 2.5 fold different despite the much larger molecular weight of 
iohexol (821.14 Da) compared to acetaminophen (151.17 Da). A better correlation 
is perhaps  found  in the molecular  size  differences.  The Stokes radius of iohexol is   






























Table 3: Extraction efficiencies of iohexol and acetaminophen after different times 










1 0.28 ± 0.11 0.78 ± 0.31 No 
2 0.81 ± 0.28 1.96 ± 0.67 p < 0.01 
3 1.30 ± 0.39 2.60 ± 0.66 p < 0.001 
4 1.62 ± 0.46 3.07 ± 0.97 p < 0.001 
5 1.83 ± 0.47 3.10 ± 0.83 p < 0.001 
6 1.96 ± 0.51 3.21 ± 0.74 p < 0.01 
* Two-way repeated-measures ANOVA followed by Bonferroni post-test. 
 
reported to be 1.1 nm [36] whereas that of acetaminophen is 0.36 nm [37]; a factor 
of 3 difference. Previous studies demonstrated a dependence of the magnitude of 
electrotransport efficiency on the molecular size of the solute [38, 39]. One 
example [38] examined the transport efficiencies of 26 polyethylene glycols 
(neutral molecules) of various molecular weights (282 – 1382 Da, corresponding to 
Stokes radii of 0.38 – 0.81 nm). The mean transport efficiencies, which were 
measured across full thickness hairless rat skin under the application of 1 mA (0.5 
mA/cm
2
) direct constant current for 14 hours, were found to decrease from 10.1 
µl/h.mA for the smallest molecule to 0.23 µl/h.mA for the bulkiest. It is interesting 
to note that the extraction efficiency of iohexol [Z6h = 5.46 ± 1.41 µl/h.mA] was 
twice higher than the iontophoretic efficiencies of two polyethylene glycols of 
similar molecular weights (810 and 854 Da; Stokes radii 0.62 and 0.64 nm) which 
measured at 2.8 and 2.64 µl/h.mA. This is although the previous study used rat skin 





B.3 Pharmacokinetic simulations 
When used in GFR tests, iohexol is given as an intravenous bolus injection and 
its concentration in the body then decreases over time. The previous experiments 
established the linear proportionality between iohexol’s subdermal concentration 
and its corresponding extraction flux under “static conditions”, in which the 
subdermal concentration of iohexol was held constant throughout the experiment. 
The next objective was to further examine this linear dependency when the 
subdermal concentrations of iohexol were gradually cleared by simulated first-
order elimination. Pharmacokinetic parameters estimated from the subdermal 
concentration data were compared to those deduced from the iontophoretic 
extraction results. 
Two experiments were performed in which the subdermal concentration of 
iohexol was progressively decreased to simulate a first-order elimination process. 
The first experiment involved no iontophoretic pre-treatment and was 
characterized by an “injected bolus” of 1144 nmoles of iohexol in a volume of 
distribution of 3.75 ml (the volume of the subdermal compartment), with a 
clearance of 1.5 ml/h (the syringe-pump flow rate). The second involved a 3 hour 
pre-treatment period at 0.5 mA (after which all compartments were refreshed with 
new solutions), an iohexol dose of 4575 nmoles directly “injected” into the 
subdermal chamber (volume again 3.75 ml), with a clearance of 1 ml/h. 
The concentration in the subdermal compartment (Ct) decays according to 
the standard first order kinetic equation: 
 =  ∙  !∙                                          Equation (4) 
Where C0 is the subdermal concentration at time (t) = 0, and Ke is the first 
order elimination constant. It is also true that: 
 = +,- #$.                 Equation (5) 
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Where Dose is the amount of iohexol introduced into the subdermal 
compartment of volume (Vd) at t = 0, and, 
" =  #$.                        Equation (6) 
Where Cl is the clearance. A model-independent estimate of the clearance 
may also be derived from: 
/0$ = +,- 1.                       Equation (7) 
Where ∞ is the area under the concentration versus time profile from t = 
0 to t = ∞. 
The iontophoretic extraction flux (Jt) as a function of time is expected to be 
proportional to Ct, that is: 
2 = 3 ∙  = 3 ∙  ∙  !∙               Equation (8) 
Where Z is a proportionality constant, previously referred to as the iontophoretic 
extraction efficiency of iohexol. 
From the linear decay of LnCt and LnJt as a function of time (Figure 6), values 








Figure 6: Mono-exponential decay simulations. Iohexol subdermal concentrations 
(Ct, open squares) and iontophoretic extraction fluxes (Jt, filled squares) as a 
function of time. (A) without iontophoretic pre-treatment, (B) following a 3 hour 
iontophoretic pre-treatment. Data are represented as the mean ± SD of 4 – 5 
replicates. 
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Table 4: Pharmacokinetic parameters derived from the simulated first-order 
elimination model of iohexol subdermal concentration (Ct) and the corresponding 






























Ct 0.98 0.38 ± 0.05 0.29 ± 0.02 4.02 ± 0.28 1.51 ± 0.14 1.53 ± 0.1 




Ct 0.99  0.28 ± 0.01  1.23 ± 0.05  3.71 ± 0.16  1.04 ± 0.05  1.04 ± 0.06  
Jt 0.90  0.25 ± 0.05  1.21 ± 0.18 3.89 ± 0.63  0.96 ± 0.05  0.96 ± 0.05  
a
 Determined from the slope of the linear regression. 
b
 Determined from the 
intercept of the linear regression. 
c
 Calculated from: Vd = Dose/C0. 
d 
Calculated from: 
Cl = Ke . Vd . 
e 
Model independent clearance: Clind = Dose/∞. 
 
iontophoretic extraction fluxes. The results in Table 4 show a remarkably good 
agreement between the two determinations, both when the iontophoresis pre-
treatment was used or not. 
Extrapolation of the linear data of the plots in Figure 6 to t = 0 yields 
intercepts equal to C0 and ZC0, respectively, for the subdermal concentration and 
iontophoretic extraction results. The former yields results (0.29 ± 0.02 mM and 1.23 
± 0.05 mM for no pre-treatment and with pre-treatment, respectively) which are 
very close to the actual values given by equation (5): 0.305 mM and 1.22 mM. 
From the results in Figure 6, and application of equation (8), it is possible to 
estimate Z for the experiments without and with iontophoretic pre-treatment: 4.8 ± 
0.5 µl/h and 5.3 ± 0.4 µl/h, respectively. With these values, and the extrapolated 
intercepts of the linear LnJt data to t = 0, C0 can be found from the reverse 
iontophoresis results. Table 4 shows that the agreement between these results and 
the actual values is rather good. 
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With the derived C0 and Ke, from the subdermal concentration and reverse 
iontophoretic flux results, together with the known iohexol doses delivered to the 
subdermal compartment at t = 0, permits Vd, Cl, and the model-independent 
clearance to be derived using equations (5), (6), and (7) (Table 4). Once again, good 
agreement between the derived values is observed in addition to the consistency 
with the “ideal” values (Vd = 3.75 ml, Cl = 1.5 ml/h and Vd = 3.75 ml, Cl = 1 ml/h for 
without and with iontophoresis pre-treatment, respectively). Similar correlations 
were also found in a previous in vitro study which investigated reverse 
iontophoresis as an alternative non-invasive sampling procedure to lithium 
monitoring [40]. 
After confirmation of the good correlation of the iontophoretic extraction 
fluxes of iohexol with its subdermal concentrations cleared by first-order 
elimination kinetics, the next experiment investigated whether an abrupt change in 
the elimination rate of iohexol from the subdermal compartment would be as well 
tracked and reflected in the iontophoretic extraction fluxes. The study started after 
a 3 hour iontophoretic pre-treatment of the skin. Then, all compartments were 
refreshed with new solutions and the subdermal chamber now contained 6.04 mM 
iohexol. The syringe pump was programmed to perfuse the subdermal 
compartment at a constant rate of 3 ml/h for the first 3 hours. At the end of 3 
hours, the infusion rate was abruptly changed to 1 ml/h for the remaining 3 hours. 
Hence, the concentration of iohexol in the subdermal compartment (Ct) decayed 
according to the following equation: 
 = + ∙ 4∙                                                          Equation (9) 
Where D = A and δ = α at times [t = 0 – 3 hours], and D = B and δ = β at times [t = 3 
– 6 hours]. As in the previous section, the iontophoretic extraction flux (Jt) deduced 
as a function of time is expected to follow: 
2 = 3 ∙ + ∙ 4∙                                 Equation (10) 









Figure 7: Simulated bi-phasic decay of iohexol. Iohexol subdermal concentrations 
(Ct, open squares) and iontophoretic extraction fluxes (Jt, filled squares), expressed 
semi-logarithmically, as a function of time. Data are represented as the mean ± SD 
of 4 – 5 replicates. 
  
 
LnJt as a function of time (Figure 7) showed excellent correlation of the extraction 
fluxes to the changes in iohexol’s concentration in the subdermal compartment. 
Once again, determination of D and δ from the two phases of the experiment  (i.e., 
[A, α] and [B, β]) demonstrated remarkable similarities between the subdermal 
concentration and corresponding iontophoretic extraction data (Table 5). 
 Overall, experiments in this part of study simulated first-order disappearance 
of iohexol from the subdermal compartment. Concomitant measurements of the 
iontophoretic extraction fluxes confirmed its sensitivity to track the concentration 
change and the kinetic parameters deduced from both data were very similar.  
 
Table 5: Kinetic parameters derived from the simulated non-compartmental model 
for iohexol subdermal concentration (Ct) and the corresponding extraction fluxes 























Ct 0.99  6.12 ± 0.16  0.80 ± 0.01  0.53 ± 0.07  0.27 ± 0.03  
Jt 0.97  6.18 ± 0.68  0.74 ± 0.02  0.55 ± 0.10  0.23 ± 0.04  











































3. In vivo study 
A. Materials and methods 
A.1 Chemicals  
Iohexol (98% pure) was purchased from Sigma Aldrich (Gillingham, UK). 
Sodium chloride, potassium chloride, and methanesulfonic acid (99%) were 
obtained from Acros (Geel, Belgium). Acetonitrile was provided by Fisher Scientific 
(Loughborough, UK). All reagents were at least analytical grade and deionised water 
(resistivity ≥ 18.2 MΩ.cm, Barnsted Nanopure Diamond
TM
, Dubuque, IA) was used 
for the preparation of all solutions. 
A.2 Subjects 
Four children, undergoing a routine iohexol GFR test at Great Ormond Street 
Hospital for Children (GOSH), participated in the study (Ages: 9.1, 13, 7.4, and 12 
years old; 1 female and 3 males). Approval was granted from the Institute of Child 
Health/ Great Ormond Street Hospital Research Ethics Committee, and prior 
written consent and assent from the parent and child, respectively, were obtained 
before beginning the study (see Appendix 2 for forms). Participants did not have 
any skin condition, such as eczema, irritated or damaged skin. 
A.3 Iohexol sampling by the routine intravenous method and the 
alternative technique, transdermal reverse iontophoresis 
The routine GFR test involved the bolus intravenous administration of 2 ml of 
Omnipaque 300 (Nycomed Amersham plc, Bucks., UK), equivalent to 1294 mg 
iohexol. Subsequently, two 1 ml blood samples were taken from the subject at 
approximately 3 and 4 hours post-injection. The samples were analysed for iohexol 
by the GOSH clinical chemistry laboratory. Transdermal reverse iontophoresis was 
carried out in parallel on the non-dominant arm of the participant. The arm was 
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first cleaned with an alcohol wipe and then allowed to dry. Constant, direct current 
(Figure 8) was delivered from a “Phoresor® II auto” device (PM850, Iomed, Salt Lake 
city, Utah, USA) to the electrode patches (Iogel small, Iomed, Salt Lake city, Utah, 
USA) affixed to the subject’s skin. The anode was a dispersive pad (active area 22.6 
cm
2
) incorporating a silver/silver chloride electrode in karaya gel. The cathode 
(active area 7.2 cm
2
) was a silver chloride electrode integrated into a dried gel 
which was hydrated with 1.3 ml of ultrapure water. The Phoresor® precisely 
delivered 0.5 mA (0.07 mA/cm
2
 at the cathode sampling site) of current (except for 
participant number 3 for whom the applied current was 0.3 mA) for 5 hours, 
beginning 0.5 hours after the intravenous dose of iohexol. Both patches were 
refreshed after 2 and 4 hours of current passage, and the cathodal patch was 
additionally replaced at 3 hours (see schematic below). When the patches were 
exchanged, the current was interrupted briefly.  
Photographs of the participants’ arms were taken before and after 
iontophoresis to investigate the effect of current passage on the skin. Participants 
also completed a short questionnaire just after the start of iontophoresis and 
towards the end of the experiment. The questionnaire used the Wong-Baker faces 
pain scale [41] to indicate the level of sensation experienced during iontophoresis. 
Subjects were also asked whether transdermal iontophoresis was preferred over 
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Figure 8: Experimental setup for transdermal reverse iontophoresis. 
A.4 Sample analysis 
The cathodal patches were immersed in 7 ml of water and shaken at 240 rpm 
(HS260 Basic, IKA, Sigma Aldrich, Gillingham, UK) for 24 hours to extract the 
reverse-iontophoretically transported compounds. The extracts were filtered by 
centrifugation (45 minutes at 7500 RCF) using Amicon® ultrafiltration tubes (MWCO 
5 kDa, Millipore, Watford, UK). 
Iohexol was quantified by high performance liquid chromatography. The 
method used a Shimadzu HPLC system (LC-2010A HT, Kyoto, Japan) comprising an 
autosampler, a UV diode array detector set at 254 nm wavelength, and a HiQ-Sil
TM
 
C18 (250 x 4.6 mm, 5 µm) reversed-phase column (Jasco, UK) thermostated at 40°C. 
The mobile phase, water:acetonitrile (70:30, %v/v), was pumped through the 
system at 1 ml/min flow rate. The effective run for each injected sample (20 µl) was 
7 minutes and a wash step (water:acetonitrile, 20:80, %v/v) for 38 minutes followed 
by a 10 minute column re-equilibration with the initial mobile phase was 
implemented after each run.  
Sodium and potassium in the extracts were analysed by ion chromatography 
with suppressed conductivity detection. The method was modified from a previous 
publication [42] and used an IC system (Dionex, Sunnyvale, CA) comprising a GP-50 
gradient pump, an AS-50 autosampler and thermal compartment, and an ED-50 







pumped at 1 ml/min through a Dionex IonPac
TM
 CS12A (250 x 4 mm) column 
thermostated at 30 °C and connected to a Dionex CSRS Ultra II suppressor (4 mm) 
set at a current of 80 mA.  
The validation parameters of the analytical methods are in Appendix (1B). 
A.5 Calculations and statistical analysis 
Data analysis and regression were performed using Graph Pad Prism V.5.00 
(Graph Pad Software Inc., CA, USA). The slope and intercept of regression lines were 
expressed as the best-fit value ± standard error of the regression (SE). Statistical 
comparisons of extraction fluxes of sodium and potassium at different times of 
iontophoresis were determined using repeated-measures ANOVA test. The level of 
significance was set at p < 0.05. The blood concentrations of iohexol were plotted at 
the exact times of blood sampling; whereas the transdermal extraction fluxes were 
plotted at the midpoint of the respective extraction interval. As the sampling times 
of blood measurements did not coincide with the sampling times of reverse 
iontophoresis, the corresponding plasma concentrations, when correlated to 
iontophoretic extraction fluxes, were adjusted by interpolation. 
A.5.1 Calculation of iohexol’s elimination rate constant (Ke)  
From blood sampling  
To obtain an estimate of the GFR from the measured iohexol concentrations 
(,6  and ,7) in the blood samples withdrawn from the subject at approximately 
3 (t1) and 4 (t2) hours post-injection, a first order mono-compartment model was 
assumed, where the distribution phase was ignored, so that: 
,6 =  ∙  !∙6     (Eq. 11)   ;      ,7 =  ∙  !∙7     (Eq. 12) 
Where C0 is assumed to be iohexol’s blood concentration at t = 0 and Ke is the 
elimination rate constant of the marker. Taking logarithms of equations (11) and 
(12) and subtracting one from the other allows Ke to be found: 
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ln:,6 ,7. ; = " ∙ <=> − =@A        (Equation 13) 
From skin sampling  
The reverse iontophoretic extraction fluxes of iohexol (Jioh) were similarly 
assumed to decay with first-order kinetics and were anticipated to follow the 
changes in the marker’s blood levels (this is after distribution of iohexol has reached 
equilibrium across the extracellular fluid, i.e., 2 – 3 hours post-injection): 
 2/B = 3 ∙  = 3 ∙  ∙  !∙        Equation (14) 
And a semi-logarithmic plot of LnJioh versus time therefore yields a straight line, the 
slope of which is - Ke: 
ln 2/B = ln<3 ∙ A − " ∙ =         Equation (15) 
Ke was also estimated after calibration of iohexol’s iontophoretic extraction 
flux (Jioh) with that of a potential internal standard candidate (JIS, either sodium or 
potassium), simultaneously extracted with iohexol:  
ln<2/B 2CD. A = ln 3′ ∙  = ln<3′ ∙ A − " ∙ =     Equation (16) 
Where 3F = 3 ∙ 2CD and JIS is expected to be constant owing to the constant 
systemic concentration of the internal standard. 
A.5.2 Calculation of iohexol’s clearance (Cl) and GFR 
Once the elimination rate constant is known, iohexol clearance () can be 
estimated assuming a value for its volume of distribution (#$, see below for 
methods of determination), and corrected according to the Brøchner-Mortensen 
formula [6, 7, 23-25]. The subject’s GFR, indexed to body surface area (BSA), is 
equivalent to the corrected clearance of iohexol (Clcorr) normalised to 1.73 m
2
 (the 
body surface area of an average adult): 
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GHI = JKK × M @.OPQDRSTU!VTW             Equation (17) 
             = X<0.990778 × A − <0.001218 × >A_ × M @.OPQDRSTU!VTW 
Where ` = " ∙ #$ ` . The volume of distribution was calculated using one of the 
following methods: 
Slope-only methods  
The volume of distribution of iohexol is equal to the extracellular volume 
(ECV) [7, 15-19], except for oedematous patients, premature babies and in other 
particular disease states. Two approaches can be used to estimate Vd:  
1) “Theoretical approach”: The ECV of an average adult (BSA 1.73 m
2
) is 
approximately 13.5 L (approximately 20% of body weight) and GFR is conventionally 
indexed to a reference BSA of an average adult. It follows that 13.5 L could be used 
directly as iohexol’s Vd already normalised to a BSA of an average adult [43, 44]. It 
should be noted though that children up to a certain age have an ECV that tends to 
be much higher than that of adults (>20% of body weight) [45]. 
2) “Empirical approach”: Formulae, which link experimentally determined Vd 
of iohexol to the height and/or weight of the patient, have been derived for 
different population groups (male, female, adults, and children) [46-48]. The 
formulae selected here (equation 18) is based on findings from 100 infants and 
children with an average age of 6 ± 1 years (range: 2 days - 14 years) [47]. The 
empirical relationship was made after determination of iohexol’s Vd from the 
marker’s concentrations determined from two blood samples taken at 3 and 4 
hours post-bolus injection of iohexol. 






 #$ = 
                      Equation (19) 
Where Dose is the amount of iohexol administered to the subject and C0 is 
estimated from blood sampling data by re-arrangement of equations 11 and 12, so 
that:   
jk lm = jk 
R,T6 jk 
R,T7 !∙<67An            Equation (20) 
C0 may also be estimated from iohexol’s reverse iontophoretic extraction data 
using the extrapolated intercepts of the linear LnJt or Ln(Jioh/JIS) data to t = 0 (based 
on equations 14 and 16, respectively). However, this requires prior knowledge of 




B. Results and discussion 
This study examined the potential use of reverse iontophoresis as a non-
invasive sampling tool for iohexol and was compared to the reference blood 
sampling method currently adopted in clinical practice.  
Iohexol was successfully extracted by transdermal iontophoresis. The blood 
concentrations of the marker and its iontophoretic extraction fluxes are presented 
semi-logarithmically in Figure 9 as a function of time post-injection. All extraction 
fluxes correspond to a current intensity of 0.5 mA except in subject 3 for whom the 
applied current was lowered to 0.3 mA as from the 5
th
















Figure 9: Iohexol transdermal iontophoretic extraction fluxes (Jioh, µg/h, filled 
squares) and its blood concentrations (Cp,ioh, µg/ml, open squares) as a function of 
time post-injection. The blood concentrations of iohexol are plotted at the exact 
times of blood sampling; whereas the transdermal extraction fluxes are plotted at 
the midpoint of the respective extraction interval. The regression lines are also 
shown for both sampling techniques. Current applied was 0.5 mA in all subjects 
except participant 3 for whom it was 0.3 mA. 
Subject 1





































































































































































Sodium and potassium were evaluated as possible internal standard 
candidates, for the calibration of iohexol’s extraction fluxes. These ions are usually 
present in the body at reasonably constant values; 125-145 mM for sodium and 3.4-
4.7 mM for potassium. Both cations are extracted with iohexol to the cathode. 
Figure 10 shows the measured extraction fluxes in the in vivo experiments. Sodium 
extraction rates (expressed as mean ± SD) measured in the first interval (361 ± 22 
µg/h.mA) were significantly lower than the subsequent values (544 ± 123 µg/h.mA); 
while potassium fluxes showed no statistical difference at any of the sampling 
intervals (mean value: 206 ± 38 µg/h.mA). Extraction rates of sodium and potassium 
were more or less in agreement with previous in vivo studies [49, 50]. High 
variability was, however, observed with coefficients of variation (CV) of 23 % and 
19% for sodium and potassium, respectively. It is not entirely clear as to why such 
high variability was observed considering that the systemic levels of these cations 
should be constant. In addition, the high mobility together with the high systemic 
concentration of sodium relative to the other competing ions imply that the 
iontophoretic extraction rates of sodium should be insensitive to variations in its 
systemic concentration; and on the contrary to the present study, previous  in  vivo  
research in adults showed a CV of less than 10 % [49, 50]. Potassium, however, 
demonstrated high variation [50] and it was suggested by the authors that 







Figure 10: Iontophoretic extraction fluxes of sodium and potassium (JNa and JK, 
expressed as mean ± SD) at each sampling interval. Extraction fluxes of sodium 
measured in the first interval are statistically different from the subsequent values. 
Differences in extraction fluxes of potassium showed no statistical significance. 




































naturally in the epidermis [51], and as a result, the skin’s continuous attempts to 
restore the concentration gradient might have been the underlying cause for the 
variability of data observed.  
It is worth noting that measurement errors were potentially present in the 
design of this study because the patches employed are originally developed for 
drug delivery rather than as collection devices for extracted analytes. The cathode 
compartment, where iohexol, sodium, and potassium were sampled, is composed 
of gel polymers. Upon removal of the cathodal patch, some gel adherent to the skin 
was left on the application site and not all of the reverse iontophoretically 
extracted analytes were recovered in the patch. 
B.1 Elimination rate constant of iohexol 
First of all, data presented in Figure 9 show that, after a period of ≤ 2 hours of 
current application starting 0.5 hour post-intravenous injection of the marker, 
iohexol extraction fluxes (expressed semi-logarithmically) decreased linearly with 
time (r
2
 ≥ 0.87). This is in line with the expected exponential decline in iohexol 
concentration present in the subdermal (interstitial) fluid, from which the marker is 
reverse iontophoretically extracted from.  
Secondly, following a bolus injection of iohexol, 2 – 3 hours are required for 
the marker to distribute fully across its volume, known to be the extracellular fluid 
volume (plasma + ISF). During this time, the concentration of iohexol in ISF 
increases from zero, and the concentration in plasma decreases from the highest 
concentration, at time = 0. At the point of equilibrium (i.e. 2 – 3 hours), there is no 
net movement of iohexol between the two compartments (plasma and ISF) and the 
average concentration of iohexol in ISF is reported to be closely similar to that in 
the plasma [3, 6, 52, 53]. Thereafter, due to the continuous first-order elimination 
of plasma iohexol by glomerular filtration, the concentration of iohexol in ISF is 
expected to 'track' the concentration in the plasma but be, at any time point, 
somewhat greater by a proportion that would depend on the GFR.  
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The preceding information in the earlier two paragraphs lead to the following 
hypothesis: transdermal iontophoretic sampling of iohexol, once steady 
iontophoretic extraction was achieved, was sensitive to the first order elimination 
of iohexol, after distribution of the administered dose reached equilibrium. Hence, 
the elimination rate constant of iohexol (Ke) for each subject was calculated 
according to equation (13) for the reference method, blood sampling, and equation 
(15) for the non-invasive alternative method, skin sampling. The results shown in 
Table 6 indicate that, except for the first subject, Ke values determined from reverse 
iontophoresis agree well with the blood sampling data. It has to be acknowledged 
that the reference method used in this study relied on two blood samples only in 
the estimation of the elimination rate constant. It follows that in the event of a 
measurement error in one of the data points, Ke could be significantly altered and 
precision of the “true” reference measurements is limited. 
Table 6 also shows Ke values, determined according to equation (16), of 
iohexol’s iontophoretic extraction flux data calibrated with those of potential 
internal standard candidates (either sodium or potassium). Although the number of 
subjects is too small for any distinct conclusions to be made,  estimation  of Ke after 
 
 
Table 6: Elimination rate constants (h
-1
, expressed as absolute values (blood 
sampling) or best-fit estimate ± SE (skin sampling)) according to equations (13), (15) 
and (16). Numbers in brackets represent the ratios of the elimination rate constants 
estimated from the reference blood sampling and skin sampling. 
                    Subject 
Technique 
1 2 3 4 
Blood sampling 0.35 0.56 0.43 0.48 
Skin sampling 
0.15 ± 0.003 
(2.33) 
0.49 ± 0.08 
(1.14) 
0.35 ± 0.09 
(1.23) 





0.18 ± 0.09 
(1.94) 
0.51 ± 0.07 
(1.10) 
0.42 ± 0.06 
(1.02) 





0.19 ± 0.03 
(1.84) 
0.47 ± 0.1 
(1.19) 
0.52 ± 0.07 
(0.83) 




internal standard normalisation may offer slightly more precision to the 
iontophoretic extraction method. Inaccuracies arising from experimental errors will 
be apparent in the extraction fluxes of the internal standards because their fluxes 
are anticipated to be constant, and normalisation of iohexol’s extraction fluxes 
may, therefore, minimise measurement errors. Such suppositions require further 
validation in a larger study.  
In general, Ke estimated by skin sampling were consistently lower than those 
calculated from blood sampling. The significance of such differences cannot be 
appropriately tested owing to the small number of subjects recruited in the study. 
When interpreting iontophoretic extraction data, it must always be remembered 
that sampling is from the interstitial fluid and not from the blood. For example, it 
was found that the response of extraction fluxes of glucose to increased blood 
concentration is delayed due to a physiological lag which exists in glucose levels in 
the interstitial fluid compared to blood concentrations at the same time [49, 54, 
55]. For iohexol, the rate at which the marker is cleared from the plasma, after 
distribution reached equilibrium, should be reflected by the same rate of change in 
iohexol levels in the interstitial fluid regardless of whether the concentrations of 
iohexol in the interstitial fluid are different from those in the blood. 
B.2 Estimation of GFR from the two sampling approaches  
GFR is best estimated with multiple blood samples whereby a complete 
profiling of iohexol’s plasma disappearance over time provides an accurate 
estimation of the marker’s clearance. In practice, however, multiple sampling 
procedures are unattractive to both patients (and especially children) and the 
medical staff. It is for this reason that simplified models have been introduced 
where a single-compartment assumption is made and only the elimination phase of 
iohexol’s plasma concentration profile is considered. As a result, the number of 
blood samples is reduced to 2 – 4 samples. Some research groups even suggest that 
only 1 blood sample may be sufficient. The reference, blood sampling, method in 
this study relied upon 2 blood samples taken approximately 3 and 4 hours after 
iohexol intravenous administration. GFR was determined from both skin and blood 
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sampling data using the slope-only and slope-intercept methods and the results are 
presented in Figure 11. Except for subject 1, estimation of GFR using the slope-only 
methods produced similar measurements between skin and blood sampling 
techniques. Obviously, the same differences observed in Ke values were translated 
proportionally into differences in iohexol’s clearance and hence to differences in 
GFR. Similarly, the drawback noted above concerning the reference method which 
used two blood samples only in the determination of Ke and hence GFR is not 













Figure 11: Calculated GFR values from blood and skin sampling data using the slope-only 
methods after determination of the volume of distribution (Vd) either theoretically or 
empirically. GFR is also calculated from blood sampling using the slope-intercept method. 3 
sets of data from Skin sampling were used: A) iohexol extraction fluxes, B) iohexol fluxes 



















































































Finally, it is worth acknowledging that the current practice of how GFR is 
represented has been questioned and a more ideal representation of glomerular 
filtration was proposed to be GFR indexed to the body fluid it regulates; that is ECV, 
rather than GFR normalised to BSA (which already carries its own pitfalls in 
children) [23, 46, 56, 57]. This alternative parameter (GFR/ECV) describes the GFR 
per unit ECF volume and closely approximates to Ke. This approach is advantageous 
because GFR is dependent on ECV. So, in the event of ECV becoming abnormal due 
to an independent factor (e.g., hypovolaemia) other than a kidney filtration 
problem, GFR will change to correct ECV. However, this change is not because of a 
renal deterioration but rather due to the kidneys adjusting the filtration rate to 
accommodate for the ECV changes.                                                                                                                              
B.3 Relation between iohexol’s systemic concentrations and iontophoretic 
extraction fluxes 
Iohexol is a neutral molecule and its iontophoretic extraction flux is, 
therefore, due to electroosmosis. The extraction flux is also expected to be linearly 
proportional to its blood concentration as discussed previously. To assess the 
relationship between iohexol’s iontophoretic extraction fluxes (Jioh) with 
corresponding blood concentrations (Cp), both direct correlation (i.e. 2/B = 3 ∙ ) 
and the use of internal standard calibration concept (2/B 2CD. = 3′ ∙ ) were 
evaluated. First, data in Figure 9 were rearranged to represent extraction fluxes, 
after 3 and 4 hours of current passage, as a function of corresponding blood 
concentrations of the marker (Figure 12A). The Z values from each subject’s data 
are shown in Table 7A along with a common Z constant representing the slope of 
the linear regression of data from all subjects. A reasonable correlation (r
2
 0.69) 
was found between blood concentrations and extraction fluxes with a common Z 
constant of 11.6 ± 3.2 µl/h.mA. The Y-intercept (i.e. when Cp, ioh = 0) of the 
regression line (0.46 ± 0.14 µg/h.mA) is probably indicative of the fact that iohexol’s 
concentration in the subdermal (interstitial) fluid, from which the marker is reverse 
iontophoretically extracted from, is higher than the respective concentration in the 












Figure 12: A) Iohexol extraction fluxes (Jioh), B) The ratio of iohexol and sodium 
extraction fluxes (Jioh/JNa), and B) The ratio of iohexol and potassium extraction 
fluxes (Jioh/JK), as a function of corresponding iohexol blood concentrations (Cp, ioh). 
Iohexol blood concentrations used in the regressions were corrected for the 




From the limited data this study provides, it can be generally observed that 
individual Z measurements varied considerably between the four subjects (range 
7.5 – 19.2 µl/h.mA) (Table 7A). However, extraction efficiencies were less variable 
within each subject; and values obtained from subjects 2 to 4, as opposed to subject 
1, were relatively similar. The extraction efficiency of iohexol between participants 
may be different as in the case for glucose whose in vivo extraction exhibited both 
inter- and intra-subject variability [49, 58]. It may, on the other hand, follow the 
same pattern as urea (another neutral molecule) which demonstrated a relatively 
constant extraction efficiency in different human volunteers [58, 59]. Both glucose 
and urea are endogenous molecules and both have abundant reservoirs present in 
the skin [60, 61]. It was suggested that the variability in glucose extraction 
efficiency  was  attributed  to  the  complex  biochemical  and  metabolic  processes  






















































Table 7: Calculated values of Z and Z’ parameters from (A) extraction fluxes of 
iohexol (Jioh), (B) the ratio of iohexol and sodium extraction fluxes (Jioh/JNa), and (C) 
the ratio of iohexol and potassium extraction fluxes (Jioh/JK), as a function of 




Subject 1 Subject 2 Subject 3 Subject 4 All subjects 
(A): Z (µl/h.mA)  
 
Jioh = Z . Cp 
3 7.5 15.2 14.3 16.3 




4 9.3 19.2 13.3 14.5 
(B): Z’Na (µl/g) 
 
Jioh/JNa = Z’Na . Cp 
3 33.1 66.5 40.7 54.5 




4 47.1 80.7 45.3 51.1 
(C): Z’K (µl/g) 
 
Jioh/JK = Z’K . Cp 
3 63.5 157.6 137.9 155.9 




4 81.2 209.6 141.5 131.2 
* Represent the slope of the pooled regression ± SE 
 
involving glucose which happen on and within the skin and hence disturb the 
constancy of glucose extraction efficiency. Iohexol may be classed as an “inert” 
molecule; it is not metabolised, it does not bind to proteins or tissue nor enter cells, 
it distribute throughout the ECF volume, and finally it is excreted, by glomerular 
filtration, unchanged almost completely in 24 hours (i.e., no accumulation). It may 
be postulated, therefore, that iohexol extraction efficiency may behave more like 
urea than glucose. Another molecule which showed excellent constant extraction 
efficiency, after depletion of the skin reservoir caused by chronic use, is lithium 
[50]. It is, however, a positively-charged drug with a significantly smaller molecular 
weight and the mechanism of transport during reverse iontophoresis is mainly by 
electromigration rather than electroosmosis. To sum up, it is clear that in order to 
establish a firm association between extraction fluxes and blood concentrations of 
iohexol, a more rigorous validation study, with a higher number of subjects and 
more sampling points with shorter intervals, is necessary. 
Calibration of iohexol extraction fluxes with sodium as a potential internal 
standard (Figure 12B) resulted in a good correlation (r
2
 0.89) between extraction 
ratio data (Jioh/JNa) from all subjects and blood concentrations (common Z’ value = 
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27.4 ± 4 µl/g, Table 7B) but individual Z’ values were scattered between 31.1 and 
80.7 µl/g. Calibration with potassium produced a lower overall correlation (r
2
 0.49, 
Figure 12C) and a common Z’ value of 42.1 ± 17.6 µl/g (range 63.5 – 209.6 µl/g, 
Table 7C). The use of sodium as an internal standard for lithium resulted in better 
linear correlation and allowed more precise prediction of serum concentration of 
lithium [50]. The same concept did not prove valid when sodium was tested as an 
internal standard for glucose calibration [49] and it was suggested that a better 
internal standard would be one that is transported by the same mechanism as 
glucose (i.e., electroosmosis) during reverse iontophoresis. This idea was 
subsequently tested using urea as a neutral internal standard [58]. Urea performed 
relatively well as a potential internal standard for glucose but the variability of 
glucose extraction due to other factors other than extraction efficiency limited the 
usefulness of such approach.            
B.4 Local effects on the skin and participant feedback 
The procedures used in the study were well tolerated and all four participants 
completed the trial. Only subject 3 was uncomfortable with the original current 
settings (0.5 mA) and the intensity was, hence, lowered to 0.3 mA as from the 5
th
 
minute post-current initiation. Mild erythema at the patch application skin sites was 
noticed in all subjects and was more pronounced at the cathodal site (Figure 13). 
The adhesive material of the cathodal patch caused mild irritation to the skin of 
subject number 2 with a few small red spots. 
Sensation was evaluated by the universal Wong-Baker pain scale 
questionnaire; with 0 representing no pain and 5 demonstrating worst pain. 
Sensation was most felt at the beginning of the study (Pain scale ranged from 0 – 2) 
and diminished completely for most participants by the end of the study (Pain scale 
ranged from 0 – 1). The causes for the pain were from the adhesives contained in 
the patches and also from the tingling or itching sensation that iontophoresis tends 
to provoke. 3 out of 4 subjects reported more tingling/itching sensations below the 
anodal pad. This may be owing to the larger surface area of the anodal pad when 
compared to the cathodal patch (22.6 versus 7.2 cm
2
) and therefore, as suggested 
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previously [62], more nociceptors (pain receptors below the skin) may have been 
stimulated as a result of electrical current application. Similar observations of 
erythema and tingling or itching sensations were reported in the literature [50, 62, 
63]. 
All participants preferred skin sampling by iontophoresis over blood sampling. 
Feedback from participants and their parents included suggestions to significantly 
improve on the iontophoresis system to a more compact, all-in-one fully-portable 
device. The frequent removal of the patches was also disliked by the children due to 
the discomfort caused by the adhesive sides of the patches. The size of the patches 
was also not appropriate for the paediatric population and changes to the design 
























































Figure 13: Local effects of the iontophoresis system on the skin for each subject. 










4. Chapter conclusions 
The overall in vitro results presented here demonstrated the feasibility of 
using transdermal reverse iontophoresis as a non-invasive sampling alternative for 
iohexol. After a period of lag time, iohexol extraction was linearly proportional to its 
subdermal concentration. Skin pre-treatment with 3 hours current passage only 
shortened the time taken to reach stable extraction by 1 hour. Reverse 
iontophoresis allowed the estimation of iohexol’s pharmacokinetic parameters 
which were remarkably similar to those calculated using the subdermal 
concentration data. Hence, the potential for GFR determination non-invasively is a 
real possibility. These findings clearly warranted for an in vivo investigation which 
was subsequently performed as a proof-of-concept study and, indeed, 
demonstrated that iohexol sampling by transdermal reverse iontophoresis was 
possible. In general, estimation of the elimination rate constant of the marker, 
which reported directly on glomerular filtration, was similar between the reference 
blood sampling technique and the alternative skin sampling. Prediction of GFR by 
iontophoresis is, therefore, potentially possible and a larger study is warranted to 
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The objective of this study was to examine whether transdermal 
iontophoresis might be useful for the delivery of ranitidine hydrochloride to 
children. Constant, direct current, anodal iontophoresis of ranitidine was 
performed in vitro across dermatomed pig skin. First, the effect of donor vehicle, 
current intensity, and drug concentration were examined using aqueous solutions. 
It was found that drug delivery was higher at pH 7 (donor vehicle: 5 mM Tris) than 
pH 5.6 (donor vehicle: water). In the presence of low levels of competing 
background electrolyte (5 mM Tris), ranitidine delivery increased linearly with 
applied current but was independent of the donor drug concentration. The second 
part of the study evaluated the use of two Pluronic® F-127 gels as potential vehicles 
for the delivery of ranitidine. The gel formulations were characterised by apparent 
viscosity, conductivity and passive permeation measurements. Iontophoretic 
delivery of ranitidine was only slightly affected when delivered from the gel 
formulations relative to aqueous solutions; and 30 %w/w F-127 gel was more 
viscous than 20 %w/w formulation. It was found that paediatric therapeutic doses 
of ranitidine (neonates: 0.09 - 0.17 µmol/kg.h; 1 month – 12 years: 0.36 – 0.71 
µmol/kg.h) could be easily achieved by transdermal iontophoresis with acceptable 







Ranitidine is used extensively in paediatric medicine especially in intensive 
care. It is prescribed in a variety of clinical indications where gastric acid reduction 
is necessary [1]. This includes gastro-oesophageal reflux disease, benign gastric and 
duodenal ulcerations, prophylaxis of acid aspiration prior to surgery, and treatment 
as well as prophylaxis from stress-induced gastrointestinal ulcers and consequent 
haemorrhage. Routes of administration include oral and intravenous delivery. 
Ranitidine’s oral bioavailability is highly variable between paediatric subjects 
especially in the neonates (40 – 80 %) [2-4]. This is due to incomplete absorption of 
the drug from the gastro-intestinal tract as well as first-pass metabolism. The need 
for frequent dosing (2 - 4 times a day), due to the short half life of ranitidine (2 – 3 
hours [3, 5]), and the bitter taste of the oral solution reduce child compliance. In 
addition, some formulations contain up to 8 % alcohol and no oral preparation is 
licensed for use in children under 3 years of age; parenteral delivery is only licensed 
for children over 6 months old [1] and has inherent pitfalls such as pain and 
distress, invasiveness, risk of infection, and technical difficulties. 
The transdermal route can provide an alternative approach for the delivery of 
ranitidine. The relatively non-invasive nature of this administration method renders 
the application particularly attractive in paediatric medicine. Iontophoresis is an 
interesting option because it is possible to control delivery rates over extended 
periods of time. Ranitidine hydrochloride (Figure 1) is a good candidate for 
iontophoresis and target rates for therapeutic delivery are as follows: neonates, 
0.09 - 0.17 µmol/kg.h; 1 month – 12 years: 0.36 – 0.71 µmol/kg.h). These values are 
equivalent to the recommended intravenous infusion rates currently used in clinical 
care [1]. Ranitidine has a molecular weight of 314.4 Da (free base), free water 
solubility and the logP (octanol/water) is reported at 0.3 [6]. Ranitidine has two 
basic groups with pKa values of 2.3 and 8.2 [7] and is thus present predominantly as 
a monovalent cation at pH values between 4 and 7. Anodal delivery of ranitidine in 
this pH range is therefore expected to be largely due to electromigration with 




Figure 1: Chemical structure of ranitidine hydrochloride (M.W. 350.9, LogP 0.3, pKa 
2.3 and 8.2). 
 
In vitro investigations of transdermal iontophoresis, as a potential 
administration route for a specific drug, are performed mostly using solution-based 
vehicles because of easy preparation and manipulation. However, transdermal 
systems for clinical usage are typically semi-solid preparations. It is, therefore, 
important to test the in vitro delivery of the drug of interest from such preparations 
and mimic the in vivo situation as closely as possible. Semi-solid formulations often 
incorporate polymeric structures and hydrogels represent a specific example. These 
are attractive because while they provide the rigidity needed to firmly hold the 
application to the skin and prevent leakage, the presence of a high water content 
also provides a suitable conductive medium for iontophoresis.  
Pluronic F-127, a surface active gel-forming agent, has been used frequently 
in percutaneous applications [8, 9]. It is composed of triblocks of polyoxyethylene-
polyoxypropylene copolymers  at a ratio of 70% ethylene oxide (hydrophilic) and 
30% propylene oxide (hydrophobic), and with an average molecular weight 
between 9840 and 14600 Da [8, 10]. F-127 forms a gel by entanglement and 
packing of the micelles [10, 11]. The higher the concentration of the polymer or the 
higher the temperature, the greater the entanglement and the more rigid the gel 
becomes. F-127 hydrogels are favoured vehicles in transdermal iontophoresis for 
the following reasons: 1) The non-ionic nature of the surfactant avoids competition 
with the drug to carry the applied current. It also reduces potential interaction 
between the polymer and the drug molecules. Charged polymers have been shown 
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to carry electrical current to a certain extent and it was also suggested that they 
may bind to the ionised drug [12-15]. 2) F-127 is safe as evident in its widespread 
use in various pharmaceutical preparations intended for different routes of 
administration [8]. 3) The thermo-reversible properties of the polymer make its use 
as a transdermal carrier attractive. At 15 – 30 %w/w concentrations in water, F-127 
exists in liquid state at low temperature (≤ 5 °C) but forms a semi-solid gel at higher 
temperatures (> 15 °C). These unique rheological properties offer the advantage of 
easy fabrication and straightforward incorporation of the electrodes. They also 
provide firm application on the skin contours preventing leakage from the 
transdermal system. 
The purpose of this in vitro study was to investigate transdermal 
iontophoresis for the delivery of ranitidine to paediatric patients. The rate of input 
when ranitidine is administered as a continuous intravenous infusion was used as a 
guide to the target transdermal flux needed to achieve effective therapeutic levels. 
In vitro experiments were conducted to examine the effects of donor vehicle, drug 
concentration, and current intensity on the iontophoretic delivery of ranitidine 
from aqueous solutions. The most appropriate conditions were then adopted in 
gelled formulations and their performance as potential delivery systems for 




2. Materials and methods 
2.1 Chemicals  
Ranitidine hydrochloride (RAN), silver wire (99.99%), silver chloride 
(99.999%), and Pluronic® F-127 were purchased from Sigma Aldrich (Gillingham, 
UK). Tris base (α, α, α-Tris-(hydroxymethyl)-methylamine) and sodium chloride 
were obtained from Acros (Geel, Belgium). Acetonitrile, hydrochloric acid, glacial 
acetic acid, and triethylamine were provided by Fisher Scientific (Loughborough, 
UK). All reagents were at least analytical grade and deionised water (resistivity ≥ 
18.2 MΩ.cm, Barnsted Nanopure Diamond
TM
, Dubuque, IA) was used for the 
preparation of all solutions. 
2.2 Skin 
Fresh pig skin was obtained from a local slaughterhouse, cleaned under cold 
running water, and stored in a refrigerator until the following day. Abdominal skin 
was dermatomed (Zimmer™ Electric Dermatome, Dover, Ohio. Nominal thickness 
750 µm), cut into pieces of appropriate size, wrapped individually in Parafilm™, and 
then kept in a freezer (-20 °C) until use. Immediately prior to the permeation 
experiment, the skin was thawed at room temperature for 30 minutes and visible 
hairs were carefully cut with scissors. The skin was then mounted directly onto the 
diffusion cells. 
2.3 Iontophoresis 
Side-by-side two-compartment diffusion cells (active transport area = 0.78 
cm
2
, volume = 3 ml) were utilised in all experiments. The skin was mounted 
between the two chambers with the epidermal side oriented towards the anode 
compartment. The receptor chamber always held 154 mM sodium chloride solution 
(unbuffered, pH ~ 6) and was magnetically stirred (Multipoint-6 stirrer, Thermo 
Scientific Variomag, Cole-Parmer, London, UK) at 400 rpm throughout the 
experiment. Anodal, direct, constant current was delivered using Ag/AgCl 
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electrodes and a power supply (KEPCO 1000M, Flushing, NY, USA). Hourly samples 
(0.5 ml) of the receptor phase were withdrawn for analysis and replaced with fresh 
solution. Separate passive diffusion controls (no current) were also performed. 
2.3.1 Ranitidine delivery from aqueous solutions 
Prior to the start of the transport study, the skin was left for 30 minutes in 
contact with the donor vehicle without drug, and 154 mM sodium chloride in the 
receptor chamber. Both compartments were then emptied and refilled with a 
donor solution containing ranitidine and fresh receptor solution. Experiments 
examined donor vehicle, drug concentration, and current intensity effects on the 
iontophoretic delivery of ranitidine. Specific conditions are described in Table 1.  
2.3.2 Ranitidine delivery from gel formulations 
Two gel formulations were prepared according to the “cold method” [16]. 
Solutions containing 150 mM ranitidine in 5 mM Tris (pH 7) were cooled to 3 – 5 °C 
under continuous gentle agitation. F-127 (at 20 and 30 %w/w) was then 
incorporated slowly into the solutions and resulting formulations were left stirring 
for 2 days to achieve complete homogeneity.  
 
Table 1: Types of experiments performed to characterise ranitidine transdermal 
delivery from aqueous solutions. 
 














5 mM Tris 7* 5 














5 mM Tris 150 7* 0 3 




For the permeation experiments, 3.3 grams of each formulation was 
introduced into the donor compartment and constant current (0.3 mA) was 
delivered for 6 hours. The voltage of each iontophoresis system was monitored 
regularly using a voltmeter (DM-51 digital multimeter, ECG®, Taiwan). All 
experiments were conducted in a laboratory with controlled temperature: 22.2 ± 
0.9 °C, and both compartments were covered with Parafilm to avoid water 
evaporation. Number of replicates were 5 (iontophoresis) and 3 (passive diffusion 
controls). 
2.4 Viscosity measurements 
The apparent viscosities of the gel formulations were determined using a 
Bohlin rheometer (Malvern, UK) equipped with a cone-plate system. The angle of 
the cone was 4° and the diameter of the plate was 40 mm. Three specific shear 
rates were tested (0.1, 1, or 10 s
-1
) under a gap size set at 150 mm. Readings were 
performed at 22.1 ± 0.2 °C and gels were allowed to equilibrate on the plate for 5 
minutes before the measurements started. The viscosities of control formulations 
(without ranitidine) were also verified and all measurements were performed in 
triplicate. 
2.5 Conductivity measurements 
The conductivities of the gel formulations were measured using a 
conductimeter (T-120, Metrohm, Herisau, Switzerland, cell reference = 0.85) at 22 
°C. These were compared to the conductivity of ranitidine in aqueous solution. 
Measurements were performed in triplicate. 
2.6 Sample analysis 
Quantification of ranitidine was performed by high performance liquid 
chromatography with UV detection (315 nm). The method was modified from a 
previous publication [17] and used a Jasco HPLC system comprising a PU-980 pump 
with an AS-1595 autosampler, a UV-975 UV-VIS detector, and a HiQ-Sil
TM
 C18 (250 x 
4.6 mm, 5µm) reversed-phase column (Jasco, UK) thermostated at 25 °C. The 
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mobile phase (pH 3.8) consisted of a mixture of water, acetonitrile, acetic acid, and 
triethylamine (85:15:1.5:0.2, respectively in volume), and was pumped through the 
system at 1 ml/min. The validation parameters are found in Appendix (1C). 
2.7 Data analysis and statistics 
Data analysis and regressions were performed using Graph Pad Prism V.5.00 
(Graph Pad Software Inc., CA, USA). Unless otherwise stated, data are represented 
as the mean ± standard deviation (SD). Transport fluxes were calculated as the 
amounts delivered per unit time. Comparisons made between different sets of data 
were assessed by either two-tailed unpaired t-test (for 2 groups) or one-way 
ANOVA (for > 2 groups) which was followed by Tukey’s post-test. Comparison of 
ranitidine transdermal delivery from gel formulations relative to aqueous solution 
was made with two-way ANOVA followed by Bonferroni post-test. Statistical 
significance was set at p < 0.05. 
The transference number () of ranitidine was computed from Faraday’s law 
[18]: 
 =
 ×  × 

                                       Equation (1) 
Where 	 is the drug flux observed at 6 h, I is the current intensity applied, F is 
Faraday’s constant, and 




3. Results and discussion 
3.1 Ranitidine delivery from aqueous solutions 
The donor concentrations of ranitidine hydrochloride (25 – 150 mM) provided 
sufficient chloride ions for the Ag/AgCl electrochemistry at the anode. The passive 
diffusion flux of ranitidine from the highest donor concentration used (150 mM) 
was only 0.1 ± 0.04 nmol/h after 6 hours and was negligible relative to that 
achieved with iontophoresis.  
3.1.1 Effect of donor vehicle 
The first iontophoresis experiment used a donor solution containing only 
ranitidine hydrochloride (25 mM) in water. The pH of this unbuffered solution was 
around 5.6 and was low enough to ensure complete ionisation of the more basic 
group of ranitidine (pKa 8.2). Ranitidine was the only cation present in the donor 
compartment therefore resulting in the maximal iontophoretic transport possible. 
The flux reached 0.61 ± 0.08 µmol/h after 6 hours of current passage (Figure 2), 
corresponding to a transference number, calculated with equation (1), of 5.47 ± 







Figure 2: Ranitidine iontophoretic transport from 25 mM drug solutions of pH 5.6 
(in water) and 7 (in 5 mM Tris buffer). Current applied was 0.3 mA. Data represent 






























pH was adjusted to 7 with HCl. Initially, the iontophoretic transport fluxes were 
similar to those at pH 5.6. However, from the fourth hour of iontophoresis, a 
significantly higher flux at pH 7 (p < 0.05) was found attainting 0.78 ± 0.07 µmol/h 
after 6 hours of current passage (Figure 2). This corresponds to a transference 
number of 6.95 ± 0.58 %. It follows that even though the addition of Tris introduced 
co-ion competition with ranitidine (4.6 mM Tris is positively charged at pH 7, pKa 
8.1), the higher pH of the donor solution also increased the magnitude of both 
electroosmosis and electromigration. The isoelectric point of porcine skin has been 
reported to be approximately 4.4 [19]; above this pH, the net charge of the skin is 
negative. The skin is therefore more permselective to cations [18-20]. Similar 
findings have been previously observed for other cations. Sieg et al. [21] found a 
significant increase in the iontophoretic flux of sodium when the pH was raised 
from 6.3 to 7.4 (8 ± 0.3 versus 10.7 ± 0.7 µmol/h.cm
2
). However, a further increase 
to pH 8.5 did not produce any difference from values obtained at pH 7.4. Wearley 
et al. [22] tested the delivery of verapamil (MW 454.6, pKa 8.9) under pulsed direct 
current using donor solutions containing 105 mM verapamil in acetate buffer (pH 4-
6). Again, the permeation rates of this fully ionised cation were enhanced as the pH 
of the donor solution was increased. Another example is sumatriptan (MW 295.5, 
pKa 9.6), the iontophoretic transport of which was significantly higher when the 
donor pH was raised from 5 to 7 [23]. 
3.1.2 Effect of current intensity 
 This part of study aimed: 1) to confirm that iontophoresis provides a 
controllable dosing system, and 2) to check that small current intensities can deliver 
therapeutic levels of ranitidine. While it is accepted that a current density of up to 
0.5 mA/cm
2
 is usually tolerable by humans, delivering target doses with smaller 
currents is very desirable in children (especially neonates) to minimise discomfort. 
Three intensities were examined: 0.1, 0.2, and 0.3 mA, (0.13, 0.26, and 0.39 
mA/cm
2
) for a fixed drug donor concentration (50 mM). As expected and in 
agreement with Faraday’s law (equation 1), an excellent linear correlation (r
2
 0.97, 
p < 0.0001) was found (Figure 3) between current intensity and ranitidine’s 








Figure 3: Delivery fluxes of ranitidine (mean ± SD) as a function of time of 
iontophoresis (left) and current intensity (right). Ranitidine was delivered from a 50 
mM donor solution (5 mM Tris, pH 7).  
 
found in previous publications [24-27]. The slope of the line in the right-hand panel 
of Figure 3 corresponds to a transference number of 7.05 ± 0.33 % (± SE); a value 
very similar to that previously obtained with 25 mM ranitidine in 5 mM Tris (pH 7) 
(6.95 ± 0.58 %, section 3.1.1). This observation is explained in the next section.  
At the lowest current (i.e., 0.13 mA/cm
2
), the delivery rate was 0.31 ± 0.02 
µmol/h.cm
2
. The recommended intravenous infusion doses of ranitidine are: 
neonates, 0.09 - 0.17 µmol/kg.h, and older than 1 month, 0.36 – 0.71 µmol/kg.h [1]. 
It follows that iontophoresis using 0.13 mA/cm
2
 can deliver therapeutically effective 
levels of ranitidine with a patch application area (anode + cathode) ranging from 
only 0.6 – 1.1 cm
2
/kg for neonates and 2.3 – 4.6 cm
2
/kg for the older group. 
Obviously the use of higher current densities would significantly reduce the patch 
size needed to deliver the same therapeutic levels of ranitidine. Indeed, using 0.39 
mA/cm
2
 current density, areas of only 0.2 – 1.4 cm
2
/kg would be required, a very 
acceptable range for transdermal delivery. Figure 4 illustrates the iontophoretic 
patch areas required for different groups of paediatric subjects as a function of 





































































                                                                                                                                             
Figure 4: Estimated patch areas (anode + cathode) required to achieve therapeutic 
input rates of ranitidine by iontophoresis, as a function of current density applied. 4 
age groups are used to illustrate the range of areas necessary in the paediatric 
population. 
 
3.1.3 Effect of drug concentration 
Figure 5 shows that the delivery rates achieved using three different drug 
concentrations (25, 50, and 150 mM) in the donor solution were not significantly 
different, ranging from 0.90 ± 0.10 to 0.78 ± 0.07 µmol/h. This is due to the fact that 
the molar fraction of ranitidine, relative to the only other competing co-ion (i.e., 
Tris) did not differ appreciably in the three conditions (0.84, 0.91, and 0.97 for 25, 
50, and 150 mM drug concentrations, respectively).  
3.2 Ranitidine delivery from gel formulations 
The optimum conditions established using solution-based donor vehicles 
were then used to develop a gel formulation based on Pluronic F-127 (at 20 or 30 
%w/w). Ranitidine was delivered from a 150 mM drug concentration in 5 mM Tris 
buffer (pH 7) and at 0.3 mA current intensity. The highest concentration of the drug 
was chosen to mitigate against any possible effects of gelation of the vehicle on the 
release of ranitidine.  
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Figure 5: Ranitidine transport fluxes (6 h) as a function its donor concentration and 
molar fraction. Data are represented as the mean ± SD. 
 
3.2.1 Apparent viscosity measurements 
Figure 6 depicts the apparent viscosity of each gel formulation measured at 
22 °C using a cone and plate rheometer. A relatively high gap size was used to avoid 
possible collapse of the micelle structures present in the gel formulations. As is 
evident in the Figure, the presence of ranitidine did not affect the apparent 
viscosity of the gel formulations implying that the drug did not interfere with either 
the micellisation or the entanglement and packing of the F-127 polymer.  
Both drug-loaded gel formulations were semi-solid at 22 °C but their 
viscosities differed significantly. For example, when the applied shear rate was 0.1 s
-
1
, the apparent viscosity of the gel containing 20 %w/w F-127 was 863 ± 67 Pa.s; 
whereas for the same shear rate, the apparent viscosity of 30 %w/w F-127 gel was 
5139 ± 302 Pa.s. Incorporation of 20 % F-127 formed a “soft” gel structure while 30 
% produced a more rigid semi-solid consistency which is more appropriate in 
transdermal applications. The flow curves of the gel formulations conformed to the 
Ostwald-De Waele power law [28-30]:       =  ×                Equation (2) 
Where η is the apparent viscosity, K is the flow consistency index, n is the 





Ionised ranitidine molar fraction (%)
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(91 ± 5) 
0.14 ± 0.01 




405 ± 8 
(375 ± 8) 
-0.07 ± 0.01 
(-0.1 ± 0.01) 
 
Figure 6: Flow curves of the apparent viscosities of the gels measured at different 
shear rates and parameters derived from data regression using the power law 
relation:  =  × . (η is the apparent viscosity measured at a particular shear 
rate ().  is the flow consistency index and  is the power-law index). Values 
between brackets in the table indicate the control formulations (i.e., no drug). 
 
 
index values of all formulations were below 1 and are indicative of pseudoplastic 
behaviour. The gels are shear-thinning fluids because an inverse relationship is 
found between the applied shear rate and the apparent viscosity. Even at high 
shear rates, the apparent viscosity of the gel formulations remained in the linear 
region of the power law. This is indicative of the stable structure of the gel 
formulations under the shear rates applied because the micelles which form the 
basis of the internal network of the gel were not perturbed.  
3.2.1 Conductivity measurements  








































Figure 7: Average voltage measurements as a function of time of current 
application (0.3 mA). Data shown represent the mean ± SD. 
 
2.9 ± 0.02 mSi/cm) for 0, 20, and 30 %w/w F-127 gels respectively. All values 
differed significantly (p < 0.0001). The viscosity of the formulation affected its 
conductivity indirectly as follows [31-33]: 1) the diffusivity of each ion present in the 
formulation is inversely dependent on the viscosity of the formulation (Stokes-
Einstein relation); 2) the conductivity of the formulation is proportional to the ions’ 
mobility; and 3) the diffusivity of the ion is directly related to its mobility (Einstein 
relation). 
3.2.2 Voltage measurements 
The voltage of each diffusion cell was monitored throughout the 
iontophoresis experiment (0.3 mA) because the resistance of the system as a 
conductive medium was expected to be higher with the gel formulations. The 
sources of resistance include the electrodes used, the donor and receptor vehicles, 
and the skin that separates both vehicles. Figure 7 describes the average voltage 
per cell as a function of time of iontophoresis. The voltage started at high levels for 
all formulations and decreased gradually until it levelled off to apparent steady 
values. The reduction in the voltage from the initially high values are due to the skin 
becoming more conductive as ions from both the donor and receptor vehicles enter 
and move across the skin. In agreement with the conductivity results, Figure 7 also 
shows  that  the  voltage  increased  with  higher  F-127  concentration  in the donor  







































Figure 8: The passive diffusion of ranitidine both from gel formulations and liquid 
solution. Data are expressed as the mean ± SD. 
 
 
formulation  due  to  the  higher  resistance  of  the  donor  vehicle  to  conduct  the 
applied current. Nevertheless, the voltage associated with 30 % gel was still 
acceptable and using such gel produced an efficient conductive medium for 
iontophoretic application. 
3.2.3 Permeation studies 
Figure 8 shows the passive diffusion profiles of ranitidine from donor 
formulations containing 0 (control), 20 and 30 %w/w of the gelling agent F-127. 
After 24 hours, cumulative amounts of 18.6 ± 6.9, 15.6 ± 4.7, and 9.2 ± 4.6 
nmol/cm
2
 of drug permeated through the skin, respectively. As suggested by 
previous investigators, the lower permeation rates accompanied by increasing the 
concentration of the gelling agent are attributed to lower release rates from the gel 
formulations [34-39]. Reduced release characteristics through the matrix of the gel 
may be because of a change in the thermodynamic activity of ranitidine in the 
donor formulation (higher solubility) and/or the resistance of the gel formulation to 
the diffusion of ranitidine through it (by either a longer diffusion path, or the higher 
formulation viscosity which leads to lower diffusivity of the drug (Stokes–Einstein 
relation [32, 33]), or both factors together). Figure 9 presents the iontophoretic 
delivery rates of ranitidine from the F-127 gels. The transport rates at 6 hours were 
0.90 ± 0.10 (0 % F-127), 0.95 ± 0.10 (20 % F-127), and 0.75 ± 0.07 µmole/h (30 % F-
127). Two-way ANOVA tests revealed that delivery  fluxes  (measured  as of the 4
th
  






































































Figure 9: Iontophoretic delivery fluxes of ranitidine from donor formulations 
containing 0, 20, and 30 %w/w F-127. Data are represented as the mean ± SD.  
 
hour  of  current  passage)  from  30 %  F-127  donor  formulation were statistically 
lower than the other two formulations. Nevertheless, the use of 30 % gel 
formulation as iontophoresis vehicle for ranitidine delivery only reduced fluxes by 
about 20 %. The corresponding transference numbers of ranitidine using  0, 20 and 
30 %w/w F-127 donor formulations are 8.05 ± 0.91, 8.48 ± 0.87, and 6.73 ± 0.63 %, 
respectively. Using the flux rates achieved with the gel formulations and assuming a 
one-to-one in vitro:in vivo correlation, patch areas required to achieve therapeutic 
input levels of ranitidine are estimated in Table 2. In summary, the use of F-127 gel 
formulations in the iontophoretic delivery of ranitidine did indeed deliver 
therapeutically meaningful fluxes with acceptable patch application areas.  
 
 
Table 2: The patch sizes (anode + cathode) required to achieve target systemic 
levels of ranitidine in different groups of the paediatric population.  
 
Target input rate 
(µmol/h.kg)
(1) 











0.09 – 0.17 Solution: 1.16 ± 0.13 
 
Gel 20%: 1.22 ± 0.13 
 
Gel 30%: 0.97 ± 0.09 
0.1 – 0.3 
0.1 – 0.3 
0.2 – 0.4 
> 1 month – 
12 years 
0.36 – 0.71 
0.6 – 1.2 
0.6 – 1.2 
0.7 – 1.5 
(1)
: = intravenous infusion rate. 
(2)
: fluxes correspond to 6 hour measurement of 
iontophoresis (0.39 mA/cm
2




4. Chapter conclusions 
Transdermal iontophoresis of ranitidine enhanced its delivery significantly 
relative to passive diffusion. The manipulation of different parameters allowed the 
selection of the best conditions under which ranitidine’s iontophoretic delivery 
achieved target doses with both solution and gel formulations. In particular, the gel 
formulation composed of 30 %w/w F-127 polymer showed good potential as a 
semi-solid matrix for the iontophoretic delivery of ranitidine. This is owing to its 
good viscosity, acceptable electrical conductivity and iontophoretic efficiency. 
Assuming a one-to-one in vitro-in vivo correlation and delivering a current of 0.39 
mA/cm
2
 through a 30 % gel containing 150 mM ranitidine, therapeutic levels of 
ranitidine in children up to the age of 12 years can be achieved with a total patch 
system of 0.2 – 1.5 cm
2
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The purpose of this study was to assess whether transdermal iontophoretic 
delivery of midazolam may provide a useful treatment strategy for paediatric 
patients. Experiments were performed in vitro using intact pig skin as well as 
barriers from which the stratum corneum had been stripped to different extents to 
model the less resistant skin of premature babies. The impact of current intensity, 
midazolam concentration, ion composition and pH of the drug formulation were 
examined. Drug delivery was increased by increasing the current, by higher pH, and 
by maximising the mole fraction of midazolam in the driving electrode formulation. 
Compromisation of the barrier to 50 % of its normal function led to an 
approximately 60-fold increase in the passive permeation of midazolam; complete 
removal of the stratum corneum resulted in a further 20-fold enhancement. In 
contrast, with iontophoresis, the current controlled transport through the half-
compromised skin; across a fully impaired barrier, however, iontophoretic control 
was undermined by the very high passive contribution. Overall, it was possible to 
control midazolam delivery in most situations, and iontophoresis could deliver a 






Midazolam, a short acting benzodiazepine, is used in paediatric medicine as a 
sedative for operations, premedication and in intensive care where continuous 
sedation is an integral part of patient care [1]. It is especially used in infants and (in 
particular) premature neonates. Depending on the individual case, midazolam is 
delivered either by the oral, rectal, buccal, nasal, or intravenous (either as bolus or 
continuous infusion) route.  
When given orally, midazolam undergoes extensive first pass metabolism 
resulting in low bioavailability of 15 – 30 % [2]. Its half life is short (2 hours, but 
longer in neonates [3]) and frequent dosing, as a result, is necessary to sustain 
therapeutic efficacy. The bitter taste of the oral solution is also problematic. Of 
course, oral delivery to infants and children in intensive care is often inappropriate, 
and the same can be said of the buccal route. Intravenous delivery is currently the 
most commonly used administration method, despite being associated with the risk 
of infection and pain. More specific problems include precipitation of midazolam at 
pH > 5, and incompatibility with both parenteral nutrition and drugs such as 
ranitidine and furosemide [4-7]. These issues are not infrequent and necessitate a 
separate intravenous line for midazolam, a far from ideal situation in infants and 
children for whom their small size renders multiple i.v access lines more difficult 
and invasive. Children in intensive care and neonates are often continuously 
infused with midazolam to provide continuous and stable sedative effects, and 
again there are complications related to compliance and scarring at the injection 
site. Rectal or nasal administration have been proposed as alternatives to 
intravenous delivery, but the former has been linked to low and inconsistent 
absorption rates [2, 8], while the latter is not recommended due to irritation of the 
nasal mucosa resulting in an intense burning sensation [1, 9].  
Transdermal iontophoresis may offer an advantageous, alternative route for 
the delivery of midazolam. To be successful, transdermal iontophoresis must deliver 
target dosing rates achieved by intravenous administration. Typical intravenous 
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regimens recommended for continuous sedation in paediatric intensive care are as 
follows: 1) premature neonates of gestational age less than 32 weeks, 30 µg/kg/h; 
2) neonates of more than 32 weeks gestational age to infants up to 6 months, 60 
µg/kg/h; 3) Older than 6 months, a loading dose of 30 – 300 µg/kg as a slow 
intravenous injection, followed by continuous infusion of 30 – 120 µg/kg/h.  
The skin barrier of neonates whose gestational age is more than 34 weeks 
resembles adult skin [10]. Premature neonates of less than 34 weeks gestation, are, 
however, characterized by an underdeveloped skin barrier with incomplete 
formation of stratum corneum structure [11, 12]. The level of barrier impairment 
depends on the post-conceptional age of the neonate (i.e., the sum of the gestation 
age at birth and the post-natal age), and has been evaluated using measurements 
of transepidermal water loss (TEWL) [13-16]. A reduced barrier function is 
associated with an elevated TEWL value. As the developing skin barrier matures, 
TEWL decreases accordingly until a fully functional barrier is established. The 
immature barrier of premature neonates often causes some critical issues such as 
thermoregulation control, and increased permeability characteristics in comparison 
with intact skin which may augment the risks of toxicity to chemicals. It could, 
however, be used in favour to the transdermal delivery of drugs and this potential 
has indeed been explored in vivo, for example, in the delivery of theophylline and 
caffeine [17, 18]. 
To study transdermal permeation of potential drugs in the paediatric 
population, a range of skin membranes, the barrier functions of which mirror those 
of premature neonates and older ages, need to be investigated. For obvious ethical 
reasons, excised skin from humans and especially children are rarely available. Pig 
skin is often used, as an alternative to human skin, to assess transdermal 
permeation of drugs [19-21]. In addition, it has been demonstrated that pig skin, 
from which the stratum corneum has been differentially tape-stripped to provide 
different degrees of compromised barriers, can be used as an in vitro model to the 
premature neonatal skin at different levels of skin maturation (i.e., different 
gestational age) [22].  
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 The objective of this study was to investigate in vitro the feasibility of 
delivery of midazolam by transdermal iontophoresis. First, intact pig skin was used 
to consider the variables determining the iontophoretic delivery of midazolam. 
Second, transdermal delivery of the drug was tested through pig skin from which 
the stratum corneum had been stripped to different extents so as to model the less 






2. Materials and methods 
2.1 Chemicals 
Midazolam hydrochloride was obtained from Apin Chemicals (Oxford, UK), 
silver wire (99.99%), silver chloride (99.999%), and sodium hydroxide pellets were 
purchased from Sigma Aldrich (Gillingham, UK). Sodium chloride, citric acid 
monohydrate, trisodium citrate dehydrate, disodium hydrogen phosphate, 
potassium dihydrogen phosphate, and phosphoric acid (85 %) were obtained from 
Acros (Geel, Belgium). Acetonitrile and hydrochloric acid were provided by Fisher 
Scientific (Loughborough, UK). All reagents were at least analytical grade and 
deionised water (resistivity ≥ 18.2 MΩ.cm, Barnsted Nanopure Diamond
TM
, 
Dubuque, IA) was used for the preparation of all solutions. 
2.2 Skin 
Fresh pig skin was obtained from a local slaughterhouse, cleaned under cold 
running water, and stored in a refrigerator until the following day. Dorsal skin was 
dermatomed (Zimmer™ Electric Dermatome, Dover, Ohio; nominal thickness 750 
µm), cut into pieces of appropriate size, wrapped individually in Parafilm™, and 
then kept in a freezer (-20 °C) until use. Prior to the permeation experiment, the 
skin was thawed at room temperature for 30 minutes and visible hairs were 
carefully cut with scissors. The skin was either used as is or was tape-stripped to 
create two impaired barriers: half compromised (40 – 60 %) and fully compromised 
(100 %).  
The tape-stripping procedure was as follows: First, a 10 x 10 cm
2
 area of skin 
was divided into 3 pieces. The first piece represented the intact skin barrier and an 
initial, baseline reading of TEWL was measured using an evaporimeter (AquaFlux 
AF-102, Biox Systems Ltd., London, UK). TEWL was recorded once the reading had 
stabilised (maximum duration set at 3 minutes) and the average reading was 9.0 ± 
1.7 g/m
2
.h. The second piece of skin was repeatedly stripped with adhesive tape (2 
x 2 cm
2
, Scotch Book Tape, 3M, St. Paul, MN) to progressively remove the stratum 
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corneum and produce 100 % barrier impairment. A 1.5 x 1.5 cm
2
 template was 
affixed onto the skin before the stripping procedure to ensure the removal of 
stratum corneum from the same skin location. Periodic measurement of TEWL 
allowed the degree of barrier impairment to be quantified and 100 % derangement 
was deemed to have been achieved when TEWL did not increase further. Between 
17 and 25 tapes were needed to produce a fully compromised skin with a mean 
TEWL of 153 ± 11 g/m
2
.h. Finally, the third piece of skin was also sequentially 
stripped until TEWL reached 40 – 60 % of that of the fully perturbed barrier. 
Between 13 and 16 tapes produced a half-compromised barrier with a mean TEWL 
of 76 ± 8 g/m
2
.h. 
2.3 Iontophoresis  
Amber side-by-side two-compartment diffusion cells (active transport area = 
0.71 cm
2
, volume = 3 ml) were utilised in all experiments. The skin was mounted 
between the two chambers with the epidermal side oriented towards the anode 
compartment. The receptor chamber always held 154 mM sodium chloride solution 
(unbuffered, pH ~ 6). For 30 minutes prior to the start of the transport study, the 
skin was left in contact with the donor vehicle without drug, and 154 mM sodium 
chloride in the receptor chamber. Both compartments were then emptied and 
refilled with a donor solution containing midazolam and fresh receptor solution. 
Both compartments were magnetically stirred (Multipoint-6 stirrer, Thermo 
Scientific Variomag, Cole-Parmer, London, UK) at 400 rpm throughout the 
experiment. A direct constant current was delivered from a power supply (KEPCO 
1000M, Flushing, NY, USA) using Ag/AgCl electrodes. Hourly samples (1 ml) of the 
receptor phase were withdrawn for analysis and replaced with fresh solution. 
Separate passive diffusion controls (no current) were also performed. The 
experiments performed are summarised in Table 1.  
To investigate possible drug accumulation in the skin, the donor and receptor 
solutions were replaced with fresh drug-free solutions at the end of iontophoresis 
and the release of midazolam into the receptor phase was then followed over the 
next 15 hours.  
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Table 1: Experimental conditions performed to characterise midazolam transdermal 
delivery. 
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* The citrate buffer comprised 7.4 mM citric acid monohydrate and 2.6 mM 
trisodium citrate dehydrate. ** Final pH of the drug solution in citrate buffer was 
always 3.5 except in pH effect experiments where it was adjusted to 3 with HCl; and 
to 4 and 4.5 with NaOH. pH change at the end of all permeation experiments did 
not exceed ± 0.1 in citrate buffer vehicles and ± 0.2 in water vehicle. 
 
 
2.4 Sample analysis 
Quantification of midazolam was performed by high performance liquid 
chromatography with UV detection (220 nm). The method used a Jasco HPLC 
system comprising a PU-980 pump with an AS-1595 autosampler, a UV-975 UV-VIS 
detector, and an Acclaim 120, C18 (150 x 4.6 mm, 5µm) reversed-phase column 
(Dionex, UK) which was thermostated at 25 °C. The mobile phase consisted of 50 
mM phosphate buffer (pH 2 with phosphoric acid) and acetonitrile (70 : 30)  and 
was pumped through the system at 1 ml/min. The validation parameters are found 
in Appendix (1D). 
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2.5 Data analysis and statistics 
Data analysis and regressions were performed using Graph Pad Prism V.5.00 
(Graph Pad Software Inc., CA, USA). Unless otherwise stated, data are represented 
as the mean ± standard deviation (SD). Transport fluxes were calculated as the 
amounts delivered per unit time. Comparisons made between different sets of data 
were assessed by either two-tailed unpaired t-test (for 2 groups) or one-way 
ANOVA (for > 2 groups) followed by Tukey’s post-test. Statistical significance was 
set at p < 0.05. 
The transference number () of midazolam was computed according to 
Faraday’s law [23]: 
 =
 ×  × 

                          Equation (1) 
Where 	 is the drug flux observed at 6 h of iontophoresis, I is the current 
intensity applied, F is Faraday’s constant, and 
 is the numerical value of the 




3. Results and discussion 
The passive flux of midazolam hydrochloride (applied as a 15 mM solution at 
pH 3.5) through intact pig skin was 0.06 ± 0.01 nmol/h.cm
2
 at 21 h. This flux value is 
substantially smaller than a previously reported value of 12.9 nmol/h.cm
2
 [24]. The 
latter result was obtained when radio-labelled midazolam maleate (11.3 mM in 
water, unbuffered) was applied to hairless mouse skin, a model which is known to 
be more permeable than the human counterpart [25, 26] and more susceptible to 
the effects of a low pH vehicle. 
As shown below, iontophoresis through intact skin was significantly higher 
than passive diffusion, the contribution of which to the observed fluxes could be 
neglected. 
3.1 pH effect 
Midazolam is a weak base with pKa value of 6.15 [27] and a molecular weight 
of 325.8. It is lipophilic (LogP 4.33, [28]) and has very low aqueous solubility at pH 
values higher than 5. The solubility is considerably higher at acidic pH where 
midazolam is ionised [29]. Hence, experiments were performed at pH values of 3, 
3.5, 4, and 4.5. Donor solutions (containing 7.5 mM midazolam) at pH 4.5 were 
slightly cloudy but no precipitation was observed for the duration of the 
experiment. Figure 1 depicts transport fluxes of midazolam as a function of pH 
when 0.36 mA current was passed for 6 hours. Drug delivery increased with 
increasing pH. Despite the lower solubility of midazolam at pH 4.5, the highest 
transport (p < 0.05) was observed in this case (J6h = 17.7 ± 3.2 nmol/h); at pH 3, in 
contrast, the flux was only 6.0 ± 3.0 nmol/h. At intermediate pHs, drug flux fell 
between these two extremes. The effect of pH on midazolam transport can be 














Figure 1: Midazolam iontophoretic transport (mean ± SD) as a function of donor 




1) Lowering the donor pH leads to a rise in the presence of hydronium ions in 
the drug formulation (0.03 mM at pH 4.5, increasing to 1 mM at pH 3). As a result, 
there is more co-ion competition against midazolam owing to the fact that 
hydronium ions are much more efficient as charge carriers due to their high 
mobility properties. Acyclovir, 5-OH-DPAT, and 5-Aminolevulinic acid are example 
drugs whose anodal iontophoretic transport was studied at low pH values with 
similar observations about the effect of hydronium ion competition [30-32]. 
2) Lowering the donor pH results in less net negative charge (or even charge 
reversal) on the skin affecting both electroosmosis and electromigration of the 
cation [23, 33, 34]. Electroosmosis in particular is severely affected at low pH 
values. Pig skin was demonstrated to have an isoelectric point of ~ 4.4 [34]. This 
means that at this pH, the skin had a net charge of zero and is neither 
permselective to cations nor anions. Above this pH, the skin is negatively charged, 
permselective to cations, and, under iontophoresis, electroosmosis takes place in 
the direction of anode-to-cathode; further boosting the anodal transport of 
midazolam. When pH values are below the isoelectric point, reversal of the skin net 
charge occurs, leading to preferential passage of anions, which in turn results in 
induction of electroosmosis at the opposite direction to midazolam transport 
(cathode-to-anode). Midazolam anodal delivery is therefore retarded as the pH is 
progressively lowered. Similar observations were noted for other cations such as  
































Figure 2: Midazolam exists in a pH-dependent equilibrium with an open-ring 
structure in acidic conditions. 
 
the dopamine agonists: apomorphine, 5-OH-DPAT, and rotigotine [30, 35, 36], 
whose anodal delivery was tested using donor solutions of pH values 3 – 6. 
3) In acidic conditions, midazolam exists in a pH-dependent equilibrium with a 
double charged ring-opened structure [29, 37] (Figure 2). Previous work which 
quantified the percentage of the open-ring structure of midazolam as a function of 
solution pH [29, 37, 38] is summarised in Figure 3. It is therefore estimated that ~ 
19, 9, 4, ad 2 % of midazolam ions are present as divalent cations at pH: 3, 3.5, 4, 
and 4.5, respectively. These are only estimates from available literature and may 
not reflect exact percentages in this study because different buffers were used. 
Divalent midazolam cations may behave differently from the monovalent ions and 
so is their iontophoretic transport efficiency. Even though equation (1) expects that 
an increase in drug valence results in lower electrotransport as fewer molecules are 
needed to carry the same quantity of charge, the transference number of the drug 
is also altered with valence as reported in a previous study where divalent peptides 
were found to be more efficient at carrying charge than monovalent peptides of 
similar molecular weight [39]. Nonetheless, even though a fifth of midazolam may 
have been present as divalent cations at pH 3, the fact that the skin was also 
positively charged at pH 3 and the higher presence of competing hydronium ions 










Figure 3: A summary of published work [29, 37, 38] which quantified the 
percentage of the open-ring structure of midazolam as a function of solution pH. 
Different symbols summarise different techniques used. 
 
 
To sum up, midazolam transport from pH 4.5 donor solution was significantly 
more effective than at lower pH values. However, solutions made at this pH (7.5 
mM midazolam) were cloudy and may have been near saturation levels. Hence, to 
ensure complete solubility, pH 3.5 was chosen for the subsequent experiments as it 
allowed usage of higher concentrations of the drug. 
Faraday’s law (equation 1) dictates that the iontophoretic transport of an ion 
is a function of both the current intensity applied and the transference number. 
These factors are the subject of the next sections. The total fluxes observed during 
midazolam iontophoresis were assumed to be attributed to its electromigration 
only. This is because: 1) as mentioned above, passive diffusion was found to be 
negligible, and 2) contribution from electroosmosis was also neglected because, at 
pH 3.5, any effect of electroosmosis would be in the direction of the cathode-to-
anode which is opposite to midazolam’s anodal delivery. 
3.2 Current effect 
As expected, increasing the current intensity led to proportional 
enhancement of midazolam iontophoretic fluxes (Figure 4), in agreement with 
Faraday’s law (equation 1). These results reaffirm the major role of current intensity 





















in controlling iontophoretic delivery and similar findings have been reported 
previously for many compounds [40-45]. The gradient of the line in the right-hand 
panel of Figure 4 equals the drug’s transference number: 0.22 ± 0.03 % (± SE, p < 
0.0001, r
2
 0.88). Midazolam’s transference number is approximately 30-fold smaller 
than that of ranitidine (chapter 3). While both cations have similar molecular 
weight (325.8 versus 314.4 Da), midazolam is much more lipophilic (LogP 4.3 versus 
0.3). The significant difference in the drug molar fraction in the donor solution 
(midazolam: 15.8 %, ranitidine: 91.1 %) and the effect of pH (3.5 for midazolam and 
7 for ranitidine) discussed above account for the much superior transport efficiency 













Figure 4: Delivery fluxes of Midazolam (mean ± SD) as a function of time (left) and 
current intensity (right). Midazolam was delivered from a 7.5 mM donor solution in 
the presence of 37.8 mM sodium ions (pH 3.5).  
 
3.3 Mole fraction effect 
It has been shown previously that the molar fraction of the drug in the donor 
solution, as opposed to its concentration, determines the transport efficiency of the 
drug [23, 46-48]. This was demonstrated in the previous chapter for ranitidine. 
However, for very lipophilic cations, this relationship sometimes does not hold (e.g., 
ropinirole, LogP 3.3, [49]).    
Midazolam iontophoretic delivery was measured from constant pH, donor 
solutions, as a function of 1) competing co-ion concentration (drug concentration is 






























































Figure 5: Midazolam transport from different donor vehicles. Flux values (mean ± 
SD) at the 6
th
 hour of iontophoresis (0.36 mA). Drug concentration was 15.9 mM in 





fixed), and 2) drug concentration (co-ion concentration is fixed). Figure 5 compares 
midazolam delivery from the different donor solutions. As expected, the most 
efficient delivery of midazolam was from water (J6h = 62.2 ± 17.3 nmol/h), where 
midazolam competes only with hydronium ions. Introduction of extraneous sodium 
ions in the donor solution buffer decreased midazolam transport as did lowering 
the concentration of the drug. Figure 6 plots the drug transference number, 
calculated using equation (1), as a function of its molar fraction. A simple linear 





 0.86, p < 0.0001) and an intercept indistinguishable from zero. The co-ions which 
competed with midazolam were sodium and hydronium ions; the latter were taken 
into account because at pH 3.5, their concentration reached 0.3 mM. The aqueous 




/s.V [50], 7 times superior to that of 




/s.V) and much higher, of course, than midazolam. It should 
be acknowledged, however, that combining the concentrations of the competing 
co-ions without consideration of the high mobility differences may introduce an 
artefact to the relation observed with the corresponding drug transference 
number. 
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Figure 6: Transference numbers of midazolam (mean ± SD), measured using flux 
values at 6 hours of iontophoresis, as a function of the drug’s molar fraction. A 
simple linear regression (broken line) is used to fit the data points. See text for 
more details. 
 
3.4 Permeation across compromised skin 
Pig skin was progressively stripped to provide either fully or half 
compromised barrier function. Figure 7 compares passive and iontophoretic 
delivery fluxes of midazolam through barrier impaired skin relative to intact skin. As 
expected, passive diffusion increased dramatically with barrier derangement. While 
midazolam flux through intact skin was only 0.03 ± 0.01 nmol/h
 
after 6 hours, 
stratum corneum removal impaired the barrier function of the skin which became 
much more permeable; drug fluxes of 1.9 ± 0.3 and 32.5 ± 8.4 nmol/h
 
were 
measured for half- and fully-compromised skin barriers, respectively. This accounts 
for more than 1000-fold enhancement when the stratum corneum was completely 
ablated.  
The same experiments performed for passive diffusion were repeated but 
now with application of a constant electrical current of 0.36 mA intensity. As 
depicted in Figure 7, delivery of midazolam through half impaired skin barrier did 
not differ from intact skin (J6h: 27.1 ± 13.8 versus 23.8 ± 5.7 nmol/h); indicating that 
 



































Figure 7: Passive (shaded bars) and Iontophoretic (filled bars) transport fluxes 
(mean ± SD) of midazolam delivered from 15 mM drug solution (pH 3.5) through 
intact, half-compromised, and fully impaired barrier function.  
 
 the applied current continued to control the rates of midazolam delivery through a 
skin barrier whose function was impaired by up to 50 %. However, across a fully 
compromised barrier, a fivefold increase in total flux, J6h = 128.3 ± 45.7 nmol/h, was 
observed. This suggests that the magnitude and contribution of the three transport 
mechanisms (i.e. passive, electroosmosis, and electromigration) to the total fluxes 
observed have changed. 
Previous studies on several compounds showed that while electroosmosis 
generally becomes absent at complete barrier compromisation, electromigration 
either remained constant or reduced with perturbed skin barrier [51-56]. In 
addition, passive diffusion was always found to increase significantly with stratum 
corneum removal. For example, the iontophoretic transport of the positively 
charged nalbufine pivalate from a pH 4 donor solution doubled across fully 
impaired hairless mouse skin barrier (138.6 ± 28.8 versus 79.2 ± 25.5 nmol/h.cm
2
) 
[51]. This effect is, however, accounted for by the enhancement of passive diffusion 
which increased from 7.2 ± 1.9 to 70.6 ± 4.0 nmol/h.cm
2
.  
For midazolam, the progressive removal of the stratum corneum led to 





































the total delivery observed under current application. In the complete absence of 
barrier function, iontophoretic control was undermined by the very high enhanced 
passive permeation of midazolam. It is worth noting that because of the lipophilic 
nature of midazolam (LogP 4.3), high amounts of the drug may have accumulated in 
the epidermal layers including the stratum corneum and may not have partitioned 
into the subsequent layers of the skin and eventually into the receptor solution. It 
follows that the removal of the stratum corneum resulted in significantly higher 
passive permeation especially under iontophoresis where the concentration 
gradient of midazolam within the skin is probably higher than that in the absence of 
electrical current. As additional information, Table 2 shows the amounts passively 
released from the skin during 15 hours after termination of the current. These 
amounts were accordingly significantly higher as the stratum corneum barrier was 
progressively compromised. 
 
Table 2: Comparison between the cumulative amount of midazolam transported by 
iontophoresis after 6 hours 0.36 mA current, with the amounts subsequently 
released from the skin 15 hours post current termination. Data shown (nmol, mean 
± SD) correspond to intact and compromised skin with 15 mM drug concentration. 
 
 
Figure 8 plots the transport fluxes, observed after passive diffusion and 
iontophoresis of midazolam, as a function of the TEWL measurements of the 
respective skin barriers. Similar to previous findings [18, 56, 57], an excellent 
relationship was observed with midazolam passive diffusion and the TEWL of the 
skin (r
2
 0.99). With iontophoresis, even though the data were more scattered, an 
empirical fit with the respective TEWL values produced a good relation (r
2
 0.80). 
Skin type Intact Half compromised Fully compromised 
Cumulative amount 
permeated at 6 hour 
101 ± 28 91 ± 57 485 ± 192 
Amount released 15 
hours after current 
cessation 











Figure 8: Relationship between the 6 hour transport fluxes of midazolam and TEWL 
values. Open symbols and discontinuous line refer to passive diffusion data and its 
empirical fit. Filled bars and continuous line correspond to iontophoresis data and 
its empirical fit. Each level of skin barrier is represented by a certain type of symbol. 
Intact, half- and fully-compromised skin barrier are respectively symbolized by star, 
triangle, and circle bars. Equations corresponding to the empirical fits are: Passive 
diffusion (n = 9, r
2
 0.99 : J6h = 0.14 . e
0.04 . TEWL
), iontophoresis (n = 16, r
2





3.5 Feasibility of midazolam transdermal delivery 
Transdermal delivery of midazolam would offer a potential advantage to the 
paediatric population and this is especially significant in premature babies. This 
special group of patients is frequently critically ill, and multiple drug therapies are 
often prescribed and administered predominantly by the intravenous route.  
Assuming a one-to-one in vitro:in vivo correlation, patch sizes required to 
achieve therapeutic levels will differ depending on the age of the paediatric patient. 
Premature neonates with significantly immature skin barrier function only require a 
~ 1 cm
2
/kg patch (anode + cathode) to deliver therapeutic doses of midazolam by 
iontophoresis. However, application of a 2 cm
2
/kg passive patch of midazolam will 
also deliver the same amount as the 1cm
2
/kg iontophoresis patch. Nevertheless, 
due the continuously developing skin barrier of the premature baby which reaches 


































fully maturity by 2 – 3 weeks postnatal age [10] (but may extend to 8 weeks in the 
very premature [14]), the passive diffusion of midazolam will dramatically decrease 
over the first few weeks and therefore the advantage of using iontophoresis instead 
is obvious.  
 Premature neonates (< 32 weeks gestational age) whose skin barrier is up to 
50 % impaired would require iontophoretic patches of ~ 2 cm
2
/kg to provide similar 
levels as typical intravenous infusion rates of midazolam (~ 0.08 µmol/h.kg). For 
neonates of more than 32 weeks gestational age to babies of up to 6 months old, 
the required size increases to ~ 4 cm
2
/kg due to the higher intravenous infusion 
rates used in this age group (~ 0.17 µmol/h.kg). Older children up to 12 years of age 
would require areas of ~ 2 – 8 cm
2
/kg corresponding to a recommended infusion 
dosing of ~ 0.08 – 0.33 µmol/h.kg.  
Overall, the iontophoretic delivery of midazolam can achieve therapeutic 
levels and further optimisation of the delivery conditions is possible. In this study, 
the highest transdermal flux of midazolam through intact skin, that is 0.09 ± 0.02 
µmol/h.cm
2
, was achieved when the donor solution contained 15.9 mM midazolam 
in water (pH 3.6). The delivery rates can be improved further by increasing the pH 
of the drug solution. As demonstrated earlier, increasing the pH from 3.5 to 4.5 
enhanced the flux by twofold; but was also associated with decreased drug 
solubility. This can, however, be circumvented by incorporation of solubilising 
agents such as the use of cyclodextrins. This potential was reported in a previous 
publication [58], whereby the solubility of midazolam at higher pH values was 
greatly enhanced upon addition of 10 % of either a negatively charged or a neutral 
cyclodextrin. Midazolam solubility at pH 5 was ~ 15 and 6 mM, respectively. 
Addition of 0.1 % hydroxypropyl methylcellulose to the negatively charged 




4. Chapter conclusions 
This study demonstrated that midazolam transdermal iontophoresis across 
intact pig skin increased with pH, current intensity, and molar fraction. Permeation 
through stripped pig skin was also tested to simulate different barrier levels found 
in premature neonates. Passive diffusion was enhanced dramatically with barrier 
derangement but iontophoresis only increased noticeably in the complete absence 
of the stratum corneum. Midazolam transdermal delivery can achieve 
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The objective of this investigation was to evaluate the potential use of 
phenobarbital transdermal delivery in paediatric care. In vitro experiments were 
performed using intact and tape-stripped pig skin to model the less resistant skin of 
premature babies. Cathodal iontophoretic delivery of phenobarbital was superior 
compared to anodal transport and optimised delivery conditions were achieved by 
reduction of competing co-ion presence in the drug formulation. Phenobarbital 
transport across intact or partially compromised skin was controlled by 
iontophoresis which was more efficient relative to passive diffusion. Across highly 
compromised skin, however, passive diffusion increased drastically and 
iontophoretic control was lost. Overall findings demonstrate the feasibility of 




Phenobarbital (Figure 1) is a barbiturate drug used in the treatment of 
different forms of epilepsy. It is the most widely used antiepileptic drug in the world 
and is frequently prescribed as a first-line choice to control neonatal seizures [1-3]. 
Due to developmental changes in children, the pharmacokinetics of phenobarbital 
are highly variable in this population group; and doses are, therefore, titrated 
according to the individual’s response for adequate seizure control. For optimum 
response, target therapeutic plasma concentrations are set between 60 – 180 
nmol/ml. Such wide window is the result of different responses of individuals. The 
lower value is usually satisfactory but other factors such as drug tolerance and 
seizure type may require higher concentrations. The elimination half-life of 
phenobarbital in children is 30 – 75 hours but it is considerably prolonged in 
neonates (100 – 200 hours) [2, 4, 5]. Phenobarbital distribution volume decreases 
with age with 0.9 – 1 L/kg reported for neonates (including premature) and infants 
of up to 4 months. For older children, the volume of distribution decreases to 0.45 – 
0.7 L/kg [4]. The average clearance of phenobarbital in neonates is about 4.3 
ml/h.kg whereas for older children (up to 12 years), a mean value of approximately 
8 ml/h.kg is observed [6, 7].  
Even though the long half-life permits once daily administration of 
phenobarbital, adverse effects associated with peak concentrations usually 









for neonates and young children and the only other approved oral alternative is an 
elixir formulation which contains 38 % alcohol [8]. Regular administration of the 
elixir may potentially cause alcohol toxicity, especially to neonates [9]. Intravenous 
injections must be delivered slowly over 20 minutes otherwise shock, hypotension, 
and apnoea occur [1, 3, 5]. The only commercially available parenteral formulation 
of phenobarbital is also very concentrated (200 mg/ml) making accurate dilutions 
to suitable doses difficult for young infants and children. In addition, injections may 
cause extravasation due to the high pH (10 – 11) as well as the high osmolality of 
the injected solution [3].  
Transdermal delivery of phenobarbital by passive diffusion has been 
previously suggested as an alternative route of administration [10]. Phenobarbital 
delivery was investigated (from an 8.6 mM drug dissolved in 100 % ethanol) across 
human epidermis excised from adults (45 ± 15 years), premature (29 – 35 weeks 
gestation age), and full-term neonates (37 – 40 weeks gestation age). While drug 
fluxes through full-term neonatal skin resembled that across adult skin (0.5 ± 0.1 
nmol/h.cm
2
), phenobarbital permeated at higher rates through premature skin and 
fluxes were inversely related to the gestational age of the neonate (Figure 2). The 
average flux was found to be around 1.8 ± 0.6 nmol/h.cm
2
 and, assuming one-to-
one in vitro:in vivo correlation, a 25 cm
2
 transdermal patch was suggested by the 
authors to be suitable for a 1 kg premature baby to reach a target systemic 
concentration of about 14 nmol/ml. Two notes should be made about these 
findings: First, practical issues such as the use of ethanol as the solvent and a 25 
cm
2
/kg patch are clinically unacceptable for neonates because: 1) ethanol toxicity 
has been reported from percutaneous absorption of alcoholic cleaning products 
[11]; and 2) the body surface area of a 1 kg premature neonate is roughly 100 cm
2
 
[1], i.e., 4 times the suggested patch area without consideration of areas which are 
not suitable for patch application (e.g., head). The second point worth 
acknowledging was that the systemic concentration implied (14 nmol/ml) was 
lower than the recommended target for paediatric patients which is reported to be 
60 – 180 nmol/ml [8]. It is also of importance to note that the skin samples tested 









Figure 2: Phenobarbital delivery fluxes through human epidermis skin samples 
excised from premature and full-term neonates. Re-drawn from [10]. 
 
The latter range does not provide a complete representation of this age group 
because premature neonates born at a gestation age as low as 23 weeks survive 
(although the rate of survival is lower with lower gestation age). Overall, conditions 
at which this early study were run were not optimum and passive diffusion of 
phenobarbital is possibly not an efficient way to deliver the drug by the transdermal 
route.  
The present study suggests an alternative and, perhaps, a better approach to 
the delivery of phenobarbital across both intact and premature skin. Using 
iontophoresis as a physical enhancement method, improved delivery of the drug is 
expected and smaller patch sizes should be needed to attain the target systemic 
levels. The sodium salt of the drug has increased aqueous solubility avoiding the 
need for the use of co-solvents such as ethanol. Barrier functions of intact and 
damaged (premature) skin were modelled in vitro using pig skin, whose stratum-
corneum was differentially tape-stripped to provide a compromised barrier at 
different levels [12].   



































2. Materials and methods 
2.1 Chemicals  
Phenobarbital sodium, silver wire (99.99%), silver chloride (99.999%), sodium 
hydroxide pellets, and NaOH 50% solution (ion chromatography eluent grade) were 
purchased from Sigma Aldrich (Gillingham, UK). Potassium dihydrogen phosphate, 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) and sodium chloride 
were obtained from Acros (Geel, Belgium). Acetonitrile and hydrochloric acid were 
provided by Fisher Scientific (Loughborough, UK). All reagents were at least 
analytical grade and deionised water (resistivity ≥ 18.2 MΩ.cm, Barnsted Nanopure 
Diamond
TM
, Dubuque, IA) was used for the preparation of all solutions. 
2.2 Skin 
Fresh pig skin was obtained from a local slaughterhouse, cleaned under cold 
running water, and stored in a refrigerator until the following day. Abdominal skin 
was dermatomed (Zimmer™ Electric Dermatome, Dover, Ohio; nominal thickness 
750 µm), ), cut into pieces of appropriate size, wrapped individually in Parafilm™, 
and then kept in a freezer (-20 °C) until use. Prior to the permeation experiment, 
the skin was thawed at room temperature for 30 minutes and visible hairs were 
carefully cut with scissors. The skin was either used as is or was tape-stripped, as 
described in chapter 4, to create different degrees of compromised skin. Three 
levels of barrier function impairment were studied: 20 – 40 % (Intermediate “less” 
barrier), 60 – 80 % (Intermediate “plus” barrier), and 100 % (fully compromised 
barrier). Between 13 and 23 tapes were needed to produce a fully compromised 
barrier. 
2.3 Iontophoresis  
Side-by-side two-compartment diffusion cells (active transport area = 0.78 
cm
2
, volume = 3.3 ml) were utilised in all experiments. The skin was mounted 
between the two chambers with the epidermal side oriented towards the cathode 
compartment. The receptor chamber always held 154 mM sodium chloride solution 
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(unbuffered, pH ~ 6). For 30 minutes prior to the start of the transport study, the 
skin was left in contact with the donor vehicle without drug, and 154 mM sodium 
chloride in the receptor chamber. Both compartments were then emptied and 
refilled with a donor solution containing phenobarbital and fresh receptor solution. 
Both compartments were magnetically stirred (Multipoint-6 stirrer, Thermo 
Scientific Variomag, Cole-Parmer, London, UK) at 300 rpm throughout the 
experiment. A direct constant current of 0.4 mA (0.5 mA/cm
2
) was delivered from 
and a power supply (KEPCO 1000M, Flushing, NY, USA) using Ag/AgCl electrodes. 
Hourly samples (0.5 ml) of the receptor phase were withdrawn for analysis and 
replaced with fresh solution. Experiments which compared phenobarbital 
iontophoretic delivery through different skin barriers were additionally examined 
for passive permeation post-current termination. Separate passive diffusion 
controls (no current) through both intact and compromised skin were also 
performed. The experiments performed are summarised in Table 1. 
Another set of investigations studied the effect of iontophoresis on the 
passive permeability of intact skin to phenobarbital. Prior to the permeation study 
and in the absence of phenobarbital (i.e. donor compartment contained water, pH 
8.5, and receptor compartment contained unbuffered 154 mM NaCl), a 0.4 mA 
current was applied through the skin for 5 hours. At this point, the current was 
terminated and both compartments were then emptied and refilled with a donor 
solution containing phenobarbital and fresh receptor solution. Passive diffusion was 
then followed over 24 hours. To account for skin hydration effect, the same 
experiment was repeated but there was no electrical current in the 5 hour pre-
treatment step.  
2.4 Sample analysis 
Quantification of phenobarbital was performed by high performance liquid 
chromatography with UV detection (215 nm). The method was modified from a 
previous publication [13] and used a Jasco HPLC system comprising a PU-980 pump 
with an AS-1595 autosampler, a UV-975 UV-VIS detector, and an Acclaim 120, C18 
(150 x 4.6 mm, 5µm) reversed-phase column (Dionex, UK) which was thermostated   
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Table 1: Summary of experimental conditions performed to characterise 
phenobarbital transdermal delivery through intact and barrier impaired pig skin. 
a
: Number of replicates, 
b
: Passive diffusion post-iontophoresis with the drug 
solution left in the donor chamber, 
c
: Three passive diffusion experiments were 
performed. The skin was either used immediately in the permeation study or was 
subjected to a 5 hour pre-treatment step prior to the start of phenobarbital 
permeation experiment. The pre-treatment step was either with iontophoresis at 
0.4 mA intensity or a hydration period with water in the donor chamber and 154 
mM NaCl in the receptor compartment.
 d
: The donor solution was exchanged hourly 
to minimise chloride ions released as a result of electrode electrochemical 
reactions. 
  
at 30 °C. The mobile phase, pumped at 1 ml/min, consisted of phosphate buffer 
(0.067 M KH2PO4) and acetonitrile (70 : 30) and the pH was adjusted to 6 with 
NaOH.  
Chloride was analysed by ion chromatography with suppressed conductivity 
detection. The method [14] used an IC system (Dionex, Sunnyvale, CA) comprising a 
GP-50 gradient pump, an AS-50 autosampler and thermal compartment, and an ED-
50 electrochemical detector. The mobile phase, 35 mM NaOH, was pumped 
Skin barrier Donor vehicle 
Drug  
(mM) 




Water (pH 8.5 adjusted 
with HCl) 
50 
(1) Cathodal iontophoresis (5h), then 
passive diffusion b (5h) 
3 
Passive diffusion (24h) c 3 – 4 
50 mM NaCl (pH 7.4 
adjusted with HCl) 
15 
(2) Cathodal iontophoresis (5h) 4 
Anodal iontophoresis (5h) 4 
Passive diffusion (24h) 6 
Water (pH 7.4 adjusted 
with HCl) 
15 
(3) Cathodal iontophoresis (5h) 6 
(4) Cathodal iontophoresis (5h). 
Donor solution exchanged hourly d 
5 
10 mM HEPES 
(pH 7.4) 
15 
(5) Cathodal iontophoresis (5h). 
Donor solution exchanged hourly  d 
5 
Impaired: 
20 – 40 % 
60 – 80 % 
100 % 
Water (pH 8.5 adjusted 
with HCl) 
50 
Cathodal iontophoresis (5h), then 










isocratically (1ml/min flow rate) through a Dionex IonPac
TM
 AS16 (250 x 4 mm) 
column thermostated at 30⁰C and connected to a Dionex ASRS Ultra II suppressor (4 
mm) which was set at a current of 90 mA. 
The validation parameters of phenobarbital and chloride analytical methods 
are found in Appendix (1E). 
2.5 Data analysis and statistics 
Data analysis and regressions were performed using Graph Pad Prism V.5.00 
(Graph Pad Software Inc., CA, USA). Unless otherwise stated, data are represented 
as the mean ± standard deviation (SD). Transport fluxes were calculated as the 
amounts delivered per unit time. Comparisons made between different sets of data 
were assessed by either two-tailed unpaired t-test (for 2 groups) or one-way 
ANOVA (for > 2 groups) followed by Tukey’s post-test. Fluxes at different times 
were compared by repeated-measures ANOVA followed by Tuckey’s post-test. 
Statistical significance was set at p < 0.05. 
The transference number () of phenobarbital was computed according to 
Faraday’s law [15]: 
 =
 ×  × 

                          Equation (1) 
Where 	 is the drug flux observed, I is the current intensity applied, F is 
Faraday’s constant, and 
 is the numerical value of the valence of the drug ion (= 1).  
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3. Results and discussion 
3.1 Permeation across intact skin 
3.1.1 Passive diffusion 
The passive diffusion of phenobarbital across the skin was determined from a 
50 mM aqueous solution of the sodium salt of the drug. Three permeation studies 
were performed using 1) untreated skin, 2) skin pre-treated with 0.4 mA current for 
5 hours (phenobarbital absent), and 3) skin pre-hydrated for 5 hours (no 
phenobarbital). The third experiment served as a control for the second. Figure 3 
shows the cumulative amount of drug permeated as a function of time. The 
cumulative amounts transported over 24 hours post-drug application were: 92 ± 34, 
415 ± 125, and 222 ± 36 nmol/cm
2
 for untreated, pre-iontophoresed, and pre-
hydrated skin, respectively. Passive diffusion across pre-iontophoresed skin was 
significantly higher than through untreated (p < 0.01) and pre-hydrated (p < 0.05) 
skin. Increased permeability of skin previously exposed to direct current was 
















Figure 3: Passive diffusion of phenobarbital through untreated and pre-treated 
intact pig skin. Pre-treatment was either with 5 hours direct current at 0.4 mA 
intensity or 5 hours hydration. Phenobarbital was not present in the pre-treatment 
periods. Data are represented as the mean ± SD. 
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3.1.2 Iontophoretic delivery 
The first iontophoresis study employed a simple drug donor of 50 mM sodium 
phenobarbital dissolved in water. The pH of this solution was 9.6 and was 
considered too alkaline for skin application. The pH was therefore reduced to 8.5 by 
the addition of HCl rendering phenobarbital ~ 93 % in the ionised form. Cathodal 
iontophoresis resulted in drug delivery which was nearly 400-fold higher than 
passive diffusion (Figure 4). After only 1 hour of current application, the 
phenobarbital flux was 222 ± 94 nmol/h, increasing to 387 ± 57 nmol/h by 3 hours; 
at the end of the experiment (5 h), the flux was 341 ± 65 nmol/h. It follows that 
iontophoretic fluxes reached relatively constant levels quickly after the start of 
















Figure 4: Passive and iontophoretic transport fluxes at 5 hours (mean ± SD) when 
phenobarbital was delivered from 50 mM drug solution in water (pH 8.5. 92.6 % of 
the drug is negatively charged). 
 
3.1.3 Anodal versus cathodal delivery 
A second set of iontophoresis experiments was performed with a donor pH of 
7.4. The solubility of phenobarbital decreased at this pH and a lower drug 







































investigated because at pH 7.4, phenobarbital (pKa 7.4) existed as equal 
concentrations of the negatively charged ions and the neutral form of the drug. This 
means that phenobarbital can be delivered by both electroosmosis (with anodal 
iontophoresis) and electromigration (with cathodal iontophoresis). A 50 mM NaCl 
solution was used as the donor vehicle to sustain the Ag/AgCl electrochemistry 
during anodal delivery. As shown in Figure 5, cathodal iontophoresis was much 
more efficient at transporting phenobarbital than anodal iontophoresis. When the 
contribution of passive diffusion was accounted for, the corrected cathodal and 
anodal fluxes at 5 hours were 42 ± 13 and 7.1 ± 3.8 nmol/h, respectively. This is, of 
course, because electromigration is a much more efficient transport mechanism 
than electroosmosis, as it has been previously observed. Merino et al. tested the 
anodal and cathodal delivery of the weak acid 5-fluorouracil (pKa 8) at various pH 
values [17]. The authors reported that at pH 8.5 (75 % of the drug was negatively 
charged) cathodal was much higher than anodal delivery. Moreover, even at pH 7.4 
whereby only 25 % of the drug was negatively charged, rates of the drug delivered 
from either the anode or the cathode were of equal magnitude. Similarly, 
electromigration of phenytoin at pH 7.4, where only 11 % of the drug was 
negatively charged, resulted in similar transport rates as electroosmosis of the 















Figure 5: Passive diffusion, anodal, and cathodal iontophoresis of phenobarbital 
when delivered from 15 mM drug solution which also contained 50 mM NaCl. The 
final pH of the donor solution was 7.4. All data points represent the mean ± SD. 







































3.1.4 Co-ion competition 
The cathodal delivery of phenobarbital was next optimised by minimising 
competition from the anions present in the donor solution. First, the background 
electrolyte in the donor solution (i.e. 50 mM NaCl) was removed. The second 
experiment, in addition to removal of NaCl, attempted to reduce the accumulation 
of the chloride ions which are gradually released from the cathode as a result of 
continuous reduction of the silver chloride under current flow. Accumulation was 
restricted by hourly replacement of the donor solution. The third experiment used 
10 mM HEPES as a buffer for the donor solution instead of the unbuffered water. 
The buffer capacity when 15 mM phenobarbital sodium was added was sufficient 
that there was no need to adjust the pH to 7.4 with HCl which, in the preceding 
experiments, led to the introduction of chloride ions at a concentration of 
approximately 6 mM. Again, to avoid the build up of chloride ions released from the 
electrode, the donor solution was exchanged hourly. It is estimated that chloride 
ions, released each hour from the electrodes at 0.4 mA current, resulted in a 
concentration of 4.5 mM. Figure 6 sketches the evolution of chloride concentration 
in the donor formulation as a  function of time of current application. Estimated 














Figure 6: Estimated donor solution content of chloride ions (dashed lines) and 
corresponding experimental measurements by ion chromatography (represented 
by the symbols, mean ± SD). Estimated concentrations assumed that the chloride 
ions remained in the donor formulation. Conditions tested refer to experiments 
number 3, 4, and 5 in Table 1. 






(5) Donor pH controlled by HEPES
buffer (vehicle exchanged hourly)
(4) Donor pH adjusted by HCl
(vehicle exchanged hourly)














































































2 3 4 5
Phenobarbital delivery using the three improved experiments are compared 
to the un-optimised condition in Figure 7. In agreement with previous findings, the 
more co-ion competition present, the lower drug transport. The dependence of 
phenobarbital transference number (calculated using equation 1) to its molar 
fraction in the donor system is shown in Figure 8. As expected, a linear relation was 
observed with a slope equal to 0.033 ± 0.002 (r
2
 0.79, p < 0.0001) and an intercept 
of 0.002 ± 0.001. From this relation, one can predict the maximal flux, which is 
obtained when the molar fraction of the drug is 100 %, to be 554 ± 30 nmol/h 
(equivalent to a transference number of 0.037 ± 0.002). As acknowledged in the 
previous chapter concerning the significantly different mobilities of hydronium and 
sodium ions, the mobility of HEPES anions is expected to be much smaller than 
chloride ions; and therefore adding the molar concentrations of the competing co-
ions without consideration of significant mobility differences may introduce an 


















Figure 7: Phenobarbital transport from different donor vehicles (pH 7.4) which 
contained various amounts of competing co-ions (See experiments 2-5 in Table 1). 
The flux values (mean ± SD) represent the 5
th
 hour of iontophoresis (0.4 mA). Drug 



















Figure 8: Transference numbers of phenobarbital (, mean ± SD) as a function of its 
molar fraction (). The latter parameter was calculated from the estimated molar 
concentrations of phenobarbital, HEPES, and chloride species. The sources for 
chloride ions included NaCl (used as background electrolyte), HCl (used to adjust 
the donor solution pH), and the electrode electrochemical reaction. Data expressed 
by the same symbol and number represent the same experimental conditions 
which are outlined in Table 1. The dashed line shows the linear regression of all 
data points. The corresponding equation for the best-fit linear regression is: 
 = 0.002±0.001 + 0.035±0.002 (r2 = 0.79).  
 
 
3.2 Permeation across compromised skin 
The objective of this part of study was to examine the permeation of 
phenobarbital across barrier compromised skin. Three impaired levels of barrier 
function were evaluated against intact skin for passive as well as iontophoretic 
delivery of phenobarbital. The average TEWL measurement (g/m
2
.h) for the 
different skin barriers was as follows: 11 ± 1, 44 ± 10, 114 ± 20, and 158 ± 25, 
respectively for intact, intermediate “less”(20 – 40 %), intermediate “plus” (60 – 80 
%), and fully compromised skin. The TEWL values were significantly higher than 
what Sekkat et al. reported in the study which validated the usefulness of serially 
stripped pig skin as a model for the developing premature skin [12], and also a 
following study which applied this principal in the transdermal permeation of 
phenobarbital, caffeine, and lidocaine [13]. The discrepancies are by a factor of two 
for intact skin TEWL and a factor of four for fully compromised skin and are 
probably due to the different TEWL measurement devices employed in each study. 
While this study used a closed-chamber evaporimeter (AquaFlux AF102, Biox), the 



























previous work was performed with an open-chamber instrument (EP1, Servomed). 
The manufacturers of Aquaflux state that although closed and open chamber 
evaporimeters correlate well, the actual TEWL readings measured by each 
instrument disagree due to calibration differences used by different manufacturers. 
They estimate TEWL values from Aquaflux to be twice higher than an open-
chamber device [19, 20]. These claims are well supported by publications 
highlighting disagreements of readings of TEWL probes from different 
manufacturers as well as from within the same manufactured model [21-23]. It is 
also worth noting that the discrepancies observed between the range of TEWL 
measurements and previously reported values may also be down to the fixed 
number of tapes (20 tapes) employed in the earlier studies which were deemed 
sufficient for removal of most of the stratum corneum. External factors such as the 
pressure applied when the tape is affixed to and removed from the skin can 
influence the amount of stratum corneum removed [24] and hence the TEWL 
readings. 
The passive diffusion results are in Figure 9A. Permeation of phenobarbital 
increased dramatically as the stratum corneum was progressively removed. Flux 
after 5 hours diffusion through intact skin was only 0.9 ± 0.2 nmol/h but increased 
to 810 ± 251 nmol/h for fully compromised skin. Barriers with intermediate 
impairment levels were between the two extreme limits mentioned above. When 
only 20 – 40 % of the barrier efficiency was compromised, more phenobarbital 
permeated the skin and fluxes reached 31 ± 12 nmol/h. Skin with 60 – 80 % barrier 
deficiency was significantly less resistant to the permeation of phenobarbital and 
flux values of 561 ± 179 nmol/h were achieved after 5 hours passive diffusion. 
A previous study [13] showed similar permeation rates of phenobarbital 
across intact full-thickness pig ear skin when delivered from a saturated solution of 
the unionised drug (4.3 mM, pH 5). Permeation through fully compromised skin was 
around 30 times higher than intact skin. In the present study, however, an 
enhancement factor of more than 900 fold was observed. Phenobarbital 
concentration used here was 50 mM of the salt form of the drug and most of it was 













Figure 9: Passive (A) and Iontophoretic (B) transport fluxes (mean ± SD) of 
phenobarbital delivered from 50 mM drug solution through intact and 
compromised skin barriers. Graph (B) also include the passive diffusion of 
phenobarbital post-current termination. 
 
 
Another study on a different drug showed similar permeation behaviour of 5-
fluorouracil (LogP -1.0) when delivered from a pH 8.5 vehicle [25]. The drug (23 
mM), 75 % of which was present as negatively charged ions, possessed small 
permeation through intact full thickness nude mouse skin (amount permeated after 
6 hours was < 0.03 µmol/cm
2
). When stratum-corneum stripped skin was used, 
however, significantly enhanced levels were observed and approximately 17 
µmol/cm
2
 permeated the skin after 6 hour diffusion (> 550 fold difference). 
Iontophoretic delivery of phenobarbital through compromised skin barriers 
was next studied. Figure 9B depicts the flux rates during 5 hours iontophoresis (0.4 
mA) followed by 5 hours diffusion in the absence of current application. Table 2 
presents the fluxes during the last hour of the permeation studies. It was found that 
the total fluxes observed during iontophoresis increased with the level of skin 
impairment. There was a 3.6 fold enhancement, relative to intact skin, when the 
stratum corneum was completely removed. If the contribution of passive diffusion 
post-phenobarbital iontophoresis is accounted for in the total fluxes observed 
during iontophoresis, electrotransport fluxes are statistically indistinguishable 
between all skin barriers tested. It follows that while iontophoretic fluxes may have 
remained constant regardless of the skin barrier, passive diffusion increased 
remarkably with highly compromised skin and this undermined iontophoretic 
contribution and control over the overall transport.  
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Table 2: Transport fluxes of phenobarbital (in µmol/h, mean ± SD), through 
different barrier-impaired skin, measured after 5 hours of (1) iontophoresis, and (2) 
passive diffusion post-iontophoresis. The corrected fluxes (3) were calculated by 











Finally, a summary of both passive and iontophoretic transport rates as a 
function of TEWL is shown in Figure 10. Similar to previous studies [13, 26, 27], the 
TEWL measurements, depicting the level of skin barrier function, were found to 
relate well to the passive diffusion of phenobarbital (r
2
 0.85, p < 0.0001). 
Iontophoretic fluxes also showed good dependence to the respective TEWL 
readings of the skin barriers (r
2
 0.82, p < 0.0001).  
3.3 Feasibility of phenobarbital transdermal delivery  
Maintenance of an effective systemic level of the anticonvulsant ensures 
successful seizure control. For phenobarbital, the target steady state concentration 
ranges between 60 – 180 nmol/ml depending on the response of the individual 
patient. Assuming one-to-one in vitro:in vivo correlation, the transdermal delivery 
of phenobarbital to neonates (including premature and full-term) is feasible. 
Permeation only by passive diffusion can be used for premature neonates with 
significantly immature skin (see Table 3 A and B). However, as the skin barrier of 
the neonate matures, iontophoresis is more effective at delivering desirable rates 
of phenobarbital with smaller patches than simply by passive diffusion (Table 3 C 
Skin barrier Iontophoresis







Intact 0.34 ± 0.06 0.05 ± 0.01 0.30 ± 0.07 
Intermediate 
“less” 
0.60 ± 0.09 0.24 ± 0.08 0.35 ± 0.08 
Intermediate 
“plus” 
0.94 ± 0.27 0.63 ± 0.31 0.31 ± 0.09 
Fully 
compromised 




















Figure 10: Relationship between the 5 hour transport fluxes of phenobarbital and 
TEWL values. Open symbols and discontinuous line refer to passive diffusion data 
and its linear regression. Filled bars and continuous line correspond to 
iontophoresis data and its linear regression. Intact, Intermediate “less” (20–40 %), 
intermediate “plus” (60–80 %) and fully compromised skin barrier are respectively 
symbolized by star, triangle, circle, and square bars. 
 
 
and D). Due to the unpredictability of the precise degree of barrier immaturity of 
the premature neonate, it may be necessary for safety purposes to use transdermal 
patches with rate-limiting membranes to deliver phenobarbital. In this way, the 
maximum permeation rate is controlled by the patch and potential toxicity is 
avoided. 
Iontophoresis can also be used to deliver therapeutic amounts of 
phenobarbital to infants over 1 month old to young children (Table 3 E). Older 
children, however, may not benefit from phenobarbital transdermal delivery 
because the requisite patch area becomes too large especially for those who 
require systemic concentrations at the higher end of the therapeutic window for 
phenobarbital. It is noteworthy to consider that the thickness of the skin used in 
this study (750 µm) meant a longer diffusion pathway for phenobarbital by the 
presence of a possible extra “barrier”, the dermis, to the permeation of 
phenobarbital through the skin. Iontophoretic delivery of R-apomorphine (M.W. 







Jionto= 372.1(±100.9) + 7.0(±0.9)*TEWL     (r
2 0.82)





























267.3, LogP 2.3) [28] and 5-OH-DPAT (M.W. 247.4, LogP 2.2) [29] was found to 
decrease when transported across dermatomed human skin (200 – 300 µm) 
compared to its delivery through human stratum corneum. It is therefore possible 
that transport fluxes could be higher in vivo whereby the presence of blood vessels 
throughout the dermis which are in close proximity to the epidermal surface [30] 
may provide quicker and probably higher uptake of the drug into the systemic 
circulation. This study showed that steady fluxes of phenobarbital through pig skin 
are achieved in less than 2 hours. It is therefore anticipated that in vivo, a stable 
input rate of phenobarbital will be achieved quickly. 
 
Table 3: The patch sizes required to achieve target systemic levels of phenobarbital 
in different groups of the paediatric population. Calculations assume a one-to-one 






















 0.26  
(but can be up 
to 0.77) 
A) Fully compromised: 
Ionto: 1.5 ± 0.4 






B) Intermediate “plus”: 
Ionto: 1.2 ± 0.4 








C) Intermediate “less”: 
Ionto: 0.7 ± 0.1 














> 1 month – 12 years 0.5 – 1.4 
E) Ionto: 0.5 ± 0.1 




: calculated by multiplying the clearance by target steady state systemic 
concentration. 
(2)
: fluxes are the average values of 2 – 5 hours of either 
iontophoresis (0.5 mA/cm
2
) or passive diffusion, using 50 mM drug solution (pH 
8.5). 
(3)




area includes anode + cathode patches. 
(5)




4. Chapter conclusions 
This study demonstrated that cathodal iontophoresis of phenobarbital 
through intact skin is more efficient than anodal iontophoresis and passive 
diffusion. Competition from anions present in the donor formulation must be 
minimised to realise maximal effects of phenobarbital delivery. Premature babies 
with significantly compromised barrier function may benefit equally from passive 
patches due to their highly permeable skin. Paediatric patients with a more 
established skin barrier will however benefit significantly from the use 
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Conclusion and perspectives 
 
In this thesis, the use of transdermal iontophoresis in paediatric medicine was 
evaluated as an alternative to the oral and intravenous routes. More specifically, 
the feasibility of delivering three commonly used paediatric drugs, ranitidine, 
midazolam and phenobarbital, at therapeutic systemic levels were evaluated in 
vitro; and the potential for the clinical sampling of a renal marker, iohexol, through 
the skin was examined both in vitro and in vivo to evaluate the use of transdermal 
reverse iontophoresis as an alternative non-invasive method to blood sampling.  
1. Drug delivery by transdermal iontophoresis 
Ranitidine, midazolam, and phenobarbital transdermal delivery was 
investigated in vitro using dermatomed pig skin. The passive delivery of all drug 
candidates through intact skin was negligible relative to iontophoretic delivery. 
Findings from ranitidine and midazolam iontophoretic transport studies confirm the 
direct control current intensity has on the delivery rates of drugs. This allows for 
easy manipulation of the dose to be delivered. Data from the three drugs confirm 
the importance of drug molar fraction and pH of the driving electrode formulation. 
The former is optimised by maximising drug concentration and minimising co-ion 
presence. The latter improves delivery of cations by setting a pH value which 
ensures maximal ionisation of the drug, minimal competition from hydronium ions, 
and finally a higher net negative charge of the skin to ensure higher electroosmotic 
and electromigration fluxes. With respect to phenobarbital, delivery of the 
negatively charged drug ions by electromigration was superior than delivery of the 
neutral form at equivalent concentration. Hence, even though half of phenobarbital 
molecules are neutral at pH 7, iontophoretic transport by electromigration 
(cathodal) is more efficient than electroosmosis (anodal). Confirmed with ranitidine 
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transport findings, pluronic gels show to be suitable drug matrices for iontophoretic 
delivery applications.  
Transdermal delivery of midazolam and phenobarbital was evaluated using 
both intact pig skin as well as barriers from which the stratum corneum had been 
stripped to different extents to model the less resistant skin of premature babies. 
Drug delivery through partially compromised skin barriers (up to 50 % barrier 
function impairment) was controlled by iontophoresis. Across highly compromised 
barrier, however, iontophoretic control was undermined by the very high passive 
contribution. Both passive and iontophoretic transport of midazolam and 
phenobarbital across different barrier functions showed good relation with the 
transepidermal water loss readings of the different skin barriers.  
With assumption of one-to-one in vitro:in vivo correlation, therapeutic 
systemic doses can be achieved by transdermal iontophoresis using patch sizes of 
A) 0.2 – 1.5 cm
2
/kg for ranitidine, B) 1 – 4 cm
2
/kg (babies up to 6 months old) and 2 
– 8 cm
2
/kg (6 months old up to 12 years) for midazolam, and C) 0.4 – 3.3 cm
2
/kg 
(neonates) and 2.1 – 6.2 cm
2
/kg (infants to 12 years) for phenobarbital. 
Overall, the in vitro iontophoretic delivery of ranitidine, midazolam, and 
phenobarbital show that iontophoresis could deliver therapeutically meaningful 
fluxes of the drugs. Further in vitro and in vivo work to explore these observations is 
now warranted. It is also recommended that due to the unpredictability of the 
precise degree of barrier immaturity in premature babies, it may be necessary for 
safety reasons to use rate-limiting membranes to control the maximum amounts of 
the drug that could transfer from the driving electrode formulation into the baby’s 
skin. Finally, the solubility of midazolam at higher pH values requires further 
improvement. Not only this is beneficial for avoidance of skin irritation due to low 
pH, but also the iontophoretic delivery fluxes of the drug can be significantly 
increased at higher pH values. The use of cyclodextrins as solubilising agents is an 
attractive option as the solubility of midazolam has already been shown to increase 
with incorporation of cyclodextrin. 
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2. Clinical sampling by transdermal reverse iontophoresis 
Iohexol is an exogenous kidney marker whose clearance is equivalent to the 
glomerular filtration rate (GFR). Blood samples withdrawn from the patient 
following a bolus injection of the marker are analysed for iohexol and the clearance 
is calculated from the plasma concentration data. In this thesis, the feasibility of 
using transdermal reverse iontophoresis, as an alternative to blood withdrawal, for 
sampling iohexol non-invasively was assessed both in vitro and in vivo. 
Iohexol extraction fluxes in vitro correlated highly, after a period of lag time, 
to the subdermal concentrations of the marker. The lag time was modestly reduced 
by 1 hour following skin pre-treatment with 3 hours current application. Extraction 
data also permitted the prediction of the pharmacokinetic parameters of the 
simulated iohexol’s subdermal concentration decay model. Most importantly was 
the estimation of the elimination rate constant which was remarkably similar to 
that calculated from the subdermal concentration data. Such high sensitivity of 
reverse iontophoresis to track instantaneous changes of the subdermal iohexol 
prompted the next step of performing an in vivo proof-of-concept study. Four 
children undergoing routine iohexol GFR test were recruited and reverse 
iontophoresis was performed simultaneously to the routine test. In agreement with 
in vitro findings, after a period of lag time, iohexol extraction fluxes tracked the 
changes in blood concentrations of the marker. Moreover, with the exception of 
one subject, estimation of the elimination rate constant from both sampling 
methodologies (blood versus skin) showed good agreement. These positive initial 
results warrant further exploration and validation in a larger study. Estimation of 
GFR by transdermal reverse iontophoresis will offer a great advantage over the 
current method (blood sampling). This was evidently apparent when feedback from 
all participants revealed their preference to having “skin sampling” over blood 
sampling. Points requiring improvement in future studies include optimisation of 
the iontophoresis collection compartments. In this study, a commercially available 
patch set originally designed for single-use drug delivery applications was used. The 
patch size, vehicle composition, and adhesive properties were all not optimised for 
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reverse iontophoretic application and for paediatric use. Alternative collection 
devices are therefore recommended with smaller areas, appropriate vehicle 
composition, and gentle-adhesive properties.  
The development of a compact, fully portable all-in-one iontophoresis device 
for iohexol sampling is the ultimate product desired for use in children. For this to 
be made possible, further validation studies are needed coupled with significant 
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Analysis of all compounds was performed with either high performance liquid 
chromatography (HPLC) with UV detection (iohexol, acetaminophen, ranitidine, 
midazolam, and phenobarbital) or ion chromatography (sodium and potassium). All 
validation parameters were obtained from a minimum number of replicate of 3. 
Specificity was always tested to exclude any peak interference from other 
compounds present in the permeation system (including the formulations used and 
possible molecules released from the skin). A minimum of 5 levels of standards 
spanning the linearity range was always used to obtain the calibration curves. 
Analysis of solutions from each skin permeation experiment involved running the 
full range of standards twice: at the beginning and at the end of each run.  
A. Chapter 2, in vitro study: iohexol and acetaminophen 
Iohexol 
Linearity range (µg/ml) 0.1 – 250 (r > 0.99) 0.01 – 100 (r > 0.99) 
Injection volume (µl) 100 200 
Retention time (min) 6.4 6.3 
Accuracy (%) 
50 µg/ml 102.2 50 µg/ml 101.7 
5 µg/ml 101.2 5 µg/ml 101.4 
0.5 µg/ml 98.9 0.5 µg/ml 101.5 
Precision (Coefficient of 
variance) 
50 µg/ml 0.61 50 µg/ml 0.08 
5 µg/ml 0.97 5 µg/ml 0.37 
0.5 µg/ml 0.79 0.5 µg/ml 0.30 
Limit of quantitation 
(µg/ml) 
0.1 (Accuracy: 101.4 %) 
(Precision: 1.02) 
0.01 (Accuracy: 103.1 %) 
        (Precision: 2.24) 
 
Acetaminophen 
Linearity range (µg/ml) 0.025 – 100 (r > 0.99) 
Injection volume (µl) 100 
Retention time (min) 7.4 
Accuracy (%) 
50 µg/ml 102.2 
5 µg/ml 101.9 
0.5 µg/ml 101.5 
Precision (Coefficient of 
variance) 
50 µg/ml 0.08 
5 µg/ml 0.28 
0.5 µg/ml 0.17 
Limit of quantitation 
(µg/ml) 




B. Chapter 2, in vivo study: iohexol, sodium, and potassium 
Iohexol 
Linearity range (µg/ml) 0.005 – 10 (r > 0.99) 
Injection volume (µl) 20 
Retention time (min) 5 
Accuracy (%) 
10 µg/ml 100.6 
1 µg/ml 98.9 
0.1 µg/ml 104.03 
Precision (Coefficient of 
variance) 
10 µg/ml 0.09 
1 µg/ml 1.15 
0.1 µg/ml 3.57 
Limit of quantitation 
(µg/ml) 
0.005 (Accuracy: 122.6 %) 
(Precision: 14.11) 
 
Sodium and potassium 
 Sodium Potassium 
Linearity range (mM) 0.5 – 10 (r > 0.99) 0.05 – 10 (r > 0.99) 
Injection volume (µl) 5 5 
Retention time (min) 4.1 5.7 
Accuracy (%) 
10 mM 99.3 10 mM 99.9 
5 mM 101.3 1 mM 102.2 
1 mM 108.7 0.1 mM 83.2 
Precision (Coefficient of 
variance) 
10 mM 2.23 10 mM 2.54 
5 mM 2.11 1 mM 6.18 
1 mM 2.78 0.1 mM 14.79 
Limit of quantitation 
(mM) 
0.5 (Accuracy: 112.9 %) 
(Precision: 9.83) 







C. Chapter 3: ranitidine 
Linearity range (µg/ml) 0.1 – 500 (r > 0.99) 
Injection volume (µl) 5 
Retention time (min) 2.5  
Accuracy (%) 
500 µg/ml 100.1 
50 µg/ml 96.68 
5 µg/ml 99.76 
Precision (Coefficient of 
variance) 
500 µg/ml 0.54 
50 µg/ml 0.88 
5 µg/ml 1.90 
Limit of quantitation 
(µg/ml) 
0.1 (Accuracy: 104.1 %) 
(Precision: 2.56) 
 
D. Chapter 4: midazolam 
Linearity range (µg/ml) 0.025 – 50 (r > 0.99) 
Injection volume (µl) 50 
Retention time (min) 6 
Accuracy (%) 
25 µg/ml 100.7 
1 µg/ml 100.1 
0.025 µg/ml 98.8 
Precision (Coefficient of 
variance) 
25 µg/ml 0.32 
1 µg/ml 0.57 
0.025 µg/ml 0.92 
Limit of quantitation 
(µg/ml) 








E. Chapter 5: phenobarbital and chloride 
Phenobarbital 
Linearity range (µg/ml) 0.1 – 50 (r > 0.99) 
Injection volume (µl) 50 
Retention time (min) 6.4 
Accuracy (%) 
50 µg/ml 101.3 
5 µg/ml 99.4 
0.5 µg/ml 101.7 
Precision (Coefficient of 
variance) 
50 µg/ml 0.47 
5 µg/ml 0.13 
0.5 µg/ml 0.45 
Limit of quantitation 
(µg/ml) 




Linearity range (mM) 0.1 – 100 (r > 0.99) 
Injection volume (µl) 5 
Retention time (min) 4.1 
Accuracy (%) 
100 mM 99.7 
10 mM 98.8 
1 mM 98.6 
Precision (Coefficient of 
variance) 
100 mM 1.51 
10 mM 1.96 
1 mM 8.26 
Limit of quantitation 
(mM) 
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Measurement of Glomerular filtration rate (GFR) is used as the best 
indicator of kidney function. GFR is measured using markers which are ideally 
completely cleared by the kidneys. There has always been ongoing research to 
improve GFR measurement and several markers have been used for this purpose 
[1]; with major limitations: creatinine, can give inaccurate estimation of GFR as its 
levels in the blood are affected by nutrition, diet, and muscle mass. Although 
traditionally regarded as the gold-standard for GFR estimation; inulin needs to be 
continuously administered by injection, and collection of timed urine samples is 
required in order to obtain correct GFR value. These make the use of inulin 
unpopular especially in children. Chromium EDTA, a radio-labelled marker, has 
been in use in Great Ormond Street Hospital for over 30 years. However, it proved 
to be impractical due to the expensive cost, the special requirements a hospital 
needs for the handling, storage, and disposal of such special radiation compounds, 
as well as the relatively large blood samples required (5ml). 
Over the past twenty years, a new filtration marker, iohexol, has been 
increasingly gaining widespread use; and since July 2007, iohexol has replaced 
Chromium EDTA in Great Ormond Street Hospital (GOSH). This is due to its 
established safety record, cost effectiveness, reliability, accurateness, and being 
non-radioactive. It is claimed by many to be the “new” gold standard for GFR 
measurement. At GOSH, iohexol is administered as an intravenous bolus injection. 
Then, two to three blood samples, taken 3, 4 and 6 hours post-administration, are 
drawn from the patient to measure iohexol blood concentration which will give 
information on how well the kidneys are clearing iohexol [2]. So, the measured 
clearance of iohexol reports directly on the GFR and kidney function. However, the 
need for blood samples to correctly estimate iohexol clearance makes the 
procedure associated with various disadvantages; namely pain and discomfort to 
the patient; invasiveness, and risk of infection. Technical difficulties are also a major 
downside for blood sampling. All these limitations are even more significant in 
certain patient populations such as children. The less frequent sampling also makes 
GFR estimation less precise. 
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Thus, the need for less invasive, but still accurate, sampling techniques of 
iohexol, that lack the disadvantages of blood sampling, is highly desirable. 
One possibility is transdermal “iontophoresis”, whereby the application of a 
small electrical current across the skin is used to facilitate the active transport of 
molecules present in the subdermal fluid (the fluid that bathes the cell layers below 
the outer layer of the skin) from inside the body into the surface of the skin at levels 
much higher than those of their passive transport [3]. The subdermal fluid is in 
direct communication with blood and can therefore serve as a good alternative 
sampling matrix. 
We are interested in performing our study in children because of the 
sensitivity that many children have about blood sampling. A non-invasive technique 













Figure 1. Example of an iontophoretic system: Phoresor
®
 II auto device (power 
supply) connected to Iogel
®
 small patches (IOMED, Salt Lake city, Utah, USA). Each 
pair of patches is composed of a karaya gel dispersive pad (the square pad) and a 
hydratable gel-sponge patch (the oval patch). 
 
Transdermal iontophoresis has been used in our laboratory (Pharmacy 
department, University of Bath) for many years and in previous human studies, we 
have demonstrated the usefulness of this technique for glucose sampling [4, 5], 
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lithium monitoring in bipolar patients [6], urea sampling for the diagnosis and 
monitoring of chronic kidney disease [7], lactate [8] and various amino-acids [9]. 
The Glucowatch
®
 Biographer (approved for both adults and children in the 
USA) [10] is an iontophoretic device used to continuously monitor glucose levels in 
diabetics by sampling glucose over 12 hours per day and therefore providing a 
superior amount of information, regarding glucose levels, over the traditional 
finger-prick technique.  
Iontophoresis is a safe technique and several devices are approved and 
available commercially for both drug delivery and monitoring, e.g. Phoresor
®
 II auto 
(figure 1) for various iontophoresis applications, LidoSite
TM
 system which delivers 
lidocaine for induction of local anaesthesia, Ionsys
TM 
for delivery of fentanyl to relief 
post-operative pain, Macroduct
®
 (approved for neonates, children and adults and 
used routinely in Great Ormond Street Hospital) for delivery of pilocarpine to 
diagnose cystic fibrosis, and, as mentioned above, the Glucowatch
®
 Biographer 
approved for glucose monitoring. 
 The iontophoretic system is typically composed of an external power-supply 
that passes current through two patches (Anode and cathode) (figure 1). The 
square pad represents the anode patch and is composed of a silver/silver chloride 
electrode incorporated in a karaya gel dispersive pad. The oval-shaped patch 
represents the cathode and is composed of a silver chloride electrode integrated in 
a hydratable gel-sponge patch. The dry gel in the oval patch is wetted with water 
before it is attached to the skin. 
Our in vitro studies performed with pig skin (a good model for human skin) 
show excellent correlation between Iohexol iontophoretic sampling levels with the 
corresponding subdermal concentrations. Two different simulated models (mono- 
and bi-exponential) of iohexol elimination have been tested and confirmed that, 
after a period of 2.5 hours lag time needed for the conditioning of the skin, 
transdermal sampling of iohexol by iontophoresis followed closely its subdermal 















Figure 2. Iohexol subdermal concentration (mg/ml) and iontophoretic sampling flux 
(µg/h) as a function of time (Mean ± SD) 
 
In clinical practice, estimation of GFR is made possible by the calculated 
pharmacokinetic parameters of iohexol, which depict a guide to how the body 
handles iohexol. The most important pharmacokinetic parameters used for GFR 
estimation are: Elimination rate constant of iohexol (Ke), calculated from the slope 
of iohexol log concentration-time profile and iohexol initial concentration at time 0 
(C0), measured by back-extrapolating the log values of iohexol concentration-time 
profile. From these two parameters, the volume of distribution of iohexol (Vd) and 
therefore its clearance (Cl) are calculated following these equations:  
 
   Vd = Administered dose of iohexol/C0 




GFR of the patient is then estimated from the corrected iohexol clearance. 
This correction is made to account for some errors arising from the less frequent 
blood samples which are not sufficient for a complete profiling of iohexol 
concentration over time. 
Our in vitro experiments show that pharmacokinetic parameters estimated 
from iohexol subdermal concentration data correlated well to those calculated 
from the transdermal iontophoresis sampling data (table 1). Similar correlations 
were also found in a previous in vitro study with lithium [11]. 


















Table 1. Iohexol pharmacokinetic parameters estimated from its subdermal 
concentration data and iontophoretic sampling data (Ke: elimination rate constant; 
C0: subdermal concentration of iohexol at time 0; Vd: volume of distribution, Cl: 
clearance)   
 
       Parameter 
















Subdermal 0.98 0.37 ± 0.01 0.29 ± 0.02 4.02 ± 0.28 1.51 ± 0.14 
Iontophoresis  0.94 0.41 ± 0.03 0.36 ± 0.08 3.26 ± 0.63 1.34 ± 0.17 
 
 
2. Objectives   
The principal objective of this study is to assess the feasibility of using 
transdermal iontophoresis, as an alternative approach to blood sampling, for the 
clinical monitoring of kidney function, using iohexol as the filtration marker.  
Data obtained from iohexol skin sampling, using iontophoresis, will be used 
to evaluate its association to that of the blood sampling approach. Pharmacokinetic 
parameters of Iohexol, estimated from both sampling techniques will then be 
compared to confirm if there is correlation.  
 
3. Protocol 
 We plan to recruit 12 children undergoing routine iohexol GFR test (see 
section 5 for calculation of sample size). At GOSH, approximately 1000 children 
have a routine GFR test each year. We intend to carry out transdermal 
iontophoresis in parallel to the routine GFR test to compare values obtained from 
both sampling procedures. Usually, the routine GFR test takes between 4 and 6 
hours. Participation in the study is for around 6 to 6.5 hours and will take place in 





The iontophoresis device 
 
 The study will be carried out using an approved (CE mark) current device, 
the “Phoresor
®
 II auto” (Model: PM850, Iomed, Salt Lake city, Utah, USA. Figure 1), 
already in the market for more than 10 years and used for iontophoresis in 
hospitals and health clinics for both adults and children.  The device has safety 
features, which will automatically activate upon, for example, an increase in the 
resistance of the current circuit above a pre-set limit. The device is also fully 
controllable manually and the current could be stopped at any time should, for 
example, the volunteer decides to withdraw from the study for any reason. Prior to 
use in the Trust, the device will be checked for electrical safety by the Department 
of Biomedical Engineering at Great Ormond Street Hospital. 
The Phoresor
®
 II device is a small, light and portable machine. A strap-worn 
pouch, to carry the device, will be used to make participation in this study more 
comfortable.  
The device will be cleansed thoroughly with alcoholic wipes before and after 
each study.   
 
Experimental protocol: 
1) A minimum of 24 hours (for inpatients) or 2 weeks (for outpatients) is given 
to potential participants and their parents to read the participant information 
sheets and decide on whether they would like to take part in the study. They are 
encouraged to ask any questions and full explanation of all steps involved is 
provided to them. The participant as well as the parent will be requested to inform 
us if the child suffers from any skin condition, such as eczema, or has irritated or 
damaged skin. Informed consent from the parent and child (as appropriate to age 
and understanding) will be taken. 
2) Upon participant and parent positive consent, a special code number 
instead of the participant’s name is used throughout the study to make 
participation completely confidential. The consent form is the only document which 
includes both the participant name as well as the allocated code number. All 
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consent forms will be stored in a locked cabinet and only the local collaborators will 
have access to it.  
3) During the 12 hours before the study’s commencement, the participant is 
required not to apply any cosmetic products, such as creams, onto the arm used in 
the study. 
4) Iontophoresis is performed on the non-dominant arm of the participant. The 
arm is first cleansed with a routine alcohol wipe and then allowed to dry naturally.                                   
5) The iontophoresis system is composed of the Phoresor
®
 II device and two 
electrode patches (a square dispersive pad and an oval gel-sponge patch). After 
hydration of the oval patch with 1.5 ml sterile water for injection, the square pad 
and the hydrated oval patch are affixed onto the arm of the participant. The 
Phoresor
®
 II device is then connected to the electrodes and is set to precisely 
deliver 0.8 mA of constant direct current (~0.1 mA/cm
2
).  
6) In total, current is passed for 5 hours starting 0.5 hours after the volunteer 
receives their routine intravenous dose of iohexol. Both patches are replaced with 
new ones after 2 and 4 hours of current passage. The oval patch is additionally 
replaced at 3 hours (see illustration below). So, a total of 7 patches are used. Each 
time we do a patch exchange, we stop the current briefly. 
7) The used patches are stored in coded containers in a secured laboratory for 
up to 6 months for analysis.  
8) When analysis is performed, each oval patch is extracted with water and 
then analysed for iohexol. Other normal body substances such as salts (e.g. sodium) 



















9) During the study, the participant can mobilise but the researcher will 
accompany the participant throughout the study. As the study is performed on the 
non-dominant arm, the participant is able to use the other arm freely. So, the 
participant can, for example, go to the play room, read, and write. We will make 
sure the participant is kept entertained during the study and they can choose to 
watch their favourite cartoons and DVDs or read their favourite books. 
10) A comfort-break is allowed at any time during the study. Unless the 
participant is already restricted from food/drink due to their routine hospital care, 
our study has no restrictions.  
11) Participants may experience some mild tingling and heat sensation, 
especially at the start of iontophoresis. Redness may also appear at the site of 
iontophoresis but tends to disappear after a few days (figure 3). Upon positive 
consent from the participant and their parents, photographs of only the 
participant’s arm will be taken before and after the study to show the effect of 
iontophoresis on the skin.  
Redness/sensitisation may also occur as a result of the adhesive material of the 
patches. 
12)  If the participant is in discomfort, or decides to withdraw from the study at 
any time and for any reason, the study will be stopped immediately. The procedure 
will be undertaken in wards staffed by nurses with skills to act appropriately in the 
unlikely event that the participant feels unwell during the study. 
13) Upon completion of the experiment, the participant will be asked to 
complete a short questionnaire, using the Wong-Baker faces pain scale, to evaluate 
the level of discomfort/tingling sensation they have experienced during the study. 
They will also be asked whether they prefer transdermal iontophoresis over blood 
sampling. 
14) Feedback with the results obtained from the iontophoresis sampling 
technique will be provided to the participant and parents should they wish to find 
out the outcome of their individual participation. A summary of the main findings 














Figure 3. Example of redness occurring after iontophoresis 
 
4. Data analysis 
 Data obtained from iohexol skin sampling, using iontophoresis, will be used 
to evaluate its association to that of the blood sampling technique. Regression 
analysis will be performed to assess the linearity of the data obtained. The slope of 
the regression line and iohexol pharmacokinetic parameters will be calculated from 
the skin sampling data. Subsequently, GFR values will be estimated from the 
pharmacokinetic data. Agreement of values obtained from the two sampling 
methods (skin and blood) will be assessed using the method of Bland and Altman 
[12]. 
 
5. Calculation of sample size: 
 Statistical input was obtained from Dr. Gavin Shaddick, a senior lecturer in 
statistics at the University of Bath. 
 The hypothesis supported by the in vitro studies, is that the slopes 
corresponding to the semi logarithmic plasma concentration versus time and the 
semi logarithmic iontophoretic flux versus time profiles are the same. If this 
hypothesis were proved to be true, then the slope obtained non-invasively could be 




 The statistical calculations relate to the ability to detect a difference 
between two slopes; the first corresponding to the iohexol plasma concentration 
values and obtained using measurements at different sampling times, the second 
corresponding to the iohexol iontophoretic fluxes. The aim of the study is to 
determine whether these two slopes are the same, which translates in terms of 
statistical testing into accepting a null hypothesis of no difference between the two 
slopes. The interpretation of a power calculation in this case would be to find the 
smallest difference at which a true difference could be detected, the smaller this 
difference the more confidence that a true finding is not being overlooked because 
of a small sample size. 
 The results of the power calculations assume that the slopes are normally 
distributed and use a significance level of 5%. The difference is expressed in a 
percentage change of a 0.4 h
-1
 slope which is representative of values found in the 
clinical setting (range 0.1-0.7 h
-1
). The standard deviation is an estimate of the 
standard deviation of the differences between the two slopes. Results for a suitable 
range for both of these are presented, with the expected standard deviation being 
approximately 0.06.  
 Using a sample of 12 individuals, 80% power can be achieved with the ability 
to detect down to a 15% difference. However, it is expected that some participants 
will not complete the study, for example if they experience discomfort or 
restlessness through the 5-6 hours sampling process. Obtaining data from 10 
individuals means that 80% power can be achieved in all but the most extreme 
estimate of standard deviation. A sample size of less than 10 sees power drop and 
only larger differences being detected. However, a difference of 20-25% between 
the slopes could be detected (depending on the standard deviation) even if half of 
the participants did not complete their participation (n=6). Differences between the 
slopes greater than 25% would be considered unacceptable for practical 
applications and the use of transdermal iontophoresis for this purpose would be no 
longer pursued. Thus, even when n=6, the main objective of this study, deciding on 






 The salary costs for the researcher are paid by a grant from the Algerian 
government sponsoring her PhD studentship. Purchase of the iontophoresis device 
and consumables is covered by existing external grants. As this study takes place in 
parallel and for the same duration as the routine clinical GFR test, no patient 
expenses are anticipated. 
 Involvement of Trust staff (Drs. van’t Hoff, Brock and Ms. Tulloh) is 
principally limited to advice, recruitment, consent and supervision. Dr van’t Hoff 
has additional involvement as Principal investigator; this time is within his funded 
role as the Director of Clinical Research Facility. 
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function without the need of blood samples?
 
   
Dear …..  
 
 The doctors taking care of your child at 
decided he/she needs to have their kidney function checked. They will do this by 
injecting a special dye called “iohexol”. Then, they check your child’s kidney 
function by taking two to three blood samples from them.
 We are writing to inform you of some new and exciting project taking place 
at the hospital. It is about the possible use of an alternative non
method for measuring your child’s kidney function. We would like to ask your 
permission to involve 
“iontophoresis”, with the conventional blood sampling. Our proposed project will 
be carried out in the same ward and at the same time as the child’s routine kidney 
test. Enclosed with this letter are two
and one for your child). Please read them and if you and your child are happy to 
participate with us, please fill in the reply slip and return it in the pre















: Can we monitor your child’s kidney 
     Date 
      
Great Ormond Street Hospital have 
 
your child in this project to compare our technique, 
 participant information sheets (one for you 
 
. 






Can we monitor your child’s kidney function without the need of 
 
 
Dear Dr. Van’t Hoff, 
 
My child and I have read the information sheets about your proposed study which is 
taking place at Great Ormond Street Hospital. 
 
 
We would like to know more information
 
   
 




Signed ……………………………………………………..… Date …………………………..
 
















             
                          (Please tick as appropriate)





 Can we monitor your child’s kidney function without the need of 
Information 
 The doctors taking care of your child have decided he/she needs to have 
their kidney function checked. They will do this by injecting a special dye called 
“iohexol”. Then, they check your child’s kidney fun
blood samples from them. We are currently doing a project to try to find an 
alternative non-invasive technique which does not need blood sampling. It is called 
“iontophoresis” and it works via the skin. We would like to ask you
include your child in this project to compare our technique “iontophoresis” with the 
conventional blood sampling.
 Before you decide, it is important for you to understand why the study is 
being done and what it will involve. Please take ti
information carefully and discuss it with others if you wish. Please ask us if there is 
anything that is not clear or if you would like more information. Take time to decide 
whether or not you wish your child to take part in this s
 
1. Why is this project being done?
 We are looking at an alternative sampling for the method for monitoring 
kidney function. This is because the current conventional method, i.e. blood 
sampling, has many disadvantages, particularly pain and discomfort to the patient; 













blood samples?  
 
sheet for the legal representative of the child
 
ction by taking two to three 
 
me to read the following 
tudy.  
 
f infection. These inconveniences are even worse in children 
 
 
r permission to 
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because of the sensitivity that many children have about blood sampling. In 
addition, the conventional blood sampling technique relies only on two to three 
samples. This may not be sufficient to precisely estimate how well your child’s 
kidneys work.  
 We, therefore, propose in our study a non-invasive alternative technique to 
blood sampling that does not use needles. Our aim is to examine whether our 
proposed technique, iontophoresis, can at least estimate kidney function as 
accurately as blood sampling. 
 Iontophoresis involves the application of a very small electrical current 
across two parts of the skin already covered with two patches. The current passage 
facilitates the transport of iohexol (the dye used to monitor kidney function) from 
inside the body into the patches situated at the surface of the skin. By doing this, 
we can measure iohexol amounts in the patches at several intervals and an 
accurate but non-invasive estimation of kidney function could be made possible.  
 
2. Why have you asked my child to help? 
 The doctors taking care of your child have decided he/she needs to have 
their kidney function checked as part of their routine hospital care. To do so, they 
will use the conventional blood sampling technique. We would like to examine 
whether our technique, iontophoresis, could prove to be an accurate, non-invasive 
alternative. We can only do this by comparing results obtained from the 
conventional blood sampling with those from our alternative technique.  
 
3. Does my child have to take part? 
 No. Taking part in the study is entirely voluntary. We fully understand that 
people may be unable or unwilling to participate. If you do not want your child to 
take part, you do not have to give a reason. This will not affect your child’s 
treatment in any way.  
 You and your child may withdraw at any time during the study. You can 
choose not to answer the questionnaire. Samples obtained from your child will be 
treated as a gift but you have the right to ask for them to be removed from the 
study at any time.  
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4. How will my child be involved? 
 Please let us know if your child suffers from any skin condition, such as 
eczema, or has irritated or damaged skin. 
 Our proposed project is planned to be carried out in parallel to the routine 
kidney test that is requested by your child’s doctors. 
 Usually, the routine kidney test takes between 4 and 6 hours. Participation 
in our study is for around 6 to 6.5 hours and will take place in the same ward and at 
the same time as the routine kidney test of your child.  
 We require that no cosmetic products, such as creams, are applied to your 
child’s arms during the 12 hours before the study’s commencement.  
 The child’s non-dominant arm is first cleansed with a routine alcohol wipe 
and then allowed to dry. 
The iontophoresis system (figure 1) is composed of the current device (a 
sophisticated battery) and two electrode patches (a square dispersive pad and an 
oval gel-sponge patch). The battery is a small, light and portable machine. A strap-
worn pouch, to carry the device, will be used to make your child’s participation in 
















 After hydration of the oval patch with 1.5 ml sterile water, the square pad 
and the hydrated oval patch are attached onto the arm of your child. The battery is 
then connected to the electrodes and set to deliver a small current.  
 In total, current is passed for 5 hours starting half an hour after your child 
receives their routine intravenous dose of iohexol, as part of their routine care.  
 Both patches are replaced with new ones after 2 and 4 hours of current 
passage. The oval patch is additionally replaced at 3 hours. So, a total of 7 patches 
are used. Each time we do a patch exchange, we stop the current briefly. 
 The used patches are then examined to give us information about iohexol 
collected by iontophoresis. We only look for specific compounds (i.e. iohexol and 
normal sugars and salts present in the body) and we will not look at anything else 
such as drugs.  
 During participation with us, your child can mobilise but the researcher will 
accompany your child throughout the study. As our study is performed on the non-
dominant arm, your child is able to use the other arm freely. So your child can, for 
example, go to the play room, read, and write. We will make sure your child is kept 
entertained during the study and they can choose to watch their favourite cartoons 
and DVDs or read their favourite books. 
 Your child is allowed to go to the toilet at any time during the study.  
 Unless your child is already restricted from food/drink due to their routine 
hospital care, our study has no restrictions. 
 Once we finish the study, we will ask your child to answer a short 
questionnaire about the level of discomfort/ tingling sensation experienced during 
the study. They will also be asked whether they prefer iontophoresis over blood 
sampling. 
 Feedback with the results obtained from the study will be provided to you 
and your child should you wish to find out the outcome of your child’s participation. 
A summary of the main findings and/or published reports will also be provided 
upon request. 
 If any step of the study is unclear to you, or if you have any questions please 




5. Will there be any effects on my child’s routine treatment? 
 No, the study will not affect your child’s routine treatment in any form. 
 
6. Will there be any side effects? 
 Iontophoresis is considered a safe technique with several devices approved 
and available commercially. It is used in hospitals, including Great Ormond Street 
Hospital, for both adults and children. 
 The current device used in our project has a CE mark which means that it 
has passed all the safety tests needed. It also means that it is licensed for use in 
humans.  
 Your child may experience slight tingling and heat sensation (especially at 
the start of iontophoresis). Redness may also appear at the sites of iontophoresis 
(figure 2) but tends to disappear after a few days.  
 Redness/sensitisation may also occur as a result of the adhesive material of 











Figure 2. Example of redness occurring after iontophoresis. 
 
 If you or your child find any of the side effects uncomfortable or 
unacceptable, or decide to withdraw for any reason, the study will be stopped 
immediately.  
 Medical staff will also be present to take appropriate action in case your 




7. What are the arrangements for compensation? 
 This project has been approved by Great Ormond Street Hospital for 
Children NHS Trust Research Ethics Committee. The committee believes that this 
project is fair and of minimal risk to your child. However, research can carry 
unexpected risks and we want you to be informed of your rights in the unlikely 
event that any harm should occur as a result of your child’s participation. 
 This project is covered by the University of Bath insurance policy (NHE-
05CA07-0013). This includes potential legal liability for harm to your child arising 
from the management and/or the design of the research. In addition, cover for 
compensation in the event of harm to your child, where no legal liability arises, can 
be claimed.  
 
8. Will there be any benefits for taking part?  
 There is no immediate benefit to your child. If the results of this study are 
promising; then a potentially non-invasive alternative sampling technique for 
monitoring kidney function is on the horizon. This, in turn, could make an end to 
the traditional invasive blood sampling. This would benefit children in particular, as 
it will give an accurate estimation of kidney function without all the disadvantages 
associated with blood sampling.  
 
9. Will anyone else be told about my child’s participation in the study? 
 We will keep all of your child’s information confidential. This means we will 
only tell those who have a need or right to know. With your positive consent, your 
child’s family doctor will be informed of their participation.  
 
10. Who will have access to my child’s information? 
 All information collected during the study (data collection, processing, and 
storage) will be treated in strict confidence.  No names, initials, or any type of 
information that could result in your child’s identification will be mentioned in any 
reports of the study. 
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 Throughout the study, we use a special code number instead of your child’s 
name to make their participation in this study completely confidential. 
 All data information will be stored and analysed in computers secured with 
a password and only the research team involved in this study will have access to it. 
 Upon your positive consent, we will take some photographs of your child’s 
arm before and after the study to show the effect of iontophoresis on the skin. The 
photographs will only include the arm. 
 
11. Who do I speak to if I have further questions, worries, or complaints?  
 If you have any questions, comments, enquiries, or complaints about this 
project, please contact either Ms. Asma Djabri (A.Djabri@bath.ac.uk, 01225383900) 
or Dr. William Van’t Hoff (VANTHW@gosh.nhs.uk, 02074059200 ext. 5583/5930).  
 If you have any unresolved issues, please contact the chairman of the 
Research Ethics Committee by post via the Research and Development Office, 
Institute of Child Health, 30 Guilford Street, London WC1N 3EH or, if urgent, by 
telephone on 020 7905 2620 and the Committee administration will put you in 
touch with him. 
 
 
Thank you for your interest in this study- please ask us any questions 
  
Can we monitor your kidney function without the need of blood 
Information sheet for participants aged over 12 
 The doctors taking care of you have decided you need to have your kidney 
function checked. They will do this by injecting a special dye called “iohexol”. Then, 
they check your kidney function by taking two to three blood samples from you. We 
are currently doing a project to try to find an alternative non
which does not need blood sampling. It is called “iontophoresis” and it works via 
the skin. We would like to ask you and your parents for permission for you to 
participate in this project to compare our technique “iontophoresis” with the 
conventional blood sampling.
 Take time to decide if you want to say YES or NO to this. Please read this 
information carefully. Don’t worry if you don’t understand it straight away. Your 
parents have also been told about this, and you can ask them to help you 
understand.  
 
1. Why is this project being done?
 We are looking at an alternative sampling method for monitoring kidney 
function. This is because the current conventional method, i.e. blood sa
many disadvantages and relies only on two to three blood samples which may not 


























 We, therefore, propose in our study a non-invasive alternative technique to 
blood sampling. Our aim is to examine whether our proposed technique, 
iontophoresis, can at least estimate kidney function as accurately as blood 
sampling. 
 Iontophoresis involves the application of a very small electrical current 
across two parts of the skin already covered with two patches. The current passage 
facilitates the transport of iohexol (the dye used to monitor kidney function) from 
inside the body into the patches situated at the surface of the skin. By doing this, 
we can measure iohexol amounts in the patches at several intervals and an 
accurate but less invasive estimation of kidney function could be made possible.  
  
2. Why have you asked me to help? 
 The doctors taking care of you have decided you need to have your kidney 
function checked as part of your routine hospital care. To do so, they will use the 
conventional blood sampling technique. We would like to examine whether our 
technique, iontophoresis, could prove to be an accurate, non-invasive alternative. 
We can only do this by comparing results obtained from the conventional blood 
sampling technique with those from our alternative technique.  
 
3. Do I have to take part? 
 No. Taking part in the study is entirely voluntary. We fully understand that 
people may be unable or unwilling to participate. If you do not want to take part, 
you do not have to give a reason. This will not affect your treatment in any way.  
 You and your parents may withdraw at any time during the study. You can 
choose not to answer the questionnaire. Samples obtained from you will be treated 
as a gift but you have the right to ask for them to be removed from the study at any 
time.  
 
4. How will I be involved? 
 Please let us know if you suffer from any skin condition, such as eczema, or 
have irritated or damaged skin. 
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 Our proposed project is planned to be carried out in parallel to the routine 
kidney test requested by your doctors. 
 Usually, the routine kidney test takes between 4 and 6 hours. Participation 
in our study is for around 6 to 6.5 hours and will take place in the same ward and at 
the same time as your routine kidney test.  
 We require that no cosmetic products, such as creams, are applied to your 
arms during the 12 hours before the study’s commencement.  
 Our study will be done on one of your arms. We will choose the one that 
you use less often. We, first, cleanse it with an alcohol wipe and then leave it to dry. 
 The iontophoresis system (Picture 1) is composed of the current device (a 
sophisticated battery) and two electrode patches (a square dispersive pad and an 
oval gel-sponge patch). As you can see from the picture, the battery is very small 











Picture 1. Example of an iontophoresis system 
 
 Firstly, we attach the square pad and the hydrated oval patch onto your 
arm. We will then connect the battery to these patches and set it to deliver a small 
current.  
 In total, current is passed for 5 hours starting half an hour after iohexol dose 
was administered to you as part of your routine treatment.  
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 Both patches are replaced with new ones after 2 and 4 hours of current 
passage. The oval patch is also replaced at 3 hours. So, a total of 7 patches are used. 
Each time we do a patch exchange, we stop the current briefly. 
 Then, we examine these patches to give us information about iohexol. We 
only look for specific compounds (i.e. iohexol and normal sugars and salts present 
in the body) and we will not look at anything else such as drugs. 
 During participation with us, you can mobilise but the researcher will 
accompany you throughout the study. As our study is performed on the arm you 
use least, you are able to use the other arm freely. So you can, for example, go to 
the play room, read, and write. We will make sure you are kept entertained during 
the study and you can choose to watch your favourite cartoons and DVDs or read 
your favourite books. 
 You are allowed to go to the toilet at any time during your participation.  
 Unless you are already restricted from food/drink due to your routine 
hospital care, our study has no restrictions. 
 Once we finish the study, we will ask you to answer a short questionnaire 
about the levels of discomfort and tingling sensation you have experienced during 
the study. You will also be asked whether you prefer iontophoresis over blood 
sampling. 
 Results obtained from the study will be provided to you and your parents 
should you wish to find out the outcome of your participation. 
 If any step of the study is unclear to you or if you have any questions please 
talk to your parents and/or contact us for more information. 
 
5. Will there be any effects on my routine treatment? 
 No, the study will not affect your treatment in any form. 
 
6. Will there be any side effects? 
 Iontophoresis is considered a safe technique, with several devices used in 
hospitals, including Great Ormond Street Hospital, for both adults and children. 
 You may experience slight tingling and heat sensation (especially at the start 












Picture 2. Example of redness occurring after iontophoresis. 
 
but tends to disappear after a few days. Redness may also occur as a result of the 
adhesive material of the patches.  
 If you find any of the side effects uncomfortable or unacceptable, or decide 
to withdraw for no reason, the study will be stopped immediately.  
Medical staff will also be present to take appropriate action in case you feel 
unwell during the study. 
 If you are worried about any of the side effects please talk to your parents 
or to us.  
 
7. What are the arrangements for compensation? 
 This project has been approved by Great Ormond Street Hospital for 
Children NHS Trust Research Ethics Committee. The committee believes that this 
project is fair and of minimal risk to you. However, research can carry unexpected 
risks and we want you to be informed of your rights in the unlikely event that any 
harm should occur as a result of your participation. 
 This project is covered by the University of Bath insurance policy (NHE-
05CA07-0013). This includes potential legal liability for harm to you arising from the 
management and/or the design of the research. In addition, cover for 





8. Will there be any benefits for taking part?  
 There is no immediate benefit to you. If the results of this study are 
promising; then a potentially non-invasive alternative method for monitoring 
kidney function is on the horizon. This could make an end to the traditional invasive 
blood sampling and could benefit children in particular, as it will give an accurate 
estimation of kidney function without all the disadvantages associated with blood 
sampling.  
 
9. Will anyone else be told about my participation in the study? 
 We will keep all of your information confidential. This means we will only 
tell those who have a need or right to know. Your parents and family doctor will be 
informed of your participation.  
 
10. Who will have access to my information? 
 As a patient, you have rights regarding medical information recorded about 
you. 
 All your personal information collected during the study (data collection, 
processing, and storage) will be treated in strict confidence. No names, initials, or 
any type of information that could result in your identification will be mentioned in 
any reports of the study. 
 Throughout the study, we use a special code number instead of your name 
to make your participation in this study completely confidential. 
 All data information will be stored and analysed in computers secured with 
a password and only the research team involved in this study will have access to it. 
 With your agreement, we will take some photographs of your arm before 
and after the study to show the effect of iontophoresis on the skin. The 
photographs will only include your arm. 
  
11. Who do I speak to if I have further questions, worries, or complaints?  
 If you have any questions, comments, enquiries, or complaints about this 
project, please talk to your parents or contact either Ms. Asma Djabri 
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(A.Djabri@bath.ac.uk, 01225383900) or Dr. William Van’t Hoff 
(VANTHW@gosh.nhs.uk, 02074059200 ext. 5583/5930).  
 
Thank you for your interest in this study- please ask us any questions 
  
Can we monitor your kidney function without the 
Information sheet for children aged between 8 and 11 
 Your doctors have decided they want to check your kidneys using 
a special dye called “iohexol”. They do this by taking some blood samples 
from you. We are working all the time to improve this tech
we can better check your kidneys without the need of blood samples. 
Our alternative technique is called “iontophoresis”. We ask you and your 
parents for permission for you to participate in this project.
 
 Take time to decide if you want to 
read this information. Don’t worry if you don’t understand it straight 
away. Your parents have also been told about this, and you can ask them 
to help you understand. 
 
1) Why are you doing this?
 We want to see if we can 
If our technique gives good results, blood sampling could be replaced in 
the future. 
 
2) Why have you asked me?
















need of blood samples?  
years 
 
say YES or NO to this. Please 
 
 
monitor your kidneys with our technique. 
 
 




3) What will be different for you? 
 If you agree, the project will be done during your routine kidney 
test that you are already booked in for. It will start half an hour after 
your routine test begins and will be carried out in the same ward.  
 As part of your routine hospital care, your doctors will test your 
kidneys by administering the dye and then taking 2 to 3 blood samples 
from you. This usually takes between 4 and 6 hours. 
 Your participation with us takes around 6 to 6.5 hours. 
 In our project, we attach two sticky sponges on your skin. These 











 Then, we connect the sponges to a small battery which will deliver 
a small current to your skin. We then keep changing these sponges for 5 
hours.  
 We will use the arm you use least. This means that you can use the 
other arm freely to play, write…etc.  
 You can also go to the play room with one of our project team. We 
will keep you entertained and you can watch your favourite DVDs and 
cartoons. We can also read you your favourite story book. 
 You are allowed to go to the toilet at any time. Food and drink are 
allowed in our project unless you are already restricted by your other 
treatments. 
 
4) Do I have to participate? 
 No, it is completely up to you and your parents. Whether you say 




5) Is it dangerous? 
 No, but you may feel slight tingling and sense some heat especially 
at the start of project. Redness may also appear on the skin below the 











 But if you don’t like something, we will stop straight away. At the 
end we will ask you some questions about how you felt during your 
participation with us.  
 
6) Who can I speak to if I have any questions? 
 We have given more information to your parents about what we 
are doing. If you have any questions, speak to your parents, or to the 
doctors or nurses in the ward. 
 
Thank you for your interest in this study- please ask us any 
questions 
  
Can we monitor your kidney function without 
the need of blood samples? 
Information sheet for children aged less than 8 years
 Your doctors want to check how good your kidneys are by using a 
special dye. They do this
improve this method. Therefore, we ask you and your parents for permission to 
help us and participate in our mission.
 Your routine test usually takes between 4 and 6 hours. If you are 
happy to help us, we need your participation for 6 to 6.5 hours. We start our 
mission at the same time as your routine test.


































 We will attach two sticky sponges on your skin. These sponges look 
like sticky band-aid. 
 We connect these sponges to a small battery. We then keep changing 
the sponges for 5 hours.  
 We will use the arm you use least. This means that you can use the 
other arm freely to play, write…etc.  
 You can also go to the play room with one of our mission team (Asma, 
see her photo below). You can watch your favourite DVDs and cartoons. We can 
also read you your favourite story book. 
 You can go to the toilet at any time. Food and drink are allowed unless 
you are already restricted by your other treatments.  
 You may feel some tingling and heat under the sponges. But if you 
don’t like it, we will stop everything at any time you want.  
 At the end, we will ask you some questions about how you felt during 
your participation with us.  
 We have given a lot more information to your mum and dad. So please 
ask them if you don’t understand something. 
 
































































































































































Can we monitor your child’s kidney function without the need of 
Consent form for the legal representative of the child
The legal representative of the child should 
himself/herself: (Please circle one of the answers)
 
1. Have you read the Participant information sheet (legal 
representative)? (Please keep one)
2. Have you had a chance to discuss the study and had satisfactory 
answers to all of your questions?
3. Do you understand that you are free to withdraw your child from the 
study at any time, without having to give any reason, and without 
affecting any of their future medical care or legal rights?
4. Do you give permission for photographs of your child’s arm to be 
taken during the study?
5. Do you give permission for the researcher to inform your child’s GP of 
his/her participation in the study?
6. Do you give your permission for the 














blood samples?  
 
 
complete the whole of this sheet 
 
 















7. Have you had enough time to come to your decision? YES/NO 




LEGAL REPRESENTATIVE OF:  …………………………………………............................................ 
 
Participant identification code ………………………………………………….................................. 
    
Signature …………………………………………….. Date ………………………..................................... 
 





I have explained the study to the above legal representative and he/she has 
indicated his/her willingness for his/her child to take part. 
 
Signature …………………………………………….. Date ………………………..................................... 
 
Name (BLOCK LETTERS).……………………………………….………………….................................... 
  
Can we monitor your kidney function without the need of blood 
 
The participant should complete the whole of this sheet himself/herself. If the child 
is too young to read, this form should be read to the child by their legal 
representative and then completed by them on their behalf.
   
(Please circle one of the answers)
 
1. I have read (or had read to me)
(Please keep one) 
2. The doctors and my parents have explained everything to me
3. I have had the opportunity to ask questions and I understand the 
answers 
4. I understand what is being asked in this project
5. I know that I can stop participating in this study at any time
6. I am happy for photographs of my arm to be taken
7. I agree to my GP being informed of my 















Assent form for Participants 
 
 





















Signature …………………………………………….. Date ……………………….…………………………....... 
 
Name (BLOCK LETTERS).……………………………………….……………...........………………………….. 
 





I have explained the study to the above participant and he/she has indicated 
his/her willingness to take part. 
 
Signature …………………………………………….. Date ………………………….................................. 
 
Name (BLOCK LETTERS).……………………………………….………………….................................... 
  




1. Please circle one of the following faces which expresses the level of tingling 
sensation and discomfort felt in your skin during the study:
 
a) Square pad 
 


























2. Which one do you prefer? 
 
 








Thank you for your participation! 
  
Assessment of kidney function: Non
Iontophoresis as an alternative to blood sampling in the iohexol GFR 
 
   
Dear Dr.  
We are trying to recruit paediatric volunteers for our investigation of the possible 
use of transdermal iontophoresis as a sampling technique for iohexol, a marker 
used to estimate the glomerular filtration rate. The study is carried out at Great 
Ormond Street Hospital for Children, London.
 
Our primary aim is to assess the feasibility of using transdermal iontophoresis, as an 
alternative approach to blood sampling of iohexol. Glomerular filtration rate 
estimated from both techniques will be compared to det
this study proves its validity, a potentially non
of kidney function could be possible.
 
Your patient: -----------------------------------------------------------------
representative have agreed to participate in the study and I am writing to inform 
you of their participation.
 
Yours Sincerely, 
Dr. William Van’t Hoff BSc, MD, FRCPCH.
Consultant Paediatric Nephrologist











      
 
ermine any correlation. If 








 and his legal 
Assessment of kidney function: Non
as an alternative to blood sampling in the iohexol GFR test
Information sheet for the GP of the participant
 We are trying to recruit paediatric volunteers for our investigation of the 
possible use of transdermal iontophoresis as a non
sampling in the iohexol GFR test. 
Transdermal iontophoresis involves the application of a small electrical 
current across the skin. This is used to facilitate the active transport of molecules 
present in the subdermal fluid from inside the body into the surface of the skin at 
levels much higher than those of their passive transport. The subdermal fluid is in 
direct communication with blood and can therefore serve as a good alternative 
sampling matrix.   
 We plan to recruit paediatric volunteers, to whom iohexol is going to be 
administered and sampled intravenously as part of their normal hospital care, and 
we intend to carry out transdermal iontophoresis in parallel to compare values 
obtained from both sampling procedures. Usually, the routine kidney function test 
takes between 4 and 6 hours
 Participation in the study is for around 6 to 6.5 hours and will take place in 
the same ward as the participant’s routine GFR test.
 The participant as well as the parent will be requested to inform us if the 
child suffers from any skin condition, such 
skin.  














-invasive transdermal iontophoresis 
 



















Figure 1. Example of an iontophoretic system: Phoresor
®
 II auto device (power 
supply) connected to Iogel
®
 small patches (IOMED, Salt Lake city, Utah, USA). Each 
pair of patches is composed of a karaya gel dispersive pad (the square pad) and a 
hydratable gel-sponge patch (the oval patch). 
   
 “Phoresor
®
 II auto” (Model: PM850, Iomed, Salt Lake city, Utah, USA. Figure 1), 
already in the market for more than 10 years and used for iontophoresis in 
hospitals and health clinics for both adults and children. 
The device has safety features which will automatically activate upon, for 
example, an increase in the resistance of the current circuit above a pre-set limit. 
The device is also fully controllable manually and the current could be stopped at 




 II device is a small, light and portable machine. A strap-worn 
pouch, to carry the device, will be used to make participation in this study more 
comfortable.  
The device will be cleansed thoroughly with alcoholic wipes before and after 
each study.   
 The experimental protocol is summarized as follows: 
1) A minimum of 24 hours (for inpatients) or 2 weeks (for outpatients) is given 
to potential participants and their parents to read the participant information 
sheets and decide on whether they would like to take part in the study. They are 
encouraged to ask any questions and full explanation of all steps involved is 
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provided to them. Informed consent from the parent and child (as appropriate to 
age and understanding) will be taken. 
2) Upon participant and parent positive consent, a special code number 
instead of the participant’s name is used throughout the study to make 
participation completely confidential. The consent form is the only document which 
includes both the participant name as well as the allocated code number. All 
consent forms will be stored in a locked cabinet and only the local collaborators will 
have access to it.  
3) During the 12 hours before the study’s commencement, the participant is 
required not to apply any cosmetic products, such as creams, onto the arm used in 
the study. 
4) Iontophoresis is performed on the non-dominant arm of the participant. The 
arm is first cleansed with a routine alcohol wipe and then allowed to dry naturally.                                         
5) The iontophoresis system is composed of the Phoresor
®
 II device and two 
electrode patches (a square dispersive pad and an oval gel-sponge patch). After 
hydration of the oval patch with 1.5 ml sterile water for injection, the square pad 
and the hydrated oval patch are affixed onto the arm of the participant. The 
Phoresor
®
 II device is then connected to the electrodes and is set to precisely 
deliver 0.8 mA of constant direct current (~0.1 mA/cm
2
).  
6) In total, current is passed for 5 hours starting 0.5 hours after the volunteer 
receives their routine intravenous dose of iohexol. Both patches are replaced with 
new ones after 2 and 4 hours of current passage. The oval patch is additionally 
replaced at 3 hours (see illustration below). So, a total of 7 patches are used. Each 

























Figure 2. Example of redness occurring post-iontophoresis. 
 
7) During the study, the participant can mobilise but the researcher will 
accompany the participant throughout the study. As the study is performed on the 
non-dominant arm, the participant is able to use the other arm freely. So, the 
participant can, for example, go to the play room, read, and write. We will make 
sure the participant is kept entertained during the study and they can choose to 
watch their favourite cartoons and DVDs or read their favourite books. 
8) A comfort-break is allowed at any time during the study. Unless the 
participant is already restricted from food/drink due to their routine hospital care, 
our study has no restrictions.  
9) Participants may experience some mild tingling and heat sensation, 
especially at the start of iontophoresis. Redness may also appear at the site of 
iontophoresis but tends to disappear after a few days (figure 3). Upon positive 
consent from the participant and their parents, photographs of only the 
participant’s arm will be taken before and after the study to show the effect of 
iontophoresis on the skin.  
Redness/sensitisation may also occur as a result of the adhesive material of the 
patches. 
10)  If the participant is in discomfort, or decides to withdraw from the study at 
any time and for any reason, the study will be stopped immediately. The procedure 
will be undertaken in wards staffed by nurses with skills to act appropriately in the 
unlikely event that the participant feels unwell during the study. 
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11) Upon completion of the experiment, the participant will be asked to 
complete a short questionnaire, using the Wong-Baker faces pain scale, to evaluate 
the level of discomfort/tingling sensation they have experienced during the study. 
They will also be asked whether they prefer transdermal iontophoresis over blood 
sampling. 
12) Feedback with the results obtained from the iontophoresis sampling 
technique will be provided to the participant and parents should they wish to find 
out the outcome of their individual participation. A summary of the main findings 












Chapter 2, in vitro study: 
B.1 Fixed-subdermal concentration extraction 
Iohexol passive diffusion fluxes (nmol/h), 2.44 mM subdermal concentration  
 
Time (h) 
Replicate 1 2 3 4 5 6 
1 0.00 0.00 0.00 0.04 0.04 0.02 
2 0.00 0.00 0.00 0.03 0.02 0.03 
3 0.00 0.00 0.00 0.04 0.03 0.05 
4 0.00 0.04 0.06 0.08 0.09 0.12 
Average 0.00 0.01 0.01 0.05 0.05 0.06 
SD 0.00 0.02 0.03 0.02 0.03 0.04 
 
Iohexol iontophoretic fluxes (nmol/h), 2.44 mM subdermal concentration  
 
Time (h) 
Replicate 1 2 3 4 5 6 
1 1.10 3.31 4.78 5.35 5.70 6.08 
2 0.36 1.64 3.11 4.30 5.01 5.55 
3 0.58 1.15 1.80 2.19 2.60 2.82 
4 0.63 1.80 3.12 4.03 4.60 4.83 
5 0.93 1.68 2.32 2.69 3.15 3.39 
6 0.47 2.07 3.51 4.40 4.92 5.06 
7 0.72 2.23 3.49 4.69 5.30 5.82 
Average 0.69 1.98 3.16 3.95 4.47 4.79 
SD 0.26 0.68 0.95 1.12 1.15 1.24 
 
Iohexol iontophoretic fluxes (nmol/h), 1.22 mM subdermal concentration  
Replicate 1 2 3 4 5 6 
1 0.21 1.17 2.01 2.64 2.92 3.28 
2 0.36 0.58 1.04 1.40 1.67 1.90 
3 0.34 0.65 1.14 1.60 1.82 2.04 
4 0.22 0.61 1.25 1.59 1.83 1.94 
5 0.11 0.35 0.58 1.02 1.24 1.41 
6 0.29 0.81 1.49 1.94 2.32 2.61 
Average 0.26 0.69 1.25 1.70 1.97 2.20 




Iohexol iontophoretic fluxes (nmol/h), 0.61 mM subdermal concentration  
 
Time (h) 
Replicate 1 2 3 4 5 6 
1 0.14 0.29 0.61 0.85 1.07 1.09 
2 0.23 0.55 0.72 0.84 0.94 0.98 
3 0.31 0.74 0.91 1.10 1.19 1.18 
4 0.89 0.59 0.90 1.01 1.26 1.18 
5 0.35 0.61 0.77 0.83 0.95 0.98 
6 0.19 0.48 0.78 0.92 1.05 1.09 
Average 0.35 0.54 0.78 0.92 1.07 1.08 
SD 0.27 0.15 0.11 0.11 0.13 0.09 
 
Iohexol iontophoretic fluxes (nmol/h), 0.31 mM subdermal concentration  
 
Time (h) 
Replicate 1 2 3 4 5 6 
1 0.10 0.08 0.20 0.30 0.40 0.44 
2 0.19 0.34 0.42 0.54 0.54 0.56 
3 0.21 0.29 0.44 0.54 0.58 0.58 
4 0.15 0.21 0.38 0.52 0.54 0.59 
5 0.24 0.39 0.45 0.45 0.50 0.45 
6 0.06 0.14 0.20 0.25 0.35 0.49 
Average 0.16 0.24 0.35 0.43 0.49 0.52 
SD 0.07 0.12 0.12 0.13 0.09 0.07 
 
Iohexol iontophoretic fluxes (nmol/h), 0.15 mM subdermal concentration  
 
Time (h) 
Replicate 1 2 3 4 5 6 
1 0.12 0.17 0.26 0.35 0.38 0.36 
2 0.10 0.12 0.19 0.25 0.30 0.33 
3 0.10 0.07 0.09 0.16 0.18 0.19 
4 0.14 0.13 0.24 0.33 0.33 0.34 
Average 0.12 0.12 0.19 0.27 0.30 0.31 







B.2 Effect of iontophoretic pre-treatment of the skin on iohexol transport 




Replicate 1 2 3 4 5 6 
1 1.30 3.62 4.31 4.94 5.28 5.12 
2 1.03 2.94 4.05 4.73 5.12 5.12 
3 1.31 4.85 6.41 6.86 7.31 7.29 
4 0.74 3.36 4.95 5.66 6.12 5.94 
5 1.27 3.36 4.32 5.09 5.55 5.36 
6 0.95 3.60 4.86 5.37 6.26 6.05 
7 1.91 4.93 5.65 5.96 6.21 6.21 
8 2.41 6.21 7.07 7.41 7.07 7.26 
9 1.87 4.04 5.15 5.75 5.66 5.66 
10 1.66 3.51 4.15 4.42 4.53 4.65 
11 0.76 3.02 4.10 5.07 5.13 5.44 
12 0.67 2.54 3.88 4.44 4.82 4.39 
Average 1.33 3.83 4.91 5.47 5.76 5.71 
SD 0.54 1.03 1.01 0.92 0.86 0.91 
  




Replicate 1 2 3 4 5 6 
1 1.10 3.31 4.78 5.35 5.70 6.08 
2 0.36 1.64 3.11 4.30 5.01 5.55 
3 0.58 1.15 1.80 2.19 2.60 2.82 
4 0.63 1.80 3.12 4.03 4.60 4.83 
5 0.93 1.68 2.32 2.69 3.15 3.39 
6 0.47 2.07 3.51 4.40 4.92 5.06 
7 0.72 2.23 3.49 4.69 5.30 5.82 
Average 0.69 1.98 3.16 3.95 4.47 4.79 









Replicate 1 2 3 4 5 6 
1 0.07 0.09 0.18 0.24 0.23 0.25 
2 0.07 0.12 0.15 0.15 0.17 0.21 
3 0.09 0.06 0.12 0.13 0.16 0.19 
4 0.11 0.17 0.21 0.27 0.24 0.26 
5 0.10 0.17 0.21 0.28 0.29 0.26 
Average 0.09 0.12 0.18 0.22 0.22 0.24 
SD 0.02 0.05 0.04 0.07 0.05 0.04 
 




Replicate 1 2 3 4 5 6 
1 0.00 0.00 0.00 0.04 0.04 0.02 
2 0.00 0.00 0.00 0.03 0.02 0.03 
3 0.00 0.00 0.00 0.04 0.03 0.05 
4 0.00 0.04 0.06 0.08 0.09 0.12 
Average 0.00 0.01 0.01 0.05 0.05 0.06 
SD 0.00 0.02 0.03 0.02 0.03 0.04 
 




Replicate 1 2 3 4 5 6 7 8 9 
1 7.42 19.70 23.79 22.95 26.05 26.04 27.22 27.01 27.32 
2 7.55 20.99 25.78 35.51 33.97 33.84 34.77 33.36 34.46 
3 7.34 15.76 21.76 26.84 23.55 24.98 26.50 25.34 25.25 
4 7.10 12.49 15.52 17.17 18.39 19.88 20.33 20.64 20.99 
5 2.80 10.18 16.49 19.14 20.78 20.67 24.03 23.38 24.26 
6 2.98 8.88 13.72 16.35 16.88 19.15 19.81 21.50 18.35 
Average 5.86 14.67 19.51 22.99 23.27 24.09 25.45 25.21 25.11 








Replicate 1 2 3 4 5 6 7 8 9 
1 0.00 0.16 0.24 0.29 0.23 0.44 0.39 0.43 0.42 
2 0.00 0.00 0.00 0.16 0.09 0.11 0.23 0.36 0.32 
3 0.00 0.07 0.14 0.11 0.23 0.28 0.37 0.41 0.48 
4 0.00 0.10 0.37 0.37 0.47 0.75 0.90 0.96 1.02 
5 0.00 0.21 0.39 0.67 0.89 1.24 1.41 1.72 1.76 
Average 0.00 0.11 0.23 0.32 0.38 0.56 0.66 0.77 0.80 










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Chapter 2, in vivo study 
1. Blood sampling data 
Time of sampling (post-bolus injection) (h): 
Patient 1 Patient 2 Patient 3 Patient 4 
2.95 2.98 3.00 3.08 
3.98 4.10 4.17 4.03 
 
Iohexol blood concentration (µg/ml): 
Patient 1 Patient 2 Patient 3 Patient 4 
92.8 25.6 52.0 29.3 
64.4 13.6 31.6 18.7 
 
 
2. Skin sampling data 
Time of sampling (post-bolus injection) (h): 
Patient 1 Patient 2 Patient 3 Patient 4 
2.75 2.57 2.63 2.57 
3.80 3.65 3.67 3.62 
4.88 4.73 4.73 4.67 
6.00 5.87 5.80 5.72 
 
Iohexol iontophoretic fluxes (µg/h): Current was 0.5 mA in all patients except 
patient 3 (0.3 mA) 
Patient 1  Patient 2 Patient 3 Patient 4 
0.59 0.31 0.27 0.39 
0.62 0.35 0.42 0.47 
0.52 0.24 0.25 0.25 
0.44 0.12 0.20 0.22 
 
Sodium iontophoretic fluxes (µg/h per 0.5 mA): 
Patient 1 Patient 2 Patient 3 Patient 4 
178.07 168.38 180.48 194.95 
226.85 228.31 350.93 299.52 
197.27 237.64 293.40 284.23 




Potassium iontophoretic fluxes (µg/h per 0.5 mA): 
Patient 1 Patient 2 Patient 3 Patient 4 
109.96 72.46 78.40 86.47 
118.27 96.35 103.64 104.78 
114.28 91.56 93.89 110.72 





Chapter 3, Ranitidine transdermal delivery study 
3.1 Ranitidine delivery from aqueous solutions 
3.1.1 Effect of donor vehicle 
Ranitidine iontophoretic fluxes (µmol/h), 25 mM drug in water (pH 5.6) 
 
Time (h) 
Replicate 1 2 3 4 5 6 
1 0.24 0.41 0.53 0.56 0.62 0.67 
2 0.21 0.46 0.51 0.56 0.55 0.58 
3 0.35 0.62 0.67 0.64 0.71 0.70 
4 0.25 0.45 0.50 0.59 0.57 0.61 
5 0.31 0.49 0.49 0.49 0.51 0.51 
Average 0.28 0.49 0.54 0.57 0.59 0.61 
SD 0.06 0.08 0.08 0.05 0.08 0.08 
 
Ranitidine iontophoretic fluxes (µmol/h), 25 mM drug in 5 mM Tris (pH 7) 
 
Time (h) 
Replicate 1 2 3 4 5 6 
1 0.13 0.37 0.49 0.58 0.66 0.71 
2 0.11 0.42 0.52 0.69 0.78 0.80 
3 0.15 0.43 0.57 0.69 1.10 0.86 
4 0.22 0.53 0.60 0.68 0.75 0.80 
5 0.25 0.50 0.58 0.66 0.73 0.71 
Average 0.17 0.45 0.55 0.66 0.80 0.78 
SD 0.06 0.06 0.04 0.05 0.17 0.06 
 
 
3.1.2 Effect of current intensity 
Ranitidine iontophoretic fluxes (µmol/h), 0.1 mA 
 
Time (h) 
Replicate 1 2 3 4 5 6 
1 0.04 0.11 0.15 0.19 0.22 0.24 
2 0.06 0.13 0.16 0.20 0.23 0.25 
3 0.07 0.14 0.17 0.21 0.21 0.22 
4 0.05 0.13 0.16 0.20 0.21 0.23 
5 0.05 0.14 0.17 0.20 0.23 0.26 
Average 0.05 0.13 0.16 0.20 0.22 0.24 
SD 0.01 0.01 0.01 0.01 0.01 0.01 
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Ranitidine iontophoretic fluxes (µmol/h), 0.2 mA 
 
Time (h) 
Replicate 1 2 3 4 5 6 
1 0.06 0.25 0.35 0.36 0.42 0.45 
2 0.08 0.24 0.32 0.32 0.38 0.41 
3 0.08 0.26 0.34 0.33 0.40 0.42 
4 0.07 0.24 0.33 0.34 0.40 0.43 
Average 0.07 0.25 0.33 0.34 0.40 0.43 
SD 0.01 0.01 0.01 0.01 0.02 0.02 
 
Ranitidine iontophoretic fluxes (µmol/h), 0.3 mA 
 
Time (h) 
Replicate 1 2 3 4 5 6 
1 0.29 0.57 0.69 0.73 0.79 0.81 
2 0.25 0.55 0.63 0.68 0.72 0.74 
3 0.16 0.46 0.58 0.67 0.75 0.80 
4 0.22 0.53 0.63 0.78 0.84 0.89 
5 0.22 0.51 0.59 0.67 0.73 0.75 
Average 0.23 0.52 0.62 0.71 0.77 0.80 
SD 0.04 0.04 0.04 0.05 0.05 0.06 
 
 
3.1.2 Effect of drug concentration 
Ranitidine iontophoretic fluxes (µmol/h), 25 mM 
 
Time (h) 
Replicate 1 2 3 4 5 6 
1 0.13 0.37 0.49 0.58 0.66 0.71 
2 0.11 0.42 0.52 0.69 0.78 0.80 
3 0.15 0.43 0.57 0.69 1.10 0.86 
4 0.22 0.53 0.60 0.68 0.75 0.80 
5 0.25 0.50 0.58 0.66 0.73 0.71 
Average 0.17 0.45 0.55 0.66 0.80 0.78 








Ranitidine iontophoretic fluxes (µmol/h), 50 mM 
 
Time (h) 
Replicate 1 2 3 4 5 6 
1 0.29 0.57 0.69 0.73 0.79 0.81 
2 0.25 0.55 0.63 0.68 0.72 0.74 
3 0.16 0.46 0.58 0.67 0.75 0.80 
4 0.22 0.53 0.63 0.78 0.84 0.89 
5 0.22 0.51 0.59 0.67 0.73 0.75 
Average 0.23 0.52 0.62 0.71 0.77 0.80 
SD 0.04 0.04 0.04 0.05 0.05 0.06 
 
Ranitidine iontophoretic fluxes (µmol/h), 150 mM 
 
Time (h) 
Replicate 1 2 3 4 5 6 
1 0.16 0.55 0.76 0.92 1.12 0.97 
2 0.25 0.66 0.83 0.88 0.96 0.94 
3 0.21 0.61 0.72 0.80 0.85 0.94 
4 0.26 0.68 0.80 0.84 1.04 0.92 
5 0.24 0.54 0.64 0.73 0.89 0.72 
Average 0.23 0.61 0.75 0.83 0.97 0.90 





3.2 Ranitidine delivery from gel formulations 
Passive diffusion fluxes (nmol/h) 
0 % F-127 formulation 
 
Time (h) 
Replicate 2 4 6 8 10 22 24 
1 0.02 0.05 0.15 0.33 0.56 1.17 1.28 
2 0.03 0.04 0.10 0.20 0.33 0.97 1.62 
3 0.02 0.04 0.06 0.09 0.15 0.50 0.82 
Average 0.02 0.04 0.10 0.21 0.35 0.88 1.24 
SD 0.00 0.00 0.04 0.12 0.20 0.34 0.40 
 
20 % F-127 formulation 
 
Time (h) 
Replicate 2 4 6 8 10 22 24 
1 0.05 0.17 0.30 0.38 0.54 0.85 1.04 
2 0.01 0.03 0.07 0.14 0.22 0.48 0.67 
3 0.07 0.20 0.27 0.32 0.45 0.75 0.87 
Average 0.04 0.13 0.21 0.28 0.40 0.69 0.86 
SD 0.03 0.09 0.12 0.13 0.16 0.19 0.18 
 
30 % F-127 formulation 
 
Time (h) 
Replicate 2 4 6 8 10 22 24 
1 0.0254 0.042 0.068 0.083 0.099 0.196 0.266 
2 0.0146 0.051 0.071 0.142 0.140 0.434 0.727 
3 0.0306 0.133 0.232 0.218 0.268 0.598 0.832 
Average 0.024 0.076 0.124 0.148 0.169 0.409 0.608 










Iontophoretic fluxes (µmol/h) 
0 % F-127 formulation 
 
Time (h) 
Replicate 1 2 3 4 5 6 
1 0.16 0.55 0.76 0.92 1.12 0.97 
2 0.25 0.66 0.83 0.88 0.96 0.94 
3 0.21 0.61 0.72 0.80 0.85 0.94 
4 0.26 0.68 0.80 0.84 1.04 0.92 
5 0.24 0.54 0.64 0.73 0.89 0.72 
Average 0.23 0.61 0.75 0.83 0.97 0.90 
SD 0.04 0.06 0.07 0.07 0.11 0.10 
 
20 % F-127 formulation 
 
Time (h) 
Replicate 1 2 3 4 5 6 
1 0.31 0.68 0.81 0.80 0.83 1.08 
2 0.28 0.73 0.72 0.90 0.70 1.02 
3 0.22 0.64 0.65 0.88 0.86 0.89 
4 0.28 0.63 0.72 0.75 0.83 0.91 
5 0.15 0.50 0.61 0.70 0.77 0.85 
Average 0.25 0.64 0.70 0.81 0.80 0.95 
SD 0.07 0.08 0.08 0.09 0.06 0.10 
 
30 % F-127 formulation 
 
Time (h) 
Replicate 1 2 3 4 5 6 
1 0.13 0.55 0.73 0.72 0.78 0.75 
2 0.23 0.60 0.69 0.68 0.70 0.72 
3 0.15 0.40 0.79 0.65 0.76 0.81 
4 0.13 0.53 0.66 0.71 0.78 0.83 
5 0.15 0.44 0.48 0.54 0.59 0.66 
Average 0.16 0.50 0.67 0.66 0.72 0.75 





Chapter 4, Midazolam transdermal delivery study 
3.1 pH effect 
Midazolam iontophoretic fluxes (nmol/h), pH 3 
 
Time (h) 
Replicate 1 2 3 4 5 6 
1 0.03 1.14 2.20 8.63 8.89 8.97 
2 0.02 0.28 1.03 3.91 3.76 3.64 
3 0.06 0.41 0.59 3.37 3.41 3.10 
4 0.08 0.75 3.19 8.46 8.72 8.21 
Average 0.05 0.64 1.75 6.09 6.19 5.98 
SD 0.03 0.38 1.18 2.84 3.02 3.04 
 
Midazolam iontophoretic fluxes (nmol/h), pH 3.5 
 
Time (h) 
Replicate 1 2 3 4 5 6 
1 0.04 1.09 5.07 10.60 11.03 7.42 
2 0.04 1.25 9.67 12.47 12.63 9.66 
3 0.25 2.44 4.86 6.05 6.80 14.06 
Average 0.11 1.59 6.54 9.70 10.15 10.38 
SD 0.12 0.74 2.72 3.30 3.02 3.38 
 
Midazolam iontophoretic fluxes (nmol/h), pH 4 
 
Time (h) 
Replicate 1 2 3 4 5 6 
1 1.82 2.21 7.94 10.61 11.53 11.77 
2 0.80 5.33 11.63 12.88 13.17 16.04 
3 0.09 2.85 8.81 9.32 9.43 10.05 
4 0.94 3.53 7.62 13.96 14.46 12.37 
Average 0.91 3.48 9.00 11.69 12.15 12.55 









Midazolam iontophoretic fluxes (nmol/h), pH 4.5 
 
Time (h) 
Replicate 1 2 3 4 5 6 
1 4.70 12.47 14.82 19.95 20.87 21.15 
2 2.63 8.37 12.07 15.28 14.91 15.02 
3 2.43 8.50 17.81 18.24 20.67 19.84 
4 2.36 18.34 13.91 15.75 14.69 14.92 
Average 3.03 11.92 14.65 17.31 17.79 17.73 
SD 1.12 4.69 2.40 2.19 3.45 3.23 
 
3.2 Current effect 
Midazolam iontophoretic fluxes (nmol/h), 0.1 mA 
 
Time (h) 
Replicate 1 2 3 4 5 6 
1 1.12 1.28 1.68 2.01 2.19 3.10 
2 0.19 0.40 0.40 0.81 1.18 1.91 
3 0.27 0.27 0.54 0.91 1.28 2.07 
Average 0.53 0.65 0.87 1.24 1.55 2.36 
SD 0.52 0.55 0.70 0.66 0.55 0.64 
 
Midazolam iontophoretic fluxes (nmol/h), 0.2 mA 
 
Time (h) 
Replicate 1 2 3 4 5 6 
1 0.06 0.54 4.29 3.62 4.15 4.77 
2 0.05 0.11 2.14 2.94 3.59 5.49 
3 0.31 2.66 1.66 6.50 5.85 5.91 
Average 0.14 1.10 2.70 4.36 4.53 5.39 
SD 0.15 1.37 1.40 1.89 1.18 0.57 
 
Midazolam iontophoretic fluxes (nmol/h), 0.36 mA 
 
Time (h) 
Replicate 1 2 3 4 5 6 
1 0.04 1.09 5.07 10.60 11.03 7.42 
2 0.04 1.25 9.67 12.47 12.63 9.66 
3 0.25 2.44 4.86 6.05 6.80 14.06 
Average 0.11 1.59 6.54 9.70 10.15 10.38 




3.3 Molar fraction effect 




Replicate 1 2 3 4 5 6 
1 0.27 0.41 1.48 2.11 2.84 3.48 
2 0.25 0.43 1.04 1.95 2.47 2.92 
3 0.16 0.32 0.67 1.50 2.43 2.72 
Average 0.23 0.39 1.06 1.85 2.58 3.04 
SD 0.06 0.06 0.41 0.32 0.23 0.39 
 




Replicate 1 2 3 4 5 6 
1 0.04 1.09 5.07 10.60 11.03 7.42 
2 0.04 1.25 9.67 12.47 12.63 9.66 
3 0.25 2.44 4.86 6.05 6.80 14.06 
Average 0.11 1.59 6.54 9.70 10.15 10.38 
SD 0.12 0.74 2.72 3.30 3.02 3.38 
 




Replicate 1 2 3 4 5 6 
1 2.10 6.42 16.68 20.19 24.17 27.33 
2 3.50 12.82 19.55 22.06 26.03 28.70 
3 2.91 7.64 32.15 36.42 32.69 32.66 
4 0.49 8.95 17.07 16.24 16.88 20.82 
5 1.47 3.57 7.53 14.34 22.46 21.84 
6 3.01 10.57 19.21 22.60 26.83 25.29 
7 11.55 27.85 22.16 25.89 27.82 25.58 
8 7.56 12.14 13.67 18.17 17.69 18.44 
9 8.40 8.22 8.05 12.02 14.60 13.82 
Average 4.56 10.91 17.34 20.88 23.24 23.83 





Midazolam iontophoretic fluxes (nmol/h), 15.9 mM midazolam, pH 3.6 
 
Time (h) 
Replicate 1 2 3 4 5 6 
1 12.05 60.15 64.02 76.57 75.75 60.67 
2 1.87 52.40 51.97 50.27 50.23 49.10 
3 65.27 74.70 72.84 80.19 85.59 90.41 
4 50.14 57.12 45.50 50.53 49.11 47.27 
5 3.38 21.26 38.84 48.66 56.98 63.56 
Average 26.54 53.13 54.63 61.24 63.53 62.20 
SD 29.20 19.67 13.78 15.71 16.31 17.28 
 




Replicate 1 2 3 4 5 6 
1 58.88 40.40 56.97 64.60 56.48 53.56 
2 21.07 42.27 47.53 57.71 63.42 60.09 
3 15.80 49.99 46.54 46.22 45.61 48.22 
4 6.83 19.22 28.32 37.66 46.84 52.37 
5 16.07 28.78 27.18 38.90 42.47 46.05 
6 6.84 22.61 29.48 33.70 35.95 36.83 
Average 20.92 33.88 39.34 46.46 48.46 49.52 
SD 19.43 12.17 12.62 12.27 9.91 7.89 
 




Replicate 1 2 3 4 5 6 
1 2.82 5.68 7.59 10.71 12.83 12.84 
2 2.51 5.10 8.22 10.41 12.36 13.54 
3 1.80 5.70 11.56 11.31 12.10 13.56 
4 3.42 9.37 13.17 16.90 20.48 20.46 
5 2.19 2.60 2.11 2.22 2.84 3.26 
Average 2.55 5.69 8.53 10.31 12.12 12.73 






3.4 Permeation across barrier compromised skin 




Replicate 2 4 6 8 10 21 
1 0.000 0.022 0.035 0.058 0.049 0.043 
2 0.000 0.015 0.019 0.047 0.049 0.038 
3 0.000 0.015 0.031 0.039 0.051 0.051 
Average 0.000 0.017 0.028 0.048 0.049 0.044 
SD 0.000 0.004 0.008 0.010 0.001 0.007 
 
Half compromised skin 
 
Time (h) 
Replicate 2 4 6 8 10 21 
1 0.06 0.43 1.49 1.92 2.45 2.30 
2 0.07 0.65 2.03 2.54 0.88 1.41 
3 0.26 0.54 2.06 2.08 2.38 2.37 
Average 0.13 0.54 1.86 2.18 1.90 2.03 
SD 0.11 0.11 0.33 0.32 0.89 0.54 
 
Fully compromised skin 
 
Time (h) 
Replicate 2 4 6 8 10 21 
1 1.12 10.97 22.99 31.30 34.31 38.83 
2 3.02 18.42 35.74 37.45 36.46 39.53 
3 3.41 23.91 38.70 47.27 50.54 47.32 
Average 2.52 17.77 32.48 38.67 40.44 41.89 








Replicate 1 2 3 4 5 6 
1 2.10 6.42 16.68 20.19 24.17 27.33 
2 3.50 12.82 19.55 22.06 26.03 28.70 
3 2.91 7.64 32.15 36.42 32.69 32.66 
4 0.49 8.95 17.07 16.24 16.88 20.82 
5 1.47 3.57 7.53 14.34 22.46 21.84 
6 3.01 10.57 19.21 22.60 26.83 25.29 
7 11.55 27.85 22.16 25.89 27.82 25.58 
8 7.56 12.14 13.67 18.17 17.69 18.44 
9 8.40 8.22 8.05 12.02 14.60 13.82 
Average 4.56 10.91 17.34 20.88 23.24 23.83 
SD 3.73 6.97 7.48 7.26 5.90 5.71 
 
Half compromised skin 
 
Time (h) 
Replicate 1 2 3 4 5 6 
1 4.65 10.79 18.99 26.27 31.45 35.61 
2 2.90 5.51 6.25 9.54 13.03 16.87 
3 0.49 2.69 6.30 9.96 12.30 17.14 
4 1.50 5.10 24.21 45.21 50.64 47.35 
5 0.23 1.96 5.50 9.66 15.52 18.67 
Average 1.96 5.21 12.25 20.13 24.59 27.13 
SD 1.83 3.47 8.74 15.75 16.53 13.76 
 
Fully compromised skin 
 
Time (h) 
Replicate 1 2 3 4 5 6 
1 16.77 69.57 93.08 110.15 127.87 126.77 
2 4.82 25.69 48.38 46.82 82.22 75.28 
3 19.87 68.21 115.35 133.40 154.77 174.56 
4 16.78 91.90 140.84 151.39 159.83 172.12 
5 0.84 9.18 21.90 35.11 47.14 57.49 
6 1.15 33.67 58.89 102.91 113.23 106.29 
7 4.49 45.31 60.25 81.18 124.39 139.21 
8 13.24 69.90 80.70 112.59 158.24 174.23 
Average 9.75 51.68 77.42 96.69 120.96 128.25 

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































   
   
  
   













































































































































































































































































































































































































































3.1.3. Anodal versus cathodal delivery 
 
Cathodal flux (nmol/h) 
 
Time (h) 
Replicate 1 2 3 4 5 
1 17.91 37.64 41.94 41.84 39.30 
2 18.23 32.69 33.64 38.52 34.17 
3 36.15 62.78 60.85 54.14 61.26 
4 18.12 50.69 49.98 51.01 55.66 
Average 22.60 45.95 46.60 46.38 47.60 
SD 9.03 13.55 11.61 7.40 12.92 
 
Anodal flux (nmol/h) 
 
Time (h) 
Replicate 1 2 3 4 5 
1 0.97 3.25 7.53 10.85 14.08 
2 0.20 1.88 5.89 7.99 10.62 
3 0.44 3.49 8.20 12.91 14.19 
4 0.21 2.24 5.14 8.43 10.49 
Average 0.45 2.71 6.69 10.04 12.34 
SD 0.36 0.78 1.42 2.29 2.07 
 
Passive flux (nmol/h) 
 
Time (h) 
Replicate 1 2 3 4 5 
1 0.14 2.01 3.99 3.26 8.03 
2 1.41 4.75 7.11 7.50 10.22 
3 0.28 0.79 0.83 1.21 2.19 
4 1.20 2.25 1.54 2.52 3.22 
5 0.69 1.49 4.40 5.19 3.59 
6 0.50 1.38 1.76 3.99 4.08 
Average 0.70 2.11 3.27 3.95 5.22 





3.1.4. Co-ion competition 
 
Phenobarbital iontophoretic fluxes (nmol/h) 
 











Experiment number 2 in Table 1 
 
Time (h) 
Replicate 1 2 3 4 5 
1 17.91 37.64 41.94 41.84 39.30 
2 18.23 32.69 33.64 38.52 34.17 
3 36.15 62.78 60.85 54.14 61.26 
4 18.12 50.69 49.98 51.01 55.66 
Average 22.60 45.95 46.60 46.38 47.60 
SD 9.03 13.55 11.61 7.40 12.92 
 
Experiment number 3 in Table 1 
 
Time (h) 
Replicate 1 2 3 4 5 
1 71.16 202.06 207.73 151.21 138.11 
2 36.70 154.98 166.85 201.07 174.45 
3 67.19 169.79 213.92 147.12 156.39 
4 99.40 253.40 226.53 210.83 164.93 
5 34.90 110.75 156.94 151.52 114.77 
6 166.07 226.74 195.18 157.09 216.89 
Average 79.24 186.29 194.52 169.81 160.92 








Replicate 1 2 3 4 5 
1 329.23 432.43 389.50 302.40 290.77 
2 153.58 408.09 442.92 411.67 413.72 
3 181.63 300.37 328.62 324.90 318.76 
Average 221.48 380.30 387.01 346.33 341.08 




Experiment number 4 in Table 1 
 
Time (h) 
Replicate 1 2 3 4 5 
1 91.54 205.79 205.25 222.10 211.07 
2 137.00 289.53 291.87 272.60 339.40 
3 120.14 221.54 208.96 211.84 199.62 
4 155.15 288.32 290.23 273.02 296.85 
5 120.89 200.33 214.91 205.06 220.33 
Average 124.94 241.10 242.24 236.92 253.45 
SD 23.52 44.35 44.69 33.32 61.36 
 
Experiment number 5 in Table 1 
 
Time (h) 
Replicate 1 2 3 4 5 
1 116.99 259.15 278.34 271.73 289.84 
2 161.42 318.32 296.86 305.53 317.71 
3 89.43 231.45 238.81 264.20 248.22 
4 203.67 334.16 313.89 344.12 293.83 
5 115.12 333.75 352.35 351.08 351.28 
Average 137.33 295.37 296.05 307.33 300.18 
SD 45.23 47.18 42.07 40.00 37.96 
 
 
3.2 Permeation across compromised skin 





Replicate 1 2 3 4 5 18 20 22 24 
1 0.09 0.33 0.56 0.71 0.92 1.66 2.83 3.46 3.80 
2 0.00 0.03 0.19 0.42 0.70 2.68 5.24 6.02 7.22 
3 0.00 0.03 0.21 0.56 1.02 3.72 6.99 7.87 8.50 
Average 0.03 0.13 0.32 0.56 0.88 2.69 5.02 5.78 6.50 
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